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Heat shock protein 90 kDa (Hsp90) is a member of the molecular chaperone family of 
proteins that processes newly synthesized polypeptides into their three-dimensional and 
biologically active form. In addition, Hsp90 assists in the stabilization, trafficking and refolding 
of denatured proteins. Many Hsp90-dependent proteins are critical to the pathogenesis of cancer, 
neurodegeneration and/or viral infection. As a result, Hsp90 has garnered attention as a 
chemotherapeutic target and has resulted in the development of more than 17 Hsp90 inhibitors that 
that have been evaluated in clinical trials. However, these inhibitors exhibit pan-inhibitory activity 
against all four Hsp90 isoforms: Hsp90D, Hsp90E, Grp94 and Trap1, which results in various side 
effects, including, hepatotoxicity, cardiotoxicity, and renal toxicity.  Therefore, the development 
of isoform-selective Hsp90 inhibitors has been proposed to delineate the contribution of each 
Hsp90 isoform towards these toxicities. 
The cytosolic Hsp90 isoforms, D and E modulate the activity of numerous Hsp90-
dependent proteins that regulate cancer progression. Hydrolysis of ATP by the N-terminal 
nucleoside-binding site provides the energy required for the maturation of client protein substrates, 
and all four Hsp90 isoforms share >85% identity within this region. Between cytosolic Hsp90 
isoforms (D and E), the N-terminal ATP-binding site exhibits >95 % identity. As a result, the 
design of inhibitors that selectively target individual cytosolic Hsp90 isoforms has been 
challenging. Described herein is the development of Hsp90E- and Hsp90D-selective inhibitors 
using a structure-based approach that has produced compounds that exhibit both high selectivity 
and affinity. The efficacy of these inhibitors has been evaluated against an array of cancer cell 
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3D: three dimensional 
ADP: Adenosine diphosphate 
Aha1: Hsp90 co-chaperone (ATPase activator) 
Akt: Protein kinase B 
Ala: Alanine 
ALK: Anaplastic lymphoma kinase 
Apaf-1: Apoptotic peptidase activating factor 1 
ARNT: Aryl hydrocarbon receptor nuclear translocator 
Asn: Asparagine 
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ATM: Ataxia-telangiectasia-mutated kinase  
ATP: Adenosine triphosphate 
BBB: Blood brain barrier 
BBr3: Boron tribromide 
Bcl-2: B-cell lymphoma 2 gene that regulates apoptosis 
Bcr-Abl: Bcr-Abl fusion protein with tyrosine-kinase activity 
BCSC: breast cancer stem cell 
BF3.etherate: Boron trifluoride diethyl etherate 
BMI1: B lymphoma Mo-MLV insertion region 1 homolog  
BRAF: B-Raf proto-oncogene 
CDK4: Cyclin-dependent kinase 4 
CDK6: Cyclin-dependent kinase 6 
CHIP: Carboxy terminus of Hsc70 interacting protein 
c-IAP1: Cellular Inhibitor of Apoptosis Protein 1 
CL: Charged linker 
c-MET: tyrosine-protein kinase Met 
CTD: C-terminal domain 




DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
EDCI: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EEVD:  A domain that recognizes the tetratricopeptide-containing repeat 
(TPR) domain 
EGCG: Epigallocatechin gallate  
eHsp90D: Extracellular heat shock protein 90 kDa alpha isoform 
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ER: Endoplasmic reticulum  
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FGFR3: Fibroblast growth factor receptor 3 
FKBP51 and FKBP52: Immunophillins that bind to FK506 protein 
FKBP8: FK506-binding protein 8 
Flt-3: fms like tyrosine kinase 3  
FP: Fluorescence Polarization 
GALAXY 1 and 2: Clinical trial studies conducted on patients with 
advanced non-small cell lung cancer 
GDA: Geldanamycin 
GHKL: Family of ATPases consisting of DNA Gyrase, Hsp90, Histidine 
Kinase, and Mut L 
GI50: 50 % growth inhibitory concentration 
GIST: Gastrointestinal Stromal Tumor 
Grp94: Glucose regulated protein 94 
HCT116: Colorectal carcinoma cell line 
hERG: Human ether-a-go-go-related gene potassium channels 
HIF-1: Hypoxia-inducible factor 1 
HIP: Hsp70 interacting protein  
HIV: human immunodeficiency virus  
HMG1: 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1 
HOBt·H2O: Hydroxybenzotriazole hydrate 
HOP: Hsp90-Hsp70 organizing protein 
HSF-1: Heat shock factor-1 
Hsp: Heat shock protein 
HSR: Heat shock response  
h-Tert: Human telomerase 
HTS: High throughput screen 
IGF: Insulin-m growth factor 
IL-6: Interleukin 6 
IL-8: Interleukin 8 
Ile: Isoleucine 
IRAK: Interleukin-1 receptor-associated kinase  
Kd: Dissociation constant 
kDa: Kilo daltons 
Leu: Leucine 
Lys: Lysine  
MAFG: Transcription factor MafG 
MCF-7: Estrogen receptor negative breast cancer cell line 
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mCPBA: meta-chloroperoxybenzoic acid 
MD: Middle domain 
MDA-MB-231: Human breast adenocarcinoma cell line 
MEK: Mitogen-activated protein kinase kinase 
MeOH: Methanol 
MG63: bone osteosarcoma cells 
MMP 1-3: Matrix metalloproteinase-1, 2- and -3 
MutL: DNA mismatch repair protein 
MYC1: Transcription factor MYC1 
Myt1: Myelin transcription factor 1 
NaN3: Sodium azide 
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NCI: National cancer institute 
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NEK: Serine/threonine-protein kinase Nek 
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells 
NMR: Nuclear magnetic resonance 
NSCLC: Non-small cell lung cancer 
NTD: N-terminal domain 
p53: Tumor protein p53 
PD: Pharmacodynamic 
PDB: Protein data bank  
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PK: Pharmacokinetic 
Plk: Polo like kinase  
RAF-1: RAF proto-oncogene serine/threonine-protein kinase 
RDA: Radamide 
RDC: Radicicol 
RIP: Receptor-interacting protein kinase 
SAR: Structure-activity relationship  
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SkBr3: Estrogen receptor positive breast cancer cell line 
SREBF1: Sterol regulatory element-binding protein 1 
STAT3: Signal transducer and activator of transcription 3 
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Trap-1: TNF receptor associated protein 1 
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                                                                CHAPTER I 
                Introduction to Hsp90 Function, Structure and Regulation  
I.1 Introduction 
Molecular chaperones are a class of protein that regulate proteostasis by assisting in the 
conformational maturation of nascent polypeptides (referred to as client proteins) and the refolding 
of denatured proteins. The heat shock proteins (Hsps) belong to the ubiquitously expressed 
molecular chaperone family that are highly conserved in eukaryotes. The 90kDa Heat shock 
protein (Hsp90) is one of the most abundant Hsps and represents ~1-2% of the total cellular protein 
in unstressed cells and ~4-6% in stressed cells, including malignancy. 1-2 Hsp90 is responsible for 
the maturation of more than 300 protein substrates, wherein numerous client proteins (e.g., ErbB2, 
B-Raf, Akt, steroid hormone receptors, mutant p53, HIF-1, survivin, telomerase, etc.) are the key 
regulators of oncogenic transformation, growth, and metastasis.3-6 Inhibition of the Hsp90 protein 
folding machinery results in client protein ubiquitination and subsequent degradation by the 
proteasome, resulting in cell death.7-8 Hsp90-dependent clients are associated with 10 hallmarks 
of cancer, thus, Hsp90 inhibition provides a therapeutic opportunity to treat cancer via 
simultaneous disruption of multiple cellular pathways involved in cancer.9 While inhibition of 
Hsp90 is being pursued for the treatment cancer, the induction of Hsp levels has been proposed as 
a novel approach towards the treatment of diseases such as Parkinson’s, Alzheimer’s, 
Huntington’s, and those caused by the aggregation of prion-related proteins. 3, 10 Hsp90 inhibitors 
can also be used  as anti-infective agents due to the importance of Hsp90 in pathogenic growth. 11 
As a result, many Hsp90 inhibitors have undergone or are undergoing clinical evaluations.12-13 
There are four human isoforms of Hsp90; Hsp90α (inducible) and Hsp90β (constitutively 
expressed) are present in cytosol, whereas the endoplasmic reticulum (ER) residing glucose 
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regulated protein 94 (Grp94/gp96/endoplasmin) and mitochondrial isoform, tumor necrosis factor 
associated protein (Trap-1/Hsp75) are present in distinct organelles.14 
 
I.2 Hsp90 Structure 
 
Hsp90 exists as a homodimer and each monomer 
comprises three structural domains: a highly conserved 
25kDa N-terminal ATP-binding domain (NTD), a 35kDa 
flexible middle domain (MD), and a 12 kDa C-terminal 
dimerization domain (CTD) (Figure 1.1).3 Hsp90 is a 
member of the GHKL (Gyrase, Hsp90, Histidine Kinase and MutL) subgroup of ATPases, which 
contain a conserved Bergerat fold in the N-terminal ATP-binding site.15 ATP binds the NTD ATP-
binding site of the GHKL superfamily in a unique bent conformation, as opposed to an extended 
ATP conformation.16 The Bergerat fold present in the NTD comprises four β-sheets and three α-
helices with an ATP-binding pocket located in the middle.17-18 Additionally, in the NTD, 
conserved residues of the Bergerat fold form an “ATP lid” which closes upon ATP binding, but 
switches to the open conformation in the ADP bound state.14 The NTD is the major site of ATP 
hydrolysis in Hsp90 and represents the most druggable binding pocket in Hsp90, as all but one of 
the Hsp90 inhibitors in clinical trials target this binding site. The MD is connected to the NTD by 
a flexible and highly charged linker (CL) that is required for interactions with co-chaperones and 
client proteins (e.g. Aha1, CHIP).19 This domain also regulates ATP hydrolysis at the NTD via 
interactions with the γ-phosphate of ATP.20 
The CTD is responsible for the homodimerization in Hsp90,21 and contains an EEVD motif 
that recognizes the tetratricopeptide-containing repeat (TPR) domain found in various co-
 
Figure 1.1. The crystal structure 




chaperones and immunophillins. In eukaryotic Hsp90, opening of the CTD is anticorrelated to 
closing of the NTD.21 The CTD has an additional nucleotide-binding site that allosterically 
regulates NTD ATPase activity.22 Natural products such as Novobiocin and EGCG bind to the 
CTD  and modulate the Hsp90 protein folding process.23-25  
I.3 Hsp90 Chaperone Cycle   
Client protein maturation, refolding, and aggregation by Hsp90 are achieved via the formation of 
a heteroprotein complex. Although the Hsp90-mediated protein folding mechanism has not been 
completely elucidated, we now know that it involves various co-chaperones, immunophilins, and 
partner proteins.26 The chaperone cycle begins with the association of nascent polypeptides with 
molecular chaperones, Hsp70 and Hsp40 in conjunction with ATP (1) (Figure 1.2). Subsequently, 
bound ATP is hydrolyzed to ADP, which prevents the aggregation of polypeptides. The resulting 
complex is further stabilized by binding to Hsp70 interacting protein (HIP) (2). 27  Hsp90-Hsp70 
     
 
                                       Figure 1.2. The Hsp90-chaperone cycle 
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organizing protein (HOP), 
which contains a 
tetratricopeptide repeat 
(TPR) domain, recognized 
by both, Hsp90 and Hsp70, 
coordinates the transfer of 
the unfolded protein from 
Hsp70 to the Hsp90 (3).28 In 
the following step, 
immunophilins (FKBP51, 
FKBP52), co-chaperones 
and partner proteins bind the 
Hsp90 homodimer to form 
an activated multiprotein 
complex (4) with 
simultaneous release of 
Hsp70, Hip and HOP.28 ATP 
then binds to the open NTD 
and promotes formation of the closed conformation of Hsp90 (5) that clamps around the bound 
client protein.29  Small molecules compete with ATP for binding to the NTD, and subsequently 
prevent formation of the closed form (5) which leads to client protein degradation via the ubiquitin-
proteasome pathway.29 However, in the presence of ATP, the co-chaperone p23 is recruited to 
further stabilize the closed Hsp90 complex and subsequent ATP hydrolysis provides the energy 






Aha1 Stimulates ATPase activity 
Cdc37 Mediates activation of protein kinase substrates 
CHIP Involved in degradation of unfolded client proteins 
Cyclophilin-40 Peptidyl propyl isomerase 
FKBP51 and 
52 Peptidyl propyl isomerase 
Hop Mediates interaction between Hsp90 and Hsp70 
Hsp40 Stabilizes and delivers client proteins to Hsp90 complex 
Hsp70 Stabilizes and delivers client proteins to Hsp90 complex 
p23 Stabilizes closed, clamped substrate bound conformation 
HIP 
PP5 
Inhibits ATPase activity of Hsp70 
Protein phosphatase 5 
Sgt1 Client adaptor, involved in client recruitment 
Tom70 Facilitates translocation of pre-proteins into mitochondrial matrix 
WISp39 Regulates p21 stability 





and the heteroprotein complex disassembles. The Hsp90 chaperone cycle is regulated by a number 
of post-translational modifications, such as, acetylation, phosphorylation, S-nitrosylation, 
methylation and by co-chaperones that modulate affinity for client proteins, ATPase activity, and 
stability of the heteroprotein complex (Table 1.1). 27, 30, 31-33.  
       
I.4 Therapeutic Disruption of Hsp90 Chaperone Cycle 
Indirect disruption of Hsp90 client maturation via Hsp90 inhibition represents a unique therapeutic 
approach for the treatment of various diseases, as these client proteins carry out a wide range of 
cellular functions that are critical in multiple diseases. Rapidly growing cancer cells require 
oncoproteins at increased levels to sustain all 10 hallmarks of cancer, many of which are Hsp90-
dependent clients (Table 1.2).34 For example, Hsp90-dependent tyrosine kinases and steroid 
hormones receptors drive the progression of various cancers by amplifying growth signals.35 
Therefore, inhibition of Hsp90 provides an alternate approach to traditional chemotherapy for the 
treatment of cancer. Hsp90 inhibition provides combinatorial disruption of multiple client proteins, 
producing effects on multiple pathways simultaneously with a single agent. Figure 1.3 explains 
the mechanism by which client proteins are directed towards their degradation upon Hsp90 
inhibition. When inhibitors bind the Hsp90 multiprotein complex and prevent formation of the 
closed form needed for the maturation of client proteins, the complex is directed toward the 
 
                         Figure 1.3 Proposed mechanism of Hsp90 inhibition for cancer treatment. 
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ubiquitin-proteasome pathway, which leads to degradation of the clients. While reduced levels of 
Hsp90 via inhibition is desired for the treatment of cancer, induction of the pro-survival heat shock 
response leads to increased levels of various heat shock proteins and is beneficial for the treatment 
of neurodegenerative disorders that manifest their pathology through accumulation of misfolded 
proteins. An overall increase in Hsp’s leads to solubilization of neurotoxic protein aggregates.36 
Hence, drugs that induce Hsp90 at non-toxic levels can serve as valuable and novel treatment 
option for neurodegenerative disorders. In addition to cancer and neurodegeneration, inhibitors of 
Hsp90 are being sought for the treatment infectious diseases.37 
Due to an abundance of Hsp90 in cells, concerns have arisen regarding selectivity of Hsp90 
inhibitors against normal tissue. It was subsequently discovered that Hsp90 inhibitors accumulate 
predominantly in tumor cells rather than in normal cells, and thus result in a large therapeutic 
window.38-39 Kamal and co-workers proposed that the accumulation of Hsp90 inhibitors in tumor 
cells 
results from the activated Hsp90 heteroprotein complex that resides in cancer cells. During the 
 
Hallmarks of Cancer Hsp90 Client Protein(s) 
1. Self-sufficiency in growth signals Raf-1, AKT, Her2, MEK, Bcr-Abl 
2. Insensitivity to anti-growth 
signals 
Plk, Wee1, Myc1, CDK4, CDK6, Myt1 
3. Evasion of apoptosis RIP, AKT, p53, C-MET, Apaf-1, Survivin 
4. Limitless replicative potential Telomerase (h-Tert) 
5. Sustained angiogenesis FAK, AKT, Hif-1α, VEGFR, Flt-3 
6. Tissue invasion and Metastasis C-MET 
7. Deregulated cellular energetics ARNT, HIF-1α, HMG1, SREBF1 
8. Avoiding immune destruction IRAK3 
9. Tumor-promoting inflammation IL-6, IL-8, IRAK1, IRAK2, IRAK3 
10. Genome instability and mutation FANCA, MAFG, NEK8, NEK9, NEK11 




studies, it was shown that the heteroprotein complex manifests enhanced affinity for ATP or 
inhibitors, whereas in normal cells, Hsp90 exists as a homodimer that exhibits lower affinity for 
ligands.40 Clinical trials with the Hsp90 inhibitor, 17-AAG, have produced promising results in 
phase I and II studies in patients with HER2 over-expressing breast cancer, which, served as proof-
of-concept for Hsp90 inhibition.41 In addition, Hsp90 inhibitors have been investigated for the 
selective delivery of cytotoxic compounds to the cancer cells by taking advantage of the enhanced 
affinity of the heteroprotein complex in tumors.42  
I.5 Hsp90 Inhibitors 
The complexity of the Hsp90 chaperone cycle represents multiple opportunities to modulate 
Hsp90’s activity. Broadly, Hsp90 inhibitors can be divided into three classes based on their binding 
modes; (1) Hsp90 N-terminal inhibitors; (2) Hsp90 C-terminal inhibitors, and (3) disrupters of 
Hsp90/co-chaperone interactions.43 At present, only N-terminal inhibitors have undergone clinical 
evaluations as anti-cancer agents. Historically, N-terminal inhibition has been the most widely 
explored and sought-after approach, however, alternative modes of Hsp90 inhibition are emerging 
as promising strategies.44-47 
I.5.1 Natural products as Hsp90 N-terminal inhibitors  
The ansamycin antibiotic natural product, geldanamycin (GDA), was the first Hsp90 inhibitor 
identified (Figure 1.4), which was originally isolated from the fermentation broth of Streptomyces 
hygroscopicus in 1970.48 GDA was found to reverse the phenotype of v-src transformed cells, 
which led to hypothesis that GDA manifested its effect via functional inhibition of v-src.49 In an 
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effort to characterize the mechanism of action manifested by GDA, Whitesell and Neckers utilized 
an immobilized GDA derivative that affinity purified with Hsp90, establishing it as major 
biological target of GDA.22 Ultimately, GDA was co-crystallized with Hsp90, which revealed 
GDA to bind to N-terminal ATP-binding site. As evaluated in the co-crystal structures, GDA 
restrains Hsp90 in its closed form (5) (Figure 1.2), and disrupts the chaperone cycle.50-51 Although 
GDA exhibited promising anticancer activities against various cell lines in vitro, it failed as a 
clinical candidate due to its poor solubility, lack of in vivo stability, and hepatotoxicity.23 However, 
it has been useful as a chemical probe to elucidate Hsp90-dependent client proteins and to study 
the mechanism of Hsp90 during malignant transformation. Subsequent structure-activity 
relationship studies with semisynthetic derivatives led to the development of 17-(allylamino)-17-
demethoxygeldanamycin (17-AAG) and 17-(2-dimethylaminoethylamino)-17-
desmethoxygeldanamycin (17-DMAG), which manifested improved toxicity profile and led to the  
clinical investigation.41, 52 17-AAG is prone to cytochrome P450 3A4-mediated oxidation of the 
alpha methylene on the 17-amino substituent which results in subsequent hydrolysis of the C-N 
bond to produce the amino analogue, IPI-493. IPI-493 manifests growth inhibitory activity against 
breast cancer cells (SKBr3) at 33 nM, which is similar to that of 17- AAG.53 Infinity 
Pharmaceuticals developed another water soluble GDA analogue, IPI-504 after it was determined 




that the hydroquinone of IPI-504 was the active component and more water-soluble than the 
quinone. Subsequent studies with IPI-504 led to its clinical evaluation.54-55 Current efforts on GDA 
research has focused on reduction of the toxicities associated with the redox-active benzoquinone 
moiety, as well as the use of GDA analogues in combination with other therapies.  
Radicicol (RDC) is a macrocyclic 
lactone that was first isolated from the 
fungi, Monocillium nordinii and 
Monosporium bonorden, and 
identified as an antifungal agent in 
1953(Figure 1.5).56  RDC was believed to be a tyrosine kinase inhibitor, but later confirmed that 
it acts via Hsp90 inhibtion of the N-terminus (Kd= 14nM).57 RDC exhibits promising anticancer 
activity in vitro, but not in vivo, likely due to the α,β,γ,δ-unsaturated ketone and epoxide, which 
make it prone to rapid metabolism.58 Therefore, SAR studies have focused on the identification of 
analogues that elicit improved in vivo stability. Modifications such as the oxime in KF 25706, have 
led to the development of derivatives that manifest improved inhibitory activity in vitro as well as 
in tumor xenograft models.23 Furthermore, replacement of the labile allylic epoxide with a 
cyclopropyl ring (cycloproparadicicol, c-RDC) was shown to manifest similar activity as the 
natural product.59 Due to these detriments, RDC has  served only as a chemical probe to study 
Hsp90 biology. However, structural modifications to RDC have led to related small molecule 
inhibitors that incorporated the resorcinol pharmacophore.    
 
I.5.2 Small Molecule Inhibitors of the Hsp90 N-terminus. Limited availability, metabolic 
liabilities and structural complexity have driven the development of small molecule Hsp90 
 
Figure 1.5: Radicicol and its derivatives. 
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inhibitors that maintain the key interactions manifested by the natural products with the N-terminal 
ATP binding site. These compounds can be classified into three categories; 1) purine-, 2) 
resorcinol-, and 3) benzamide-derived. Initially, the endogenous ligand for the N-terminal binding 
site, ATP, served as a template for the design of small molecule inhibitors. In 2001, Chiosis and 
co-workers used X-ray 
crystallographic analysis and 
molecular modeling to design 
PU3, which contained a purine 
moiety linked to an aryl ring that 
mimicked the unique shape 
adopted by ATP when bound to 
the N-terminal binding pocket 
(Figure 1.6). PU3 was the first 
rationally designed Hsp90 
inhibitor that manifested low 
micromolar affinity (Kd = 15-20 μM) with moderate anti-proliferative activity (IC50 = 50 μM) 
against MCF-7 breast cancer cells.60 Optimization of PU3 led to the more potent compound, 
PU24FCl , which manifested improved anti-proliferative activity against breast, lung, colon, and 
prostate cancer cell lines, and induced the degradation of Hsp90-dependent client proteins 
including HER2, Akt, Raf-1 and mutant p53. Evaluation of PU24FCl in vivo revealed its tumor 
specificity over normal tissue.61-62 CNF2024/BIIB021 is an optimized and  purine-based inhibitor 
that contains a pyridylmethylene group that was disclosed in 2005 and represented the first purine-
based inhibitor to enter clinical trials (evaluated in Phase I trials for gastrointestinal stromal tumor 
 
 




and chronic lymphocytic leukemia).63-64   
Subsequent studies focused on improving the low bioavailability associated with the purine 
analogues and eventually led to the incorporation of an alkylamino group which manifested 
increased solubility (Figure 1.6, PU-H71).63 PU-H71 contained a 3-isopropylamino-propyl side 
chain that exhibited ~16 nM binding affinity for Hsp90 with an IC50 of ~50 nM in HER2 
degradation assays.65  This analog showed significant efficacy in vivo and advanced into clinical 
trials for the treatment of patients with low-grade non-Hodgkins lymphoma, as well as patients 
with advanced malignancies. Results from the clinical evaluations of PU-H71 are encouraging as 
tumor regression has been observed.66 MPC-3100 is another purine based compound developed 
by Myrexis Inc. that underwent Phase I trials for recurrent and refractory tumors along with a safe 
and tolerable dosing profile and manageable adverse effects.67 Unfortunately, further development 
of MPC-3100 has been halted due to poor solubility and formulation issues. To alleviate these 
concerns, pro-drugs were incorporated into the molecule and resulted in the identification of L-
alanine mesylate ester (Figure 1.6, MPC-0767), which exhibited improved pharmacokinetic (PK) 
and pharmacodynamic (PD) profiles.68 EC144 (Figure 1.6) is an alkyne-containing purine analog 
that is based on the BIIB021 structure, and exhibits improved in vitro (IC50=1.1 Vs 5.1 nM) and 
in vivo (~20-fold efficacy improvement in mice) activity when compared to BIIB021.69 BIIB028 
is a phosphate ester prodrug of the homopropargylic alcohol of EC144 sans the dimethyl group, 
which exhibits improved solubility and is currently under phase I clinical evaluation for patients 
with solid tumors.70  
 Since the resorcinol ring of Radicicol maintains key interactions with the Hsp90 N-
terminal binding pocket, it has served as a template for the development of inhibitors, many of 
which have entered clinical trials (Figure 1.7). NVP-AUY 922 (Luminespib) is an optimized hit 
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obtained from a high throughput screen (HTS) by Vernalis. After acquisition, Novartis advanced 
the compound into both Phase I and II clinical trials, as a single agent therapy and in combination 
with other drugs including a kinase inhibitor (Erlotinib) and/or a proteasome inhibitor 
(bortezomib).12, 71-73  However, a limited response was observed during these trials that 
discouraged further evaluation of NVPAUY922. Sigma-Tau Research has explored variants of 
NVPAUY922 via 
replacement of the isoxazole 
ring with a triazole.74 
SST0116CL1 represents a 
compound developed by 
Sigma Tau that contains an 
amide linker between the 
morpholine and isoxazole 
and maintains  binding 
affinity.75 STA9090 
(Ganetespib) is a potent 
Hsp90 inhibitor developed by Synta Pharmaceuticals. In the clinic, STA9090 was shown to be 
well tolerated and without the notable toxicities associated with the GDA analogs. STA9090 has 
shown promise as a single agent in trials for patients with non-small cell lung cancer (NSCLC) 
and HER2-positive metastatic breast cancer. In particular, it manifested single-agent activity 
against NSCLC, in patients with anaplastic lymphoma kinase (ALK)-positive disease. STA9090 
was the first rationally designed compound to progress into Phase III studies.  In combination with 
docetaxel during II GALAXY-1 studies, STA9090 improved patient outcomes in overall and 
     
       Figure 1.7: Resorcinol containing Hsp90 inhibitors 
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progression-free survival as comparison to docetaxel alone in patients with advanced lung 
adenocarcinoma.76 Based on encouraging data from the Phase II study, a subgroup of patients were 
chosen for a Phase III GALAXY-2 evaluations, unfortunately, the overall response rate of 
ganetespib and docetaxel was 13.7% as compared to 16% with docetaxel alone. Additionally, the 
disease stability was slightly higher in the combination arm (56%) as compared to the docetaxel 
arm (50%).77 Many Phase I/II, clinical trials are being conducted in combination with other agents 
that may potentiate the effects and range of STA9090 for the treatment of other cancers.24, 78-79  
KW-2478 was developed by Kyowa Hakko Kirin Pharma through a combinatorial of drug 
development strategies that included lead optimization, microbial screening, X-ray 
crystallography, cell-based assays and in vivo evaluations.80 Due to low nM binding affinity and 
anti-proliferative activity, KW-2478 was shown to be well tolerated in Phase I studies for  multiple 
myeloma, chronic lymphocytic leukemia and B-cell non-Hodgkin's lymphoma along with no dose-
limiting toxicity at doses up to 99 mg/m2.81 In combination with bortezomib, KW-2478 was well 
tolerated and produced an overall response rate of 39% during  Phase I/II studies that investigated 
relapsed/refractory multiple myeloma patients.82 Astex pharmaceuticals developed AT13387 
(Onalespib), a small molecule inhibitor that manifests subnanomolar Hsp90 binding affinity and 
low nanomolar cellular activity. AT13387 resulted from a unique fragment-based screening 
approach that utilized a combination of NMR and high throughput X-ray crystallography.83 This 
compound entered Phase I studies for investigation against solid tumors and advanced to Phase II 
studies for GIST (alone and in combination with imatinib),84 Phase II  for prostate cancer (alone 
or in combination with abiraterone), and PhaseI/II for NSCLC (alone or in combination with 
crizotinib).85 AT13387 has also shown promise against malignant gliomas (alone and in 
combination with temozolomide).86 AT13387 is one of the most recent compounds to enter clinical 
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evaluations and six studies are currently in the recruitment phase, which will further investigate 
the  Hsp90 inhibition as therapeutic target for various cancers. In contrast with other resorcinol-
containing inhibitors, NMS-E973 is phloroglucinol-derived compound, wherein the additional 
phenol has been substituted with a p-nitrophenyl ring.87 NMS-E973 can cross the blood brain 
barrier (BBB), and induce the tumor shrinkage of different human tumor xenografts with increased 
efficacy against tumors resistant to kinase inhibition. Furthermore, NMS-E973 was evaluated in 
an intracranially implanted melanoma model.88 Recent work on the resorcinol scaffold resulted in 
the development of CPUY201112, a tetrahydropyridopyrimidine-containing molecule that 
exhibits antiproliferative activity in a wild type p53 dependent cells, as well as efficacy against 
MCF-7 cells in xenograft models.89-90 Modifications to CPUY201112 led to compound 73, which 
exhibits improved pharmacokinetic properties and growth inhibitory efficacy against HCT116 and 
MCF-7 cells alongside reduced ocular toxicities as compared to NVPAUY922 in in vivo models.91  
XL888 and SNX5422 belong to the 
benzamide-containing class of Hsp90 inhibitors. 
XL888 is a tropane containing compound that 
resulted from HTS of ~4.1 million compounds 
from Exelixis.92 XL888 was found to reduce the 
proliferation of  vemurafenib resistant melanoma 
cell lines in 3D cell culture as well as mouse 
xenograft models.93 Clinical studies continue for XL888 in combination with vemurafenib and 
cobimetinib to treat unresectable BRAF mutated stage III/IV melanoma. Serenex discovered SNX 
2112 via an affinity-based chromatography screen for ligands that could displace Hsp90 proteins 
from a purine-based resin.94-95  SNX 5422 is a mesylate salt of the parent drug which provides 




improved solubility and oral administration. Due to concerns arising from ocular toxicities during 
clinical evaluations, subsequent studies with SNX 5422 as a clinical candidate were discontinued. 
Recently, this compound was acquired by Esanex, and is sponsoring a Phase I study for the 
treatment of neuroendocrine tumors in combination with everolimus. In addition, a recent patent 
disclosure by Esanex has proposed the use of SNX 5422 and related benzamide analogs for the 
treatment of HIV via the modulation of viral DNA integration into the host genome.96  
I.5.3 Induction of the Heat Shock Response (HSR) 
The progress of Hsp90 N-terminal inhibitors as clinical candidates has been fraught with many 
challenges. One of the major drawbacks is the induction of pro-survival heat-shock response 
(HSR),97-98 which leads to increased expression of various Hsp’s including Hsp90, Hsp70, Hsp27, 
and Hsp42. This pro-survival response is mediated by heat shock factor-1 (HSF-1), an Hsp90 
bound transcription factor that remains inactive in unstressed/normal cells due to its association 
with Hsp90.99-100 However, during cellular stress or the administration of an Hsp90 N-terminal 
inhibitor, HSF-1 is dissociated from Hsp90.101 When unbound to Hsp90, HSF-1 trimerizes in 
cytosol, becomes hyperphophorylated, and then translocates into the nucleus, wherein it 
upregulates the transcription of Hsp’s upon binding to heat shock element (Figure 1.9).102-103 Due 
to the increased levels of Hsp90 following the treatment with the inhibitor, subsequent dosing and 
scheduling issues emerge, which leads to the exacerbation of adverse effects and higher doses. As 
          





a result, alternative methods to modulate Hsp90 function have been sought, which led to C-
terminal inhibitors, HS90/co-chaperone disruptors, allosteric modulators and the development of 
isoform-selective Hsp90 inhibitor.6, 25 
I.5.4 Isoform-selective Hsp90 Inhibitors 
Hsp90 inhibitors undergoing clinical evaluation are known to target all four Hsp90 paralogs, which 
is termed as pan-inhibition.  Collectively, Hsp90’s are involved in the folding and maturation of 
over more than 300 client protein substrate.104 As a consequence of pan-inhibition, the endogenous 
functions of all Hsp90-dependent client proteins are affected, and collateral disruption of these 
clients is believed to result in adverse effects. Targeting a specific Hsp90 isoform may enable the 
treatment of diseases that are driven by an isoform-dependent client population without 
manifesting the undesired on target effects that are observed with pan-inhibitors. Toxicities 
observed with the pan-inhibitors include hepatotoxicity, ocular toxicity, hyponatremia, 
hypoglycemia, renal failure and induction of the heat shock response.4  
The rational design of isoform-selective Hsp90 inhibitors has been a challenging task, due 
to the highly conserved and structurally identical nature of the Hsp90 isoforms.  Overlay of the N-
terminal ATP-binding site residues of all four isoforms reveals >85% identity, whereas, within the 
cytosolic isoforms Hsp90D and Hsp90E, the sequence identity is >95%. 105  Grp94 shares the least 
homology between among the four isoforms, which results from a 5-amino acid insertion that 
causes a conformational change within the ATP-binding pocket and produces distinct subpockets 
that have been exploited for the development of Grp94-selective inhibitors.  
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I.5.4.1 Grp94-Selective Inhibitors  
N-ethyl-carboximido adenosine (NECA) (Figure 1.12), an agonist at the adenosine receptors was 
the first compound to exhibit selective inhibition of Grp94, as it was found to bind Grp94 with 200 
nM Kd, but not Hsp90.106 The co-crystal structure of NECA bound to the N-terminus of Grp94 
revealed the ethyl amide to project into a subpocket that does not exist in other isoforms (Figure 
1.10 and 1.11).107 Due to an unfavorable PK profile and its affinity for the adenosine A2 receptor, 
NECA does not represent a scaffold that is amenable to further development. The chimeric Hsp90 
inhibitor, Radamide (RDA), upon crystallization with Grp94 was found to project its quinone ring 
into the same subpocket as NECA. However, only the cis-amide conformation of the amide was 
able to project the quinone ring into this subpocket, as the trans-amide projected the quinone into 
solvent and negated Grp94-selectivity.108 In subsequent studies, the inclusion of an imidazole ring 
that served as a cis-amide isostere resulted in the first rationally designed Grp94-selective 
compound, BnIm.109 BnIm exhibited a Kd of ~1.1 PM and ~12-fold selectivity against Hsp90D. 
  
Figure 1.10: a) Structures of Grp94-selective compounds b) NECA bound crystal 
structure of Grp94, NECA atoms are depicted as spheres (PDB code:1yq5).  
18 
 
Optimization of BnIm has led to inhibitors that exhibit improved affinity and selectivity for Grp94 
(Kd ~200 nM and ~41-fold selectivity).110 Furthermore, replacement of the imidazole with a phenyl 
ring in BnIm led to improved potency and selectivity (Kd ~540 nM and ~73-fold selectivity).111 A 
screen of purine-based Hsp90 inhibitors resulted in the discovery of PU-WS13, a highly selective 
Grp94 inhibitor that bound  Grp94 in a previously unseen conformation.112  An overview of the 
N-terminal binding pocket of Grp94 is provided in Figure 1.11 with BnIm as a reference ligand. 
Interestingly, the thioether of the PU-WS13 was found to orient the 3, 5-dichlorophenyl moiety 
into Site 2, a pocket that was not observed in the NECA-Grp94 Complex. Occupation of this 
unique Grp94 subpocket provided PU-WS13 ~140-fold selectivity over Hsp90D The benzamide 
based compound, SNX 2112 (Figure 1.8) is distinct from other scaffolds, in that it binds Grp94 
with ~100-fold weaker affinity than it does to cytosolic 
Hsp90. Based on the molecular modeling studies, the 
structural features preventing SNX2112 binding to 
Grp94 were determined and then modified to reverse 
the selectivity of SNX2112 to develop a Grp94-
selective compound, ACO1. ACO1 manifested a Kd of 
~440nM and >200 fold selectivity against Hsp90D.113 
Functionally, Grp94 is responsible for the maturation 
of secreted client proteins such as, Toll-like receptors 
(1, 2, 4, and 9), IGF-I, IGF-II, integrins, and HER2. 
Therefore, Grp94-selective inhibitors are under investigation for the treatment of various diseases, 
 
Figure 1.11: Subpockets in Grp94 N-
terminal ATP-binding site 
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including liver cancer, multiple myeloma, rheumatoid arthritis and glaucoma.114-116 Selective 
inhibition of Grp94 does not induce Hsp90 nor Hsp70, and therefore represents a significant 
advantage over pan-inhibitors.  
I.5.4.2 Trap1-selective Inhibitors  
TNF receptor associated protein 1 (Trap1), the 
mitochondrial Hsp90 isoform is less 
investigated than other isoforms. Recent 
studies suggest that Trap-1 exhibits high 
similarity to both Grp94 and Hsp90. Like 
Grp94, Trap1 contains a 2-amino acid 
insertion (Ala191, Glu192) between helices 4 and 5 of the lid region, however, helix 4 of Trap1 is 
highly similar to that of Hsp90.117 Due to the lack of well-defined structural differences that could 
guide the rational design of selective Trap1 inhibitors, initial efforts to target Trap1 focused on 
organelle-specific drug delivery. As an example, triphenylphosphonium was conjugated to a 
purine based Hsp90 inhibitor, PU-H71, to produce SMTIN-P01. SMTIN-P01 (Figure 1.12) 
exhibited ~100-fold increased accumulation in the mitochondria and also induced mitochondrial 
membrane depolarization in Hela cells.118 In addition, SMTIN-P01 did not increase the levels of 
Hsp70, indicating a minimum effect on cytosolic chaperones.  The crystal structure of human 
Trap1 in complex with the pan-Hsp90 inhibitors, PU-H71 and BIIB-021, have been solved (PDB 
codes 4ZIF, 4Z1G),118 which has shed light onto the structural disorder of the lid in Trap1 upon 
occupation by a ligand. To exploit the difference in the Trap1 lid rearrangement, BIIB021 was 
modified to contain a pyrazolopyrimidine ring that produced a ~9-fold Trap1-selective compound, 
DN401 (Kd for Trap1= 79 nM). This compound manifests efficacy against multiple cancer cell 




lines and was evaluated in a PC3 xenograft model.119 Due to high similarity with other isoforms, 
selectivity of ligand binding will depend upon an increased understanding of Trap1 binding site 
and conformational changes within.  
I.5.4.3 Hsp90 DE-selective dual inhibitors. 
The benzamide series of Hsp90 
inhibitors have shown an inherent 
selectivity for the cytosolic isoforms, 
Hsp90D/Eversus Grp94 and Trap1. 
This is exemplified by, SNX 2112, 
which shows >100-fold decreased 
affinity for both Grp94 and Trap1. Two 
key differences between the cytosolic 
Hsp90’s and Grp94/Trap1 is closure of 
the lid upon ligand binding, 113 as well 
as presence of Ile247 in Grp94 (PDB 
code: 4NH9) and Ile253 in Trap1(PDB code: 4Z1F) which serve in lieu of Val186 in both DE 
(Hsp90D PDB code: 2XAB, Hsp90E PDB code: 1UYM), that present a steric clash with the 
benzamide compounds (Figure 1.13). Increased selectivity for the cytosolic isoforms was achieved 
with SNX0723 by incorporation of a fluorine atom onto the benzamide ring and exacerbating a 
steric clash with Trap1, which led to enhanced selectivity over Trap1 (~400 fold). TAS-116 is 
another benzamide containing compound that manifested DE-selectivity. Interestingly, TAS-116 
manifests potent activity against NCI-H1975 non-small cell lung carcinoma tumors, with minimal 
accumulation in retinal tissue as compared to NVPAUY922. The difference in distribution of 
 
Figure 1.13: Hsp90 DE-selective compounds. 
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TAS116 has been hypothesized to produce minimal ocular toxicity.120 In 2014, a cyclic benzamide 
series was prepared resulting in compound 31 (Figure 1.13), which exhibited >1000 fold selectivity 
against Grp94 and Trap1 while binding to Hsp90DEwith ~5 nM Kd.121 Compound 31 was found 
to be equipotent to pan-HSP90 inhibitors in its ability to promote the clearance of mutant 
huntingtin protein (mHtt) in vitro, while exhibiting an improved tolerability profile.121 
Furthermore, EC144 (Figure 1.6), a purine based compound, manifests 300- and 1200-fold weaker 
binding affinity to Grp94 and Trap1, respectively, presumably, due to unfavorable interactions 
between the lid region and the substituted pyridine ring (Figure 1.6).69  
I.5.4.4 Hsp90D-selective compounds 
The inducible isoform Hsp90Dand the constitutively expressed isoform,+sp90Eboth reside in 
the cytosol and share the highest identity among the four isoforms, consequently, >95% amino 
acids within the N-terminal ATP binding site are identical. In fact, only two amino acids differ 
within NTD between Hsp90Dand+sp90ESer52/Ala52 and Ile91/Leu91 differ between 
Hsp90DEHsp90D PDB 
code: 2XAB, Hsp90E PDB 
code: 1UYM). Therefore, 
the rational design of 
Hsp90Dor Eselective 
compounds has been a daunting task. Not surprisingly, little progress has been made toward the 
development of Hsp90D-selective compounds. However, researchers have  serendipitously 
discovered compounds that exhibit Hsp90D selectivity, which include PU-11trans and PU-29F 
(Figure 1.14), both of which bind Hsp90D with Kd of ~5 and ~18 PM, respectively  and exhibit ~4 
  




fold selectivity versus Hsp90E.112 In a separate study, resorcinol-based compound 14a, was found 
to manifest ~9 fold selectivity for Hsp90D over Hsp90E  
 I.5.4.5 Hsp90E-selective compounds 
As discussed previously, both cytosolic isoforms are highly identical. 
Therefore, discovery efforts for Hsp90E-selective inhibitors, much 
like Hsp90D have been discouraging. Overlay studies performed 
with the Hsp90 isoforms suggest that Hsp90E ATP binding site is 
slightly more hydrophobic than Hsp90D.112 However, in a ground-
breaking study, Khandelwal and coworkers discovered the first 
rationally designed Hsp90E-selective compound, KUNB31. With the 
aid of modeling studies and a series of modifications  to the resorcinylic scaffold, an isoxazole ring 
was incorporated into the clinical candidate AT13387 (Figure 1.7) to yield KUNB31, which binds 
selectively to Hsp90E N-terminal binding site with ~180 nM Kd and ~45-fold selectivity versus 
Hsp90D.123 KUNB31 showed degradation of Hsp90E-dependent client proteins such as c-IAP1, 
CXCR4, and CDK6 with minimum induction of Hsp70 and Hsp90, alluding to Hsp90E-selective 
inhibition as a safer alternative to pan-Hsp90 inhibition.123  
I.6 Conclusions and Future Directions 
The excitement surrounding the discovery of Hsp90 as the master regulator of >300 client proteins 
responsible for disease progression has led to extensive efforts toward the discovery of Hsp90 
inhibitors. As a consequence, more than 17 clinical candidates entered trials, but the enthusiasm 
soon passed after a series of disappointments resulting from clinical trials were reported. The 
failures of these initial inhibitors, which were mostly natural product derived, were attributed to 







pharmacophoric dissection of the natural products led to the second-generation inhibitors with 
smaller molecular structures. The wave of second-generation inhibitors that entered clinical trials 
included PU-H71, NVPAUY922, STA9090, SNX5422, and AT13387, which also suffered some 
setbacks. However, AT13387 has shown promise. Despite their high affinities, two major concerns 
plaguing current Hsp90 inhibitors in clinical trials are toxicities (ocular-, cardio-, hepato-toxicities) 
and the induction of heat shock response, these concerns have resulted in the termination of many 
trials, suggesting a need for alternate strategies to Hsp90 inhibition. Adverse reactions or lack of 
efficacy may be attributed to indiscriminate inhibition of all Hsp90 isoforms that results in reduced 
accumulation of the drug at the site of action. During the early stages of Hsp90 inhibitor 
development, rational design of isoform selective inhibitors was considered a tedious task. 
However, discovery of Grp94-selective inhibitor proved that the achievement of selectivity was 
within reach with the aid of rational design to modulate ligand binding and exploit conformational 
flexibility of Hsp90 binding sites. The cytosolic isoforms Hsp90D and E offer very little binding 
site differences in contrast to Grp94, which exhibits significant conformational changes. As a 
result, various scaffolds such as BnIm, PU-WS13 and ACO1 have been developed for Grp94- 
selective inhibition. Grp94 inhibitors have shown promise in the treatment of disease such as 
cancers, glaucoma, and current research is ongoing to improve potency and PK properties such 
that these inhibitors can be translated into successful therapies. Trap1 has remained a relatively 
unexplored isoform, however, recent studies have revealed peculiarities about its ligand bound 
conformation which have been exploited to discover compound such as DN401. Despite structural 
homology amongst Hsp90D and Hsp90E, the minimal differences in the binding site have been 
carefully exploited to discriminate binding of ligand. A remarkable example being KUNB31, that 
has uncovered that Hsp90E-selective inhibition can be a viable approach to develop agent with 
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reduced heat shock response induction, leading to potentially safer Hsp90 inhibitors. 
Comparatively, Hsp90Dpresents greater challenges towards the design of isoform selective 
inhibitor as it lacks spatial subpockets that can be occupied by the ligand. However, selectivity has 
been observed with compounds such as PU-29F and compound 14a, that bind to the N-terminal of 
Hsp90D with slightly higher affinities versus Hsp90E. The design of the Hsp90D-selective 
inhibitors with high potency and selectivity is still an unexplored avenue and future designs may 
take advantage of the thermodynamic differences in binding of ligand between the isoforms. With 
the rapid advancement of structural and biological understanding of Hsp90 and its isoforms, the 
future of Hsp90 inhibitors appears hopeful for the treatment of not only cancer but a range of 
diseases with lesser adverse effects and safer therapeutic dosing profile.  
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                                                           Chapter II 
               Development of a Novel Series of Compounds for Hsp90E-Selective Inhibition 
Hsp90 inhibitors evaluated in clinical investigations bind to the N-terminal nucleotide-
binding pocket and manifest pan-inhibition of all four Hsp90 isoforms; Hsp90D (cytosolic and 
inducible), Hsp90E (cytosolic and constitutively expressed), Grp94 (endoplasmic reticulum 
residing) and TRAP1 (mitochondrial).1-2 Pan-inhibition leads to non-specific functional disruption 
of the entire Hsp90 client population (>300 substrates), which may not be desired for the treatment 
cancer and/or other diseases. Some cancers, depending on their nature of origin or stage of 
progression, express varying needs for certain oncogenic pathways. In such cases, the disruption 
of only the upregulated sub-population of Hsp90 clients is desired, thereby, sparing the remaining 
substrates and minimizing undesired and on-target effects. For this purpose, Hsp90 isoform-
selective inhibition has emerged as a promising and new approach to target the diseases regulated 
by both clients and co-chaperones that exhibit Hsp90 isoform-dependency.3-10   
II.1 Hsp90Eand Cancer 
The cytosolic isoforms, Hsp90D and Hsp90E, are responsible for the proper folding of many 
oncogenic proteins that are critical for cancer sustenance.11 Hsp90Erepresents the constitutively 




Until recently, it was believed that the cytosolic isoforms share overlapping chaperone function 
for the majority of clients, and that each isoform could compensate for the loss of other. However, 
recent studies have identified clients that exhibit isoform-dependency. For example, survivin, c-
Raf , and the hERG channel depend solely on Hsp90D, whereas, c-IAP1, CDK6 and CXCR4 rely 
upon Hsp90Efor their matuaration.10, 12-13 The Hsp90E-isoform has been shown to play a key role 
in early embryonic development, germ cell maturation, cytoskeleton stabilization, cellular 
transformation, and long term cellular adaptation.14-19 In contrast, Hsp90Dis required for the 
promotion of growth, cell cycle regulation, and stress-induced cytoprotection.20-21 Along with 
client proteins, co-chaperones also interact differently with each cytosolic isoform. For example, 
co-chaperone FKBP8 and GCUNC45 have been found to interact preferentially with  Hsp90E.22-
23 Furthermore, Hsp90E interacts with P-glycoproteins, therefore, its expression is associated with 
drug-resistance.24 Isoform specific phosphorylation of  Hsp90E has been found to be important for 
activation of the glucocorticoid receptor.25 Hsp90E also associates with focal adhesion kinase 
(FAK), and promotes the migration and invasion of breast cancer cells.26  In addition, 
Hsp90Eforms a complex with Bcl-2 and facilitates the survival of laryngeal carcinoma.27 
Recently, Hsp90E was shown to promote angiogenesis in hepatocellular carcinoma via increased 
expression of vascular endothelial growth factor receptors (VEGFRs).28 Extracellular functions of 




extracellular Hsp90E can also exist and negatively regulate latent TGF-E activation in MG63 
osteosarcoma cells, which inhibits proliferation. In contrast, Hsp90β and TGF-β1 act 
synergistically to stimulate the migratory aptitude of colon cancer cells, in response to activation 
of αvβ6 integrin as opposed to the canonical TGF-β1 pathway.29 Interestingly, extracellular 
Hsp90E associates with matrix metalloproteinase-3 (MMP-3) to facilitate breast cancer invasion.30  
Recently, Neckers and co-workers developed conformational mutants of Hsp90 to discriminate 
binding affinities of clients and inhibitors. Their study concluded that Hsp90D binds to clients with 
a greater affinity relative to Hsp90E, whereas, small molecule inhibitors, such as ganetespib, bind 
Hsp90E with slightly greater affinity than Hsp90D.9 The presence of Hsp90E in serum and 
bronchoalveolar lavage fluid has been proposed to represent a biomarker for lung cancer.31-32 
These studies establish that clients depend upon both cytosolic isoforms despite the high degree 
of functional and structural overlap, supporting the hypothesis that isoform-selective inhibition 
represents an innovative approach to improve upon the therapeutic potential of Hsp90 inhibitors. 
Hsp90E-selective inhibition may avoid some of the detriments associated with pan-inhibitors. For 
example, Hsp90E-selective inhibition may avoid disruption and maturation of the hERG channel, 
which is critical for normal cardiac rhythm, thus, reducing cardiotoxicity. In addition, Hsp90E-
specific inhibitors can serve as a chemical probe to identify additional clients that may be 




Collectively, these studies establish Hsp90Etocontribute to disease pathology and that Hsp90E-
selective inhibition represents a promising and new therapeutic alternative to pan Hsp90 inhibition. 
II.2 Overlay Studies with the Hsp90 Isoform N-Terminal ATP-Binding Sites. 
Sequence alignment of the four Hsp90 isoforms was performed, which despite high similarity and 
identity, revealed structural differences that could be used to guide the design of isoform selective 
inhibitors (Figure 2.1). The differences in the primary sequences between these isoforms were 
correlated with a change in the overall three-dimensional structure of the binding pockets.  Due to 
a 5-amino acid insertion in the primary sequence, Grp94 exhibits a structural change that is most 
significant as compared to the other isoforms. In fact, a new binding pocket in Grp94 was observed 
and has been exploited for the development of Grp94-selective inhibitors.33-35 In contrast, Trap-1 









Figure 2.1: Sequence alignment of Hsp90 isoforms. Key residues comprising N-terminal 
binding pocket are highlighted in yellow. Residues in blue boxes indicate the amino acid 




resembles the cytosolic Hsp90s as well as Grp94.36 The cytosolic Hsp90 isoforms, D and E exhibit 
the highest homology (>95% identical within the N-terminal ATP-binding site), suggesting that 
the design of selective inhibitors for Hsp90D and Hsp90E would be a challenge. In the N-terminal 
ATP-binding site, Hsp90D and Hsp90E vary only by two amino acids, i.e. Hsp90β contains Ala52 
 
Figure 2.2: Modeling of Radicicol into the N-terminal ATP binding site of Hsp90 isoforms: i) 
Hsp90D (PDB code: 2XAB) ii) Hsp90E(PDB code: 1UYM) iii) Grp94 (PDB code: 4NH9) 
iv) Trap-1 (PDB code: 4Z1F) isoforms. Water molecules are depicted as red spheres and 
hydrogen bonds are represented as yellow dashed lines. Radicicol is depicted as green colored 




and Leu91, in lieu of Ser52 and Ile91, which are present in Hsp90α (Figure 2.1). For comparison, 
radicicol, a resorcinol containing natural product and Hsp90 pan-inhibitor was modeled into the 
N-terminal ATP-binding pocket of each isoform.  
As shown in Figure 2.2, a network of water mediated hydrogen bonds are present in the 
adenine-binding region of the ATP-binding pocket that surrounds the resorcinol of radicicol. The 
carbonyl and 2-phenol of radicicol interact with Thr184 and Asp93 via hydrogen bonds (Figure 
2.2i) through conserved water molecules labeled as 1’and 2’ (Figure 2.2i). Residues Leu48, Lys58, 
Asp93, Ile96, Gly97, Met98, Leu107, Thr109, Phe138, Tyr139, Trp162, and Thr184 (numbered 
for Hsp90E) represent the amino acids that comprise the N-terminal ATP-binding pocket that are 
conserved amongst the four isoforms. The Grp94 and Trap1 binding pockets contain Val147 and 
Ile156 in place of Leu91, whereas, Val186 in Hsp90D is replaced with Ile247 in Grp94 and Ile253 
in Trap-1. Therefore, Grp94 and Trap-1 may produce a steric clash between ligand and Ile247 and 








II.3 Modeling of the Resorcinol-based 
Hsp90E-selective Inhibitor, KUNB31.  
Recently, our lab developed the first 
Hsp90E-selective inhibitors via a 
structure-based approach. For this 
purpose, a resorcinol containing 
compound, 2.1, a simplified version of 
AT13387 developed by Astex 
Therapeutics, was chosen as a starting 
point due to its simplistic preparation and high affinity. Our model was developed using the co-
crystal structures of Hsp90D bound to 2.1 (PDB code:2XAB) and Hsp90E (bound to purine-based 
ligand, PDB code: 1UYM) to study the structural differences between these isoforms. It was 
observed that Leu91 and Ala52 in Hsp90E leads to an extended hydrophobic subpocket in lieu of 
a smaller and polar subpocket that’s present in Hsp90DFigure 2.3). As discussed previously, the 
subpocket of each isoform is occupied by two water molecules that serve to coordinate a hydrogen 
bonding network and are present in most Hsp90 crystal structures. Careful modification to the 3-
and 4-position of compound 2.1 led to KUNB31, an isoxazole containing compound that occupies 
the Hsp90E extended subpocket by displacing the two conserved water molecules. Co-
D E
Figure 2.3: Modeling of 2.1 into the Hsp90D 
(PDB:2XAB) and Hsp90EPDB:1UYM. 




crystallization of KUNB31 with 
Hsp90E revealed that the isoxazole 
ring occupied the Hsp90E 
subpocket as hypothesized, leading 
to selectivity against Hsp90D and 
Grp94 (Grp94 presents a steric clash 
with isoxazole and Ile 247). 
However, the size of the Hsp90E hydrophobic subpocket was smaller as compared to the purine 
co-crystal (PDB:1UYM), as the Leu91 rotamer was pointing toward the Asp93, whereas in the 
purine bound Hsp90E crystal structure, Leu91 rotates away from Asp93, creating a larger and more 
flexible pocket (Figure 2.3 and 2.4). Therefore, new scaffolds were designed that could induce 
opening of this Hsp90E-specific hydrophobic subpocket.   
II.4 Design of a 
Benzamide Based 
Hsp90E-selective 
Inhibitor.                    
 SNX 2112, a 
unique benzamide 
 
Figure 2.4: Apparent Kds of KUNB31 and its binding 










containing Hsp90 inhibitor developed by Serenex Inc., exhibits a binding profile to Hsp90 
isoforms that differs from the resorcinol and purine containing compounds, as it binds equipotently 
to Hsp90D and Hsp90E, but manifests >100-fold reduced affinity for both Grp94 and Trap-1 
(Figure 2.5).11 SNX 0723 is a variant of SNX 2112, which contains of a fluorine atom ortho to the 
amide group.11  By taking advantage of prior binding studies with SNX 0723 that suggested 
additional space about benzamide, Vertex pharmaceuticals developed a ring constrained 
benzamide analog, Compound 31, as a Hsp90DE-selective compound that exhibited no affinity 
for Grp94 and Trap1. Additionally, the co-crystal structure of Compound 31 bound to Hsp90D 
was obtained and revealed the presence of a bulky group such as a cyclopentyl ring facing the 
solvent phase could reduce the dielectric 
constant within the binding pocket and 
improve potency. During our modeling 
studies, the co-crystal structure of  31 (PDB 
code: 4O0B) with Hsp90D was overlaid with 
the Hsp90E co-crystal structure (PDB code: 
1UYM). These studies   suggested that 31 does not interfere with the conserved water molecules 
that are present in the Hsp90DE subpockets (depicted as red spheres in Figure 2.6, labeled as 1’ 
and 2’ in Figure 2.2i). Prior Studies that include the development of KUNB31 suggest that these 
 
Figure 2.6: Compound 31 modeled into the N-
terminal ATP-binding pocket of Hsp90D 




conserved water molecules can be displaced, without a significant loss in affinity.37 Compound 
31 contains ring-constrained benzamide group, which appears to lock the amide group into a 
conformation that is favored for interacting with Asp93 and appears to represent a key interaction 
between the ligand and the 
Hsp90 ATP-binding pocket.38 
As observed in KUNB31, 
Hsp90E-selective inhibitors 
require modification of the 4-
phenol (Figure 2.2 and 2.4). However, modeling studies performed with 31 suggest that 
modification to the 2’-position (Figure 2.6) with substituents could displace the conserved water 
molecules and extend into the Hsp90E subpocket; leading to Hsp90E-selective inhibitors. 
II.4.1 Proposal of the Isoquinolin-1(2H)-one Based Hsp90E-Selective Series 
The cyclopentyl group was replaced with a trans-4-cylcohexanolamine in order to simplify 31. 
The tetrahydroindazolone fragment was incorporated in lieu of the pyrazolone present in 31, as it 
does not affect affinity for Hsp90. Incorporation of unsaturated alkene was used to rapidly explore 
the special constrains of the Hsp90E-subpocket, as modeling supported that its introduction would 
maintain the benzamide interactions with Asp93 and Thr184 (Figure 2.2 and 2.6). Orientation of 
the 2’-position was hypothesized to project substituents into the Hsp90E subpocket as depicted in 
 
Figure 2.7: Overlay of proposed unsaturated compound 




Figure 2.7. After taking the hydrophobic nature of the Hsp90E subpocket into consideration, linear 
aliphatic chains were attached to the 2’-position to develop the initial analogs. Additionally, 
methoxy and methylene alcohol groups were incorporated at the 2’-position to investigate potential 
interactions with Leu-48 (in both D and E) and Ser-52 in Hsp90D and to determine whether there 
was an effect on selectivity and/or potency.  
II.4.2 Synthesis of the Isoquinolin-1(2H)-one Series.  
Synthesis commenced via installation of the saturated indazolone ring in intermediate 2 (Scheme 
2.2). For this purpose, 2,4,6-
trifluorobenzonitrile, 1, was treated with 
hydrazine hydrate and 2-acetyl 
dimedone.39 This reaction mixture 
resulted in the formation of the 
indazolone substituted intermediate, 2. 
Upon purification, 2 was reacted with the 
E-ketoester that contains the desired R-
group in the presence of potassium 
carbonate to yield the corresponding E-





intermediate. The resulting amide was used as a crude mixture in the subsequent condensation and 
cyclization reaction to yield intermediates 3a-i. In the final SNAr reaction, the trans-4-
aminocyclohexanol was installed in the presence of DIPEA to furnish the final products, 4a-i. 
Additionally, the demethylated version of compound 4i was prepared via the treatment of 3i with 
boron tribromide and subsequent installation of the amine to yield 4j (Scheme 2.2). Intermediate 
3j provided access to the alkyne via oxidation with manganese oxide to produce the corresponding 
aldehyde 3k, which 
upon treatment with 
the Bestmann-Ohira 
reagent and in the 
presence of 
potassium carbonate yielded the alkyne, 3l. 3l was then reacted with the trans-4-








II.4.3 Determination of Binding Affinities for 4a-j using a Fluorescence Polarization Assay. 
Once prepared, the compounds were evaluated for their binding affinities against the cytosolic 
isoforms, Hsp90D and Hsp90E, by measuring their ability to competitively displace FITC 
conjugated GDA in a fluorescence polarization assay. The first compound in the series, 4a, 
contained a methyl group at the 2’-carbon and exhibited a 3-fold selectivity for Hsp90E, 
establishing that further modification could validate the proposed hypothesis. Homologation to an 
ethyl resulted in 4b, which exhibited enhanced affinity for both Hsp90E and Hsp90D and results 
from occupation of the subpockets found in both isoforms. To further probe the subpockets, an 
isopropyl group was installed onto 4c, which maintained the affinity and selectivity manifested by 
4b, establishing that a branched chain can also be accommodated within the subpockets. Moreover, 
increasing the chain length to propyl, led to an improvement in both affinity and selectivity, as 4d 
manifested ~40nM Kd for Hsp90E and ~21-fold selectivity over Hsp90D. Additionally, 4d 
exhibited lower binding affinities towards Trap-1 and Grp94 (>5PM for both                                      
isoforms). Encouraged with the results obtained from compound 4d, a butyl chain was 
incorporated to probe the depth of the Hsp90E subpocket. As hypothesized, the compound 




but ~4-fold loss in affinity was observed. Recalling that the isopropyl group was accommodated 
       
Compound R group Hsp90D Kd (PM) Hsp90E Kd (PM) 
4a Methyl 0.294+0.023 0.101+0.003 
4b Ethyl 0.180+0.036 0.068+0.008 
4c Isopropyl 0.173+0.036 0.051+0.008 
4d n-Propyl 0.886+0.040 0.040+0.003 
4e n-Butyl >50 0.156+0.018 




4h Cyclopropyl 1.88+0.28 0.946+0.038 
4i -CH2OCH3 0.306+0.023 0.159+0.003 
4j -CH2OH 0.824+0.104 0.233+0.018 





in both Hsp90D and Hsp90E, a t-butyl 
group was incorporated as demonstrated 
by 4f to determine whether the pockets 
could expand and accommodate 
spherical bulk. Not surprisingly, 4f did 
not bind either isoform, which was 
consistent with the modeling study and 
suggested a steric clash between the t-
butyl group and the protein surface. Compound 4g was then synthesized to contain an isobutyl 
group, which maintained selectivity, but lost affinity. A cyclopropyl group was evaluated in 4h to 
determine whether such geometry would have any effect on ligand binding to either isoform. 
Unfortunately, loss of potency was observed with 4h when compared to 4c. Compounds 4i and 4j 
were synthesized to determine whether the methoxy or the corresponding alcohol could affect 
affinity or selectivity via interactions with Ser52 in Hsp90D or Leu48 in both Hsp90DE. 
Surprisingly, these compounds still displayed a slight preference for Hsp90E binding, despite the 
presence of polar appendages, which may be attributed to the methoxy and the methylene alcohol 
being accommodated in the slightly larger Hsp90E subpocket. An acetylene group was 
incorporated as shown with 4k to probe whether a linear projection into the Hsp90E subpocket 
 
Figure 2.8: Compound 4d modeled in Hsp90D 





could impact selectivity. Disappointingly, the acetylene group occupies both Hsp90 isoform 
subpockets without discrimination, resulting in a loss of selectivity. 
II.4.4 Replacement of the trans-4-aminocyclohexanol in 4d.  
Compound 4d established that a propyl 
chain at the 2’-position produced good 
affinity and moderate selectivity for 
Hsp90E. Further modeling performed on 4d 
suggested that modifications of the trans-4-
aminocyclohexanol could also lead to a 
change in conformation within the binding 
site (Figure 2.9), which might result in 
increased potency and selectivity. Structure-
activity relationship studies with 31 (Figure 
2.6) and analogs established that the trans-4-aminocyclohexanol could be replaced with spherical 
and aliphatic bulk, such as t-butyl or cyclopentane. Replacement of the amine with an aliphatic 
group does not affect selectivity for the compounds against Hsp90D or Hsp90E (Figure 2.6).40 The 
conformational change that appears to result from introduction of the tertiary amine is depicted in 
Figure 2.9. The proposed binding modes of both 4d and the morpholine containing analog 5a, are 
 
Figure 2.9: Overlay of the proposed binding 







presented and reflect a slight variation in binding of the isoquinolin-1(2H)-one ring, which may 
result from a clash between the morpholine ring and the protein surface. The change in 
conformation was hypothesized to produce an increase in selectivity and potentially, affinity for 
Hsp90E. Another reason for seeking replacements of the trans-4-aminocyclohexanol to disrupt 
planarity of the benzamide ring, in particular between the amine and carbonyl groups (4d, Figure 
2.9), which may decrease 
solubility. For this purpose, 
amine replacements were 
investigated that included various 
functional groups, such as 
ionizable tertiary amines to 
improve solubility.41  
Compounds 5a-g were prepared 





II.4.5 Evaluation of Binding 
Affinities for 5a-g.  
Upon their preparation, 
compounds 5a-g were evaluated 
for their binding affinity against 
the cytosolic Hsp90 isoforms 
(Figure 2.10). The binding profile 
of the morpholine-containing 
compound, 5a, was consistent 
with the proposed hypothesis and 
exhibited excellent selectivity for 
Hsp90E with a Kd of ~121 nM. 
The binding profile for 5a 
mirrored 4e, which contains a n-butyl group at the 2’-position. This data informed us that with 5a, 
the propyl chain aligns in Hsp90E in a manner similar to the butyl chain in 4e, and thus affects 
selectivity. Compound 5b, which contains a hydroxyl moiety, was hypothesized to interact with 





Compound Hsp90D Kd (PM) Hsp90E Kd (PM) 
5a >50 0.121+0.017 
5b 38.00+1.10 0.091+0.010 
5c 8.52+0.24 0.426+0.053 
5d >50 4.47+0.278 
5e >50 0.463+0.031 
5f 17.083+0.66 0.513+0.067 






In fact, 5b was found to exhibit ~91 nM Kd for Hsp90E with >400-fold selectivity over Hsp90D, 
supporting our hypothetical model for binding.  
Incorporation of N-methyl piperazine into compound 5c, led to a decrease in affinity and 
selectivity when compared to 5a and 5b, which might result from unfavorable interactions of the 
tertiary amine with the Lys-58 that is present in both isoforms. A decrease in binding affinity for 
compound 5d, could result from similar disfavored interactions. Furthermore, a t-
butyloxycarbonyl (Boc) protected piperazine containing compound (5e) was also evaluated to 
determine whether incorporation of an acceptor group could be beneficial. Upon evaluation, it 
exhibited a binding affinity comparable to that of the N-methyl piperazine compound, 5c, however, 
it manifested greater selectivity over Hsp90D. 1-Methylpiperidin-4-amine was installed to produce 
5f and to investigate whether the tertiary amine could replace the trans-4-aminocyclohexanol, 
while increasing solubility.  Unfortunately, a loss in affinity was observed with 5f, while selectivity 
for Hsp90E was found to be similar to 4d. An open chain amine was also installed as shown with 
5g, it too exhibited a loss in affinity. Both 5f and 5g were found to be more soluble than 4d.  
II.5 Cellular Studies 
II.5.1 Determination of Growth-Inhibitory Effects on Cancer Cells.                                                                                 
Due to its high binding affinity, compound 4d was evaluated for its growth inhibition activity 








          






growth inhibition across various cancer types. Exciting and unusual results from the single dose 
screening of 4d led to further investigations via the NCI to determine the GI50 values against the 
cell lines represented in the NCI-60 cell panel (Figure 2.12 and 2.13).        
Interestingly, 4d exhibited GI50’s below 100 nM for many cancer types, including, leukemia, 
colon, breast and renal cancer cells. Amongst the colon cancer cell lines, HT29 cells were found 
to be most sensitive to 4d, which manifested GI50 of 26 nM, the other colon cancer cells also 
exhibited strong growth inhibition with GI50’s ranging 56-80 nM. Two prostate cancer cell lines 
were also found to be sensitive to 4d, with a GI50 value of ~0.5 PM for PC3 and ~47 nM for DU-
145 cells. Among the breast cancer cell lines evaluated, MCF7, BT549, T-47D and MDA MB 468 
exhibited the greatest growth inhibition. The K562 and SR cell lines were the most sensitive among 
leukemia cell lines.  The NCI-60 cell panel assay established that 4d, a 21-fold Hsp90E-selective 
inhibitor, exhibited GI values comparable to clinically evaluated Hsp90 pan-inhibitors, 
validating Hsp90E-selective inhibition as a viable approach for the treatment of cancer. 42-43 
II.5.2 Determination of the Growth-
Inhibition and Client Protein Degradation in 
Urological Cancer Cells. In collaboration with Dr. 
Jeffery Holzbeierlein at The Univerisity of Kansas 
Medical Center, compound 4d was evaluated for 
  
Table 2.2: GI50 values of 4d against 
urological cancer cells. 
Cell Line GI50 
(Moles)
Bladder Cancer UM-UC3 5.084e-007
T24 1.969e-007







growth inhibition against urological cancers, 
such as bladder and prostate cancer cells not 
represented in the NCI-60 cell panel. As noted 
in Table 2.2, 4d exhibits GI50 values of ~508 
nM and ~196 nM against UM-UC-3 and T24 
bladder cancer cells, respectively, whereas, the 
efficacy of 4d against evaluated prostate cancer 
cells ranged between 1-2.5 PM (Table 2.2).  
 Since Hsp90 inhibition induces the 
degradation of Hsp90-dependent substrates via 
the ubiquitin-proteosome pathway, the levels of both kinase and non-kinase Hsp90 clients were 
assessed via Western blot analysis. Known Hsp90 clients, fibroblast growth factor receptor 3 
(FGFR3) (highly mutated and/or overexpressed in nonmuscle-invasive urothelial carcinomas),44-
46 CXCR4, and B-Raf, along with HSR elements Hsf-1 and Hsp27, were analyzed following the 
administration of 4d to UM-UC-3 cells. After a 24-hour incubation with 4d, Hsp90-dependent 
client proteins were reduced at concentrations that mirrored the cellular IC50 value, clearly linking 
cell viability to Hsp90ß inhibition (Figure 2.13). A marked dose-dependent reduction in FGFR3 
level was observed along with Hsp90E-dependent clients, CXCR4 and B-Raf. Heat shock related 
 
Figure 2.13: Western blot analysis of client 
proteins with 4d in UM-UC-3 cells. 10PM 
GDA was included as positive control and 




proteins Hsp27 and Hsf-1, were found to decline with increasing doses of 4d, which mirrored the 
trend observed previously with the Hsp90E-selective compound, KUNB31.                                 
II.5.3 HER2 Dependency on Hsp90 Isoforms. In collaboration with Dr. Len Neckers at the 
National Institute of Health, compound 5b, being the most selective Hsp90E inhibitor, was 
evaluated in SkBr3 cells for its effect on the maturation of proteins known to drive oncogenesis. 
Hsp90D knockdown via Hsp90α siRNA was carried out to distinguish the roles of Hsp90Dand 
Hsp90Eon the maturation of the known Hsp90 client, ErbB2 (HER2). HER2 belongs to the 
epidermal growth factor receptor family of proteins (EGFR), and exhibits intrinsic receptor 
tyrosine kinase activity that is overexpressed in ~30% of breast cancers and many other cancers.47-
 





49 It is hypothesized in the literature that 
membrane bound HER2 in SkBr3 cells is 
dependent upon Grp94, however, the 
cytosolic HER2 population is maintained 
by Hsp90D and Hsp90E.34 Compound 5b 
was utilized as a chemical tool to inhibit 
Hsp90Ewhich revealed HER2 to be 
dependent on both cytosolic isoforms, as 
the inhibition of Hsp90E with 5b was not effective at reducing HER2 maturation (control siRNA, 
18h reading), however, upon knockdown of Hsp90D with siRNA in the presence of 5b, the levels 
of HER2 were significantly reduced. Therefore, maturation of HER2 exhibits redundant 
dependency upon both Hsp90 isoforms and therefore a functional loss of Hsp90E can be 
compensated by Hsp90D. Unlike the pan-inhibitor, GDA, 5b did not induce the heat shock 
response even at 10 PM (control siRNA, 18h), which is an advantage manifested by Hsp90E-
selective inhibitors. In addition, known Hsp90E dependent clients such as CDK4 and c-IAP1 were 
degraded in a dose-dependent manner upon increasing concentrations of 5b, but were unaffected 
via Hsp90D knockdown.  
 
Figure 2.15: Effect of 5b on viability of MDA-
MB-231 wild type and MDA-MB-231 Hsp90D 

































 In a parallel study, triple negative breast cancer cells, MDA-MB-231 and a Hsp90D 
knockout variant of MDA-MB-231 cells, were treated with increasing concentrations of 5b (Figure 
2.15). Interestingly, in MDA-MB-231 cells treated with control siRNA, 5b exhibited growth 
inhibition that was significantly less (4.5 PM- 5 PM) than that in the Hsp90D knockdown cells 
(~0.5 PM). Again, this study highlighted that Hsp90D and Hsp90E functions may overlap in certain 
cases, as cellular viability may be rescued by compensatory chaperones. The functional 
redundancy manifested by the Hsp90 cytosolic isoforms may not exist for all clients, and therefore, 
further investigation is needed to identify the oncogenic drivers that are specifically dependent 
upon each isoform.   
II.6 Conclusions and Future Directions  
Using a structure-based approach, a new series of Hsp90E-selective inhibitors has been discovered. 
The developed series exhibits both high affinity and selectivity for the Hsp90E isoform versus 
other Hsp90 isoforms. Analogs based on the benzamide derived inhibitor, SNX2112 were 
developed, and exhibit Hsp90E-selectivity by differentiating between minor structural differences 
between the Hsp90D and Hsp90E1terminal binding site, which until recently, was considered 
indistinguishable by ligands. The reported isoquinolin-1(2H)-one series of compounds provides 
an improvement over the reported Hsp90E-selective compounds in terms of affinity (~40-90 nM), 




 Compound 4d was screened in the NCI-60 cancer cell panel which identified cancer types 
that may be sensitive to Hsp90E inhibition. Excitingly, a number of cancers showed growth 
inhibition at low nanomolar concentrations, which is comparable to the pan-inhibitors that have 
been evaluated clinically. Furthermore, Hsp90E-selective inhibition does not induce heat shock 
response, and consequently, may be a safer alternative to pan-Hsp90 inhibition.   
Moving forward, the SAR trends observed with the current series will be utilized to develop 
more efficacious derivatives. As suggested by the modeling studies, the introduction of saturation 
into the 5b may increase selectivity and affinity for Hsp90E. Co-crystallization studies with 4d 
and 5b are underway in collaboration with Dr. Robert Matts at Oklahoma State University to 
validate the proposed binding modes.   
II.7 Method and Experiments 
All reactions were performed in oven-dried glassware under argon atmosphere unless otherwise 
stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed through a 
column of activated alumina prior to use. Anhydrous acetonitrile, methanol, N,N-
dimethylformamide (DMF) were purchased and used without further purification. Flash column 
chromatography was performed using silica gel (40−63 μm particle size). The 1H (500 and 400 
MHz) and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz 




broad singlet, m = multiplet; coupling constant(s) in Hz. High resolution mass spectral data were 
obtained on a time-of-flight mass spectrometer and analysis was performed using electrospray 
ionization. 
Fluorescence Polarization Assay  
 
Assay buffer (25 µL, 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 20 mM 
Na2MoO4, 0.01% NP-40, and 0.5 mg/mL BGG) was added to 96-well plate (black well, black 
bottom) followed by the desired compound at the indicated final concentrations in DMSO (1% 
DMSO final concentration). Subsequently, 10nM Recombinant Hsp90Dor Hsp90Eor cGrp94 or 
Trap-1 and 6 nM FITC-GDA were added in 50 µL and 25 µL assay buffer respectively resulting 
in a 100 µL final volume. Plates were incubated for 5 h at 4°C on a rocker. Fluorescence was 
determined using excitation and emission filters of 485 and 528 nm, respectively. Percent FITC-
GDA bound was determined by assigning the DMSO millipolarization unit (mP) value as the 
100% bound value and 0% for FITC-GDA in assay buffer without any protein.  Plates were 
incubated at 4 °C with rocking for 2 hrs. Polarization values (in mP units) was measured at 37 °C 
with an excitation filter at 485 nm and an emission filter at 528 nm. Polarization values were 
correlated to % tracer bound and compound concentrations. The concentration of inhibitor at 
which the 50% displaced tracer was observed, represented apparent Kd. 
Molecular Modeling. Surflex-Docking module in SybylX was used for molecular modeling and 
docking studies. The co-crystal structures of SNX 2112 bound to Hsp90 (PDB code: 4NH7) , 
compound 31 bound to Hsp90a (PDB code:4O0B) and PU-3 bound to Hsp90b (PDB code:1UYM) 








2,6-difluoro-4-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)benzonitrile (2):  
a) To a solution of 2,4,6-trifluurobenzonitrile (1) (5g, 31.8 mmol, 1 eq.) in 50 mL of ethanol heated 
to 60oC, was added hydrazine hydrate (50-60% solution) (3.4g, 63.6 mmol, ~2 eq.). Upon 
consumption of 1 (monitored using TLC), the solvent was evaporated from the reaction mixture 
under vacuum. To the remaining white semisolid mass was added 50 mL water and the organic 
mass was extracted with ethyl acetate (3 X 50mL). The combined organic fractions were combined 
and washed with brine (100 mL). The organic fraction was separated and dried over sodium 
sulfate. Subsequently, evaporation of the organic layer provided ~6.5 g of white mixture that was 
utilized in the next reaction without further purification.  
b) Above obtained crude product (6g, 35.5 mmol, 1 eq.) was suspended in 100mL ethanol in a 
250mL capacity sealed reaction vessel. 2-acetyldimedone (16.1g, 88.75 mmol, 2.5 eq), an orange 
colored oil, was subsequently added to the reaction vessel which was sealed and heated to 100o C 
for 6 hr. The reaction vessel was allowed to cool to rt, ethanol was removed in vacuo, and the 
remaining mass was extracted with ethyl acetate (3X 100 mL) and water (200mL). Organic layers 
were combined and washed with 100 mL water. Separated organic layer was dried using sodium 




hexanes/ethyl acetate) to afford 2 (5.8 g, 52%) as light-yellow solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.39 – 7.33 (m, 2H), 2.91 (s, 2H), 2.55 (s, 3H), 2.45 (s, 2H), 1.17 (s, 6H). 13C 
NMR (126 MHz, Chloroform-d) δ 192.9, 164.5 (d, J = 6.5 Hz), 162.5 (d, J = 6.4 Hz), 151.8, 149.4, 
144.5 – 144.1 (m), 118.8, 108.5, 106.2 (d, J = 4.1 Hz), 106.0 (d, J = 3.9 Hz), 99.9, 52.0, 38.0, 36.0, 
28.4 (2), 13.3. HRMS (ESI) m/z [M+H] calculated for C17H16F2N3O, 316.1261, found 316.1237.  
 
General Method for Preparation of 3a-i:  
a) To a solution of Benzonitrile 2 (200 mg, 0.64 mmol, 1 eq) in 2 mL DMF in a 10 mL round 
bottom flask, desired E-ketoethylester (0.76 mmol, 1.2 eq), potassium carbonate (106 mg, 0.76 
mmol, 1.2 eq) was added and stirred at 70o C until 2 was consumed, as determined by TLC.  Upon 
completion, the reaction was acidified to pH 5 with 1N aq. HCl, subsequently, 10 mL NH4Cl 
saturated solution was added and extracted using ethyl acetate (3X 10 ml). The combined organic 
fractions were washed with brine and dried over sodium sulfate. The organic fraction was then 
adsorbed on silica and a quick flash column chromatography was performed using 3:7 ethyl 
acetate/hexane as solvent system. The product fractions were collected, dried and the resulting 
mass was utilized in the further reaction.  
b) The crude mass obtained (~210 mg) was taken in a 15 ml sealed reaction vessel, to which 1mL 
sulfuric acid (36N), 8.5 mL acetic acid and 0.5 mL water were added. The vessel was sealed and 
heated to 140o C for 8h. The reaction was then quenched with addition of the reaction mixture to 
100 mL water. Precipitated solid was filtered under vacuum to yield brown colored solid cake that 




chromatography with 5:5 Hexane/ethyl acetate, the desired product was isolated as white solid 
(30-40 % yield).  
 
8-fluoro-3-methyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)isoquinolin-
1(2H)-one (3a):  78 mg,Yield 35%; 1H NMR (500 MHz, Chloroform-d) δ 10.63 (s, 1H), 7.40 – 
7.35 (m, 1H), 7.29 – 7.25 (m, 1H), 6.34 (s, 1H), 2.91 (s, 2H), 2.57 (s, 3H), 2.44 (s, 2H), 2.41 (d, J 
= 1.0 Hz, 3H), 1.15 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 193.3, 163.0 (d, J = 265.2 Hz), 
161.3 (d, J = 3.9 Hz), 150.8, 149.2, 142.4 (d, J = 11.7 Hz), 142.1 (d, J = 1.8 Hz), 140.5, 117.8, 
114.3 (d, J = 4.2 Hz), 112.0 (d, J = 6.4 Hz), 107.5 (d, J = 25.6 Hz), 103.9 (d, J = 2.7 Hz), 52.2, 








J = 2.0 Hz, 1H), 7.27 (d, J = 0.6 Hz, 1H), 6.33 (s, 1H), 2.92 (s, 2H), 2.64 (q, J = 7.5 Hz, 2H), 2.57 
(s, 3H), 2.44 (s, 2H), 1.36 (t, J = 7.5 Hz, 3H), 1.15 (s, 6H). 13C NMR (151 MHz, Chloroform-d) δ 
193.3, 162.1, 160.8, 150.8, 149.2, 145.4, 142.5, 142.0, 117.9, 114.6 (d, J = 4.1 Hz), 112.3, 107.6 
(d, J = 25.5 Hz), 102.8, 52.3, 37.7, 36.0, 28.4 (2), 26.4, 13.4, 12.0. HRMS (ESI) m/z [M+Na] 
calculated for C21H22FN3O2Na, 390.1594 found 390.1609.  
 
8-fluoro-3-isopropyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)isoquinolin-1(2H)-one (3c): 96 mg, Yield: 40 %; 1H NMR (600 MHz, Chloroform-d) δ 9.31 
(s, 1H), 7.41 (d, J = 2.0 Hz, 1H), 7.27 (dd, J = 11.7, 2.0 Hz, 1H), 6.32 (s, 1H), 2.91 (s, 2H), 2.86 – 
2.79 (m, 1H), 2.57 (s, 3H), 2.44 (s, 2H), 1.36 (d, J = 6.9 Hz, 6H), 1.15 (s, 6H). 13C NMR (151 
MHz, Chloroform-d) δ 193.31, 162.99 (d, J = 265.3 Hz), 160.6, 150.8, 149.4, 149.2, 142.4 (d, J = 
11.7 Hz), 142.0, 117.9, 114.8 (d, J = 4.3 Hz), 112.4, 107.6 (d, J = 25.6 Hz), 100.9 (d, J = 2.6 Hz), 
52.3, 37.7, 36.0, 32.2, 28.4 (2), 21.2 (2), 13.4. HRMS (ESI) m/z [M+Na] calculated for 






1(2H)-one (3d) : 113 mg, Yield 45 %; 1H NMR (500 MHz, Chloroform-d) δ 10.32 (s, 1H), 7.40 
(d, J = 2.0 Hz, 1H), 7.26 (d, J = 14.0 Hz, 1H), 6.37 – 6.29 (s, 1H), 2.91 (s, 2H), 2.61 (t, J = 7.6 Hz, 
2H), 2.57 (s, 3H), 2.44 (s, 2H), 1.80 (h, J = 7.4 Hz, 2H), 1.15 (s, 6H), 1.04 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, Chloroform-d) δ 193.3, 162.9 (d, J = 265.2 Hz), 161.1 (d, J = 4.5 Hz), 150.8, 
149.3, 144.5, 142.8 (d, J = 11.9 Hz), 142.0 (d, J = 2.4 Hz), 117.8, 114.6 (d, J = 4.6 Hz), 112.2 (d, 
J = 7.2 Hz), 107.5 (d, J = 25.7 Hz), 103.3 (d, J = 3.5 Hz), 52.3, 37.8, 36.0, 35.2, 28.4 (2), 21.4, 
13.5, 13.4. HRMS (ESI) m/z [M+Na] calculated for C22H24FN3O2Na, 404.1750, found 404.1765. 
 
3-butyl-8-fluoro-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)isoquinolin-
1(2H)-one (3e): 100 mg, Yield 40%; 1H NMR (600 MHz, Chloroform-d) δ 9.99 (d, J = 20.1 Hz, 
1H), 7.40 (d, J = 1.9 Hz, 1H), 7.25 (dd, J = 11.6, 2.0 Hz, 1H), 6.32 (s, 1H), 2.91 (s, 2H), 2.61 (t, J 




1.15 (s, 6H), 1.01 – 0.95 (m, 3H). 13C NMR (151 MHz, Chloroform-d) δ 193.3, 163.0 (d, J = 265.5 
Hz), 161.1 (d, J = 3.6 Hz), 150.8, 149.2, 144.6, 142.4 (d, J = 11.5 Hz), 142.1, 117.9, 114.6 (d, J = 
4.1 Hz), 112.3 (d, J = 6.3 Hz), 107.5 (d, J = 25.5 Hz), 103.2 (d, J = 2.6 Hz), 52.3, 37.8, 36.0, 33.1, 
30.1, 28.4 (2), 22.1, 13.7, 13.4. HRMS (ESI) m/z [M+Na] calculated for C23H26FN3O2Na, 
418.1907, found 418.1902.  
 
3-(tert-butyl)-8-fluoro-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)isoquinolin-1(2H)-one (3f) : 95 mg, Yield 38%; 1H NMR (600 MHz, Chloroform-d) δ 8.78 (s, 
1H), 7.44 (d, J = 1.9 Hz, 1H), 7.27 (d, J = 0.7 Hz, 1H), 6.37 (s, 1H), 2.91 (s, 2H), 2.56 (S, 3H), 
2.44 (s, 2H), 1.38 (S, 9H), 1.15 (s, 6H). 13C NMR (151 MHz, Chloroform-d) δ 193.3, 161.2 (d, J 
= 254.3 Hz), 155.6, 151.3, 150.8, 149.2, 142.4 (d, J = 11.5 Hz) 141.9, 140.8, 117.9, 115.1, 107.7 
(d, J = 25.8 Hz), 100.3, 52.3, 37.8, 36.0, 34.5, 28.8 (3), 28.4 (2), 13.4. HRMS (ESI) m/z [M+Na] 






1(2H)-one (3g): 88 mg, Yield 35 % ; 1H NMR (600 MHz, Chloroform-d) δ 8.74 (s, 1H), 7.43 (d, 
J = 2.0 Hz, 1H), 7.24 (dd, J = 11.7, 2.0 Hz, 1H), 6.28 (s, 1H), 2.91 (s, 2H), 2.56 (s, 3H), 2.44 (s, 
2H), 2.41 (d, J = 7.4 Hz, 2H), 1.15 (s, 6H), 1.02 (d, J = 6.6 Hz, 6H). 13C NMR (151 MHz, 
Chloroform-d) δ 197.0, 171.0, 161.3 (d, J = 3.9 Hz), 150.8, 149.2, 148.7, 142.5 (d, J = 11.7 Hz), 
142.1 (d, J = 1.8 Hz), 139.2, 122.4, 114.3 (d, J = 4.2 Hz), 112.0 (d, J = 6.4 Hz), 107.5 (d, J = 25.6 
Hz), 103.9 (d, J = 2.7 Hz), 53.4, 42.8, 37.7, 36.0, 28.4, 22.2 (2), 14.2 (2). HRMS (ESI) m/z [M+Na] 
calculated for C23H26FN3O2Na, 418.1907, found 418.1913. 
 
3-cyclopropyl-8-fluoro-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)isoquinolin-1(2H)-one (3h): 80 mg, Yield 33%; 1H NMR (600 MHz, Chloroform-d) δ 9.43 (s, 
1H), 7.38 – 7.35 (m, 1H), 7.23 (dd, J = 11.8, 2.0 Hz, 1H), 6.24 – 6.20 (m, 1H), 2.90 (s, 2H), 2.56 
(s, 3H), 2.43 (s, 2H), 1.90 – 1.83 (m, 1H), 1.14 (s, 6H), 1.10 – 1.08 (m, 2H), 0.93 – 0.90 (m, 2H). 
13C NMR (151 MHz, Chloroform-d) δ 193.3, 163.0 (d, J = 265.1 Hz), 160.6, 150.8, 149.2, 145.7, 
142.5, 142.0, 117.9, 114.4 (d, J = 4.2 Hz), 112.2 (d, J = 6.3 Hz), 107.4 (d, J = 25.5 Hz), 101.1 (d, 
J = 2.7 Hz), 52.3, 37.8, 35.9, 28.4 (2), 13.5, 13.4, 7.4 (2). HRMS (ESI) m/z [M+Na] calculated for 






yl)isoquinolin-1(2H)-one (3i): 80 mg, Yield 33%; 1H NMR (600 MHz, Chloroform-d) δ 8.74 (s, 
1H), 7.38 (d, J = 2.0 Hz, 1H), 7.22 (dd, J = 11.7, 2.0 Hz, 1H), 6.30 (s, 1H), 4.30 (s, 2H), 3.39 (s, 
3H), 2.83 (s, 2H), 2.49 (s, 3H), 2.36 (s, 2H), 1.07 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 
193.2, 162.9 (d, J = 265.1 Hz),  159.7, 150.9, 149.2, 142.6, 141.2 (d, J = 2.2 Hz), 139.5, 117.9, 
114.9 (d, J = 4.6 Hz), 113.3 (d, J = 6.2 Hz), 108.2 (d, J = 25.7 Hz), 102.6 (d, J = 3.3 Hz), 70.0, 
58.7, 52.2 37.8, 35.9, 28.4 (2), 13.4. HRMS (ESI) m/z [M+H] calculated for C21H23FN3O3, 
384.1723, found 384.1716. 
 
8-fluoro-3-(hydroxymethyl)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)isoquinolin-1(2H)-one (3j): To a solution of 3i (100 mg, 0.26 mmol, 1eq) in 3 mL DCM cooled 
to 0oC was added 0.8 mL of 1M BBr3 solution in DCM (0.78 mmol, 3 eq) dropwise, the reaction 




saturated sodium bicarbonate solution, resulting biphasic mixture was extracted using ethyl acetate 
(10mL X 2). The organic fractions were collected, washed with water and dried over sodium 
sulfate. Organic fraction was adsorbed onto silica for column chromatography purification using 
(4:6 ethyl acetate/hexanes) to furnish     55 mg (0.155 mmol, Yield 60%) as white solid. 1H NMR 
(600 MHz, Chloroform-d) δ 10.28 (s, 1H), 7.35 (d, J = 1.9 Hz, 1H), 7.24 (dd, J = 11.8, 2.0 Hz, 
1H), 6.36 (s, 1H), 4.59 (s, 2H), 2.83 (s, 2H), 2.49 (s, 3H), 2.36 (s, 2H), 1.07 (s, 6H). 13C NMR (126 
MHz, Chloroform-d) δ 193.25, 166.29(d, J = 265.1 Hz) 151.0, 149.3, 142.3, 141.4, 118.0, 114.9 
(d, J = 4.6 Hz), 112.7, 108.2 (d, J = 25.4 Hz), 102.7 (d, J = 2.9 Hz), 100.8, 99.9, 61.1, 52.2, 37.7, 




dihydroisoquinoline-3-carbaldehyde (3k): To a solution of 3j (30 mg, 0.081 mmol, 1 eq) in 3 
mL DCM in a 15 mL sealed reaction vessel, was added activated MnO2 (70 mg, 0.81 mmol, 10 
eq). The reaction vessel was sealed and heated to 45oC for 6 h. Upon completion, the reaction 
mixture was cooled, filtered through a plug of celite, and a quick flash column chromatography 
(5:5 ethyl acetate/hexanes) afforded 3k (28 mg, 0.076 mmol, 94%) as white solid. 1H NMR (500 
MHz, Chloroform-d) δ 9.63 (s, 1H), 8.91 (s, 1H), 7.77 (s, 1H), 7.53 (dd, J = 11.6, 2.0 Hz, 1H), 




Chloroform-d) δ 193.1, 183.6, 161.3 (d, J = 265.2 Hz), 151.4, 143.1, 149.3, 139.1, 136.3, 124.1, 
118.4, 117.2 (d, J = 4.8 Hz), 116.2 (d, J = 6.2 Hz) , 116.0 (d, J = 3.7 Hz), 111.5 (d, J = 26.0 Hz), 
52.2, 37.9, 36.0, 28.5 (2), 13.4. HRMS (ESI) m/z [M+H] calculated for C20H24NO3, 326.1756, 
found 326.1781. 
                                         
3-ethynyl-8-fluoro-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-yl)isoquinolin-
1(2H)-one (3l): Dimethyl-1- diazo-2-oxopropylphosphonate (60 μL, 0.40 mmol, 1.2 eq.) was 
added to a stirred solution of aldehyde  3k (50 mg, 0.13 mmol, 1.0 eq.) and potassium carbonate 
(36 mg, 0.26 mmol, 2.0 eq) in 3 mL methanol. The resulting mixture was stirred for 24 h at rt. 
Subsequently, methanol was evaporated in vacuo and remaining mass was diluted with water and 
ethyl acetate 10 mL each. The organic layer was washed with saturated sodium bicarbonate 
solution (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was 
purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to afford 3l (40 mg, 0.11 
mmol, 85%).1H NMR (400 MHz, Chloroform-d) δ 8.97 (s, 1H), 7.48 (s, 1H), 7.38 (dd, J = 11.7, 
1.7 Hz, 1H), 6.78 (d, J = 1.8 Hz, 1H), 3.41 (s, 1H), 2.92 (s, 2H), 2.57 (s, 3H), 2.45 (s, 2H), 1.15 (s, 
6H). 13C NMR (101 MHz, Chloroform-d) δ 193.2, 159.1, 151.1, 149.2, 142.9, 140.4, 135.9, 135.1, 
123.5, 118.1, 115.2, 111.3, 109.4 (d, J = 25.9 Hz), 82.7, 52.2, 37.8, 36.0, 29.7, 28.5 (2), 13.4. 
HRMS (ESI) m/z [M+H] calculated for C21H26NO3, 340.1912, found 340.1916. 




A solution of the desired intermediate 3a-l (0.07 mmol, 1 eq) in 1 mL DMSO was taken in a 5mL 
sealed reaction vessel, the corresponding amine (trans-4-aminocyclohexanol for 4a-k) (0.212 
mmol, 3 eq) then disopropyl ethyl amine (DIPEA)(0.212 mmol, 3eq) was introduced. The reaction 
vessel was then sealed and heated to 140o C for 12 h, cooled and water (25 mL) was added. The 
aqueous layer was extracted with ethyl acetate (25 mL X 3), the organic fractions were combined 
and washed with brine (25mL) and dried over sodium sulfate. Purification with column 
chromatography (SiO2, 4:96 methanol:DCM for 4a-k, 5a,5b,5e and 5:1:94 methanol:7M NH3 in 
methanol:DCM for 5c,5d,5f,5g) resulted in the desired products which were further purified by 
preparative TLC to give the desired compounds 4a-k, 5a-g as light yellow solids.  
 
8-(((1r,4r)-4-hydroxycyclohexyl)amino)-3-methyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4a): 22 mg, Yield 70%; 1H NMR (400 
MHz, Chloroform-d) δ 9.16 (d, J = 7.5 Hz, 1H), 9.05 (s, 1H), 6.51 – 6.40 (m, 2H), 6.09 (s, 1H), 
3.74 – 3.59 (m, 2H), 3.31 (d, J = 24.2 Hz, 1H), 2.78 (s, 2H), 2.49 (s, 3H), 2.34 (s, 2H), 2.19 (s, 
3H), 2.17 – 2.08 (m, 2H), 2.04 – 1.95 (m, 2H), 1.38 (q, J = 11.1, 9.9 Hz, 4H), 1.04 (s, 6H). 13C 
NMR (101 MHz, CDCl3) δ 193.4, 185.3, 169.7, 165.5, 151.4, 150.0, 149.1, 143.5, 143.2, 142.1, 
137.4, 107.3, 105.7, 104.8, 100.3, 69.7, 52.4, 50.2, 37.8, 35.8, 33.5, 29.9, 28.4 (2), 19.0, 13.4. 






1H-indazol-1-yl)isoquinolin-1(2H)-one (4b): 19 mg, Yield 58 %; 1H NMR (500 MHz, 
Chloroform-d) δ 9.77 (s, 1H), 9.45 (s, 1H), 6.67 (d, J = 28.0 Hz, 2H), 6.26 – 6.16 (m, 1H), 3.77 
(dd, J = 8.7, 4.4 Hz, 1H), 3.44 (s, 1H), 2.89 (s, 2H), 2.62 – 2.55 (m, 5H), 2.43 (s, 2H), 2.30 – 2.17 
(m, 2H), 2.10 (d, J = 10.4 Hz, 3H), 1.54 – 1.42 (m, 4H), 1.32 (q, J = 7.6 Hz, 3H), 1.14 (s, 6H). 13C 
NMR (126 MHz, CDCl3) δ 193.4, 165.6, 150.9, 150.1, 149.5, 149.1, 143.4, 143.1, 142.1, 119.4, 
117.3, 104.3, 99.9, 88.4, 69.6, 52.4, 37.8, 35.8 (2), 33.5 (2), 29.7, 29.7, 28.4 (2), 26.1, 13.5, 12.4. 




tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4c): 21 mg, Yield 65 %; 1H NMR (500 




6.52 (d, J = 1.9 Hz, 1H), 6.21 (d, J = 1.8 Hz, 1H), 3.79-3.70 (m, 1H), 3.47-3.38 (m, 1H), 2.88 – 
2.77 (m, 3H), 2.56 (s, 3H), 2.41 (s, 2H), 2.25 – 2.18 (m, 2H), 2.10 – 2.04 (m, 2H), 1.52 – 1.38 (m, 
4H), 1.34 (d, J = 6.9 Hz, 6H), 1.11 (s, 6H). 13C NMR (126 MHz, Chloroform-d) δ 193.6, 166.8 – 
165.9 (m), 151.3 (d, J = 15.4 Hz), 149.9, 149.2, 147.6 (d, J = 17.2 Hz), 143.1, 142.2, 117.1, 107.6 
(d, J = 2.7 Hz), 105.1 (d, J = 2.7 Hz), 102.9 (t, J = 2.6 Hz), 100.1, 69.7, 52.4, 50.1 (d, J = 11.0 Hz), 
37.7, 35.9, 33.6 (2), 31.9 (d, J = 6.7 Hz), 30.2 (2), 28.4 (2), 21.4 (2),  13.48. HRMS (ESI) m/z 
[M+Na] calculated for C28H37N4O3Na, 499.2685, found 499.2672. 
 
8-(((1r,4r)-4-hydroxycyclohexyl)amino)-3-propyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4d): 22 mg, Yield 65%; 1H NMR (500 
MHz, Chloroform-d) δ 10.44 (s, 1H), 9.29 (d, J = 7.4 Hz, 1H), 6.56 (dd, J = 41.9, 1.9 Hz, 2H), 
6.21 (d, J = 1.9 Hz, 1H), 3.80-3.73 (m, , 1H), 3.47-3.38 (m, 1H), 2.87 (s, 2H), 2.58 (s, 3H), 2.54 
(t, J = 7.5 Hz, 2H), 2.43 (s, 2H), 2.28 – 2.20 (m, 2H), 2.12 – 2.03 (m, 2H), 1.76 (h, J = 7.4 Hz, 
2H), 1.55-1.36 (m, 4H), 1.13 (s, 6H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, Chloroform-
d) δ 193.5, 166.3, 151.4, 149.9, 149.1, 143.1, 142.2, 141.9, 117.2, 107.5, 105.4, 104.9, 100.0, 69.8, 
52.4, 50.2, 37.7, 35.9, 34.8, 33.6 (2), 30.1 (2), 28.4 (2), 21.3, 13.5, 13.5. HRMS (ESI) m/z [M+Na] 






tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4e): 20 mg, Yield 58%; 1H NMR (500 
MHz, Chloroform-d) δ 10.21 (s, 1H), 9.27 (d, J = 7.5 Hz, 1H), 6.55 (dd, J = 39.0, 1.9 Hz, 2H), 
6.20 (d, J = 2.0 Hz, 1H), 3.79-3.72 (m, , 1H), 3.47-3.37 (m, 1H), 2.87 (s, 2H), 2.60-2.52 (m,  5H), 
2.42 (s, 2H), 2.26 – 2.19 (m, 2H), 2.11 – 2.05 (m, 2H), 1.74 – 1.64 (m, 2H), 1.54 – 1.32 (m, 6H), 
1.12 (s, 6H), 0.96 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 193.5, 166.1, 151.4, 
149.9, 149.1, 143.1, 142.2, 142.1, 117.2, 107.5, 105.2, 104.9, 100.1, 69.8, 52.4, 50.2, 37.7, 35.8, 
33.7 (2), 32.6, 30.1 (2), 30.0, 28.4 (2), 22.1, 13.9, 13.5. HRMS (ESI) m/z [M+H] calculated for 
C29H39N4O3, 491.3022, found 491.3011.  
 
3-(tert-butyl)-8-(((1r,4r)-4-hydroxycyclohexyl)amino)-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4f): 22 mg, Yield 65%; 1H NMR (500 




Hz, 1H), 3.80-3.73 (m, 1H), 3.47-3.43 (m, 1H), 2.88 (s, 2H), 2.58 (s, 3H), 2.43 (s, 2H), 2.25 – 2.18 
(m, 2H), 2.13 – 2.06 (m, 2H), 1.53 – 1.40 (m, 4H), 1.38 (s, 9H), 1.13 (s, 6H). 13C NMR (126 MHz, 
Chloroform-d) δ 193.5, 165.7, 150.9, 150.0, 149.3, 149.1, 143.2, 141.9, 117.2, 107.6, 105.8, 102.3, 
100.7, 69.8, 52.4, 50.6, 37.8, 35.9, 34.3, 33.7 (2), 30.1 (2), 28.9 (3), 28.4 (2), 13.5. HRMS (ESI) 
m/z [M+Na] calculated for C29H38N4O3Na, 513.2842, found 513.2821. 
  
8-(((1r,4r)-4-hydroxycyclohexyl)amino)-3-isobutyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-
tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4g): 19 mg,  Yield 55%; 1H NMR (500 
MHz, Chloroform-d) δ 9.57 (s, 1H), 9.24 (d, J = 7.5 Hz, 1H), 6.60 (d, J = 1.9 Hz, 1H), 6.50 (d, J 
= 1.9 Hz, 1H), 6.17 (d, J = 2.0 Hz, 1H), 3.80-3.72 (m, 1H), 3.46-3.37 (m, 1H), 2.87 (s, 2H), 2.63 
(s, 4H), 2.42 (s, 2H), 2.39 (d, J = 7.4 Hz, 2H), 2.23 (dd, J = 9.4, 5.0 Hz, 2H), 2.11 – 1.97 (m, 3H), 
1.53 – 1.39 (m, 4H), 1.12 (s, 6H), 0.99 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, Chloroform-d) δ 
193.5, 165.9, 151.4, 150.0, 149.1, 143.1, 142.0, 141.0, 117.2, 107.5, 106.1, 105.0, 100.1, 69.8, 
52.4, 50.3, 42.4, 37.7, 35.8, 33.7 (2), 30.1 (2), 28.4, 27.9 (2), 22.3 (2), 13.5. HRMS (ESI) m/z 






tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4h): 22 mg, Yield 66%; 1H NMR (500 
MHz, Chloroform-d) δ 9.67 (s, 1H), 9.26 (d, J = 7.2 Hz, 1H), 6.58 (d, J = 1.9 Hz, 1H), 6.53 (d, J 
= 2.0 Hz, 1H), 6.15 (d, J = 1.9 Hz, 1H), 3.80-3.73 (m, 1H), 3.48 – 3.39 (m, 1H), 2.88 (s, 2H), 2.59 
(s, 3H), 2.44 (s, 2H), 2.26 – 2.18 (m, 2H), 2.12 – 2.04 (m, 2H), 1.87 – 1.78 (m, 1H), 1.55 – 1.38 
(m, 4H), 1.14 (s, 6H), 1.04 – 0.99 (m, 2H), 0.95 – 0.90 (m, 2H). 13C NMR (126 MHz, Chloroform-
d) δ 193.5, 165.7, 150.0, 149.1, 143.2, 143.2, 142.0, 117.2, 107.5, 105.0, 103.4, 100.2, 69.8, 52.4, 
50.3, 37.7, 35.8, 33.7 (2), 30.0 (2), 28.4 (2), 13.5, 13.4, 7.1 (2). HRMS (ESI) m/z [M+H] calculated 
for C28H35N4O3,475.2709, found 475.2698.  
 
8-(((1r,4r)-4-hydroxycyclohexyl)amino)-3-(methoxymethyl)-6-(3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4i): 20 mg, Yield 60%; 1H NMR 




(s, 1H), 6.25 (s, 1H), 4.32 (s, 2H), 3.42 (s, 3H), 2.86 (s, 2H), 2.57 (s, 3H), 2.42 (s, 2H), 2.21 (s, 
2H), 2.07 (s, 2H), 1.49 (q, J = 11.9, 10.3 Hz, 4H), 1.12 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
193.3, 164.9, 151.5, 150.0, 149.0, 143.2, 141.2, 137.1, 117.3, 108.4, 105.3, 105.1, 101.0, 70.2, 
69.7, 58.4, 52.4, 50.3, 37.8, 35.8, 33.5 (2), 29.9 (2), 28.4 (2), 13.4. HRMS (ESI) m/z [M+H] 
calculated for C27H35N4O4, 479.2658, found 479.2665. 
 
8-(((1r,4r)-4-hydroxycyclohexyl)amino)-3-(hydroxymethyl)-6-(3,6,6-trimethyl-4-oxo-
4,5,6,7-tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4j): 20 mg, Yield 63 %; 1H NMR 
(400 MHz, Chloroform-d) δ 9.31 (s, 1H), 9.19 (d, J = 7.4 Hz, 1H), 6.53 (dd, J = 16.9, 1.8 Hz, 2H), 
6.22 (s, 1H), 4.49 (s, 2H), 3.79 – 3.64 (m, 1H), 3.40 (d, J = 16.0 Hz, 1H), 2.83 (s, 2H), 2.55 (s, 
3H), 2.40 (s, 2H), 2.19 (d, J = 11.2 Hz, 2H), 2.09 – 2.00 (m, 2H), 1.44 (dd, J = 18.9, 9.5 Hz, 4H), 
1.10 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 193.6, 172.2, 151.4, 150.1, 149.3, 143.1, 141.5, 139.9, 
117.2, 108.2, 105.4, 103.9, 100.8, 69.5, 60.7, 52.3, 50.2, 37.7, 35.8, 33.4 (2), 29.9 (2), 28.3 (2), 






tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (4k): 11 mg, Yield 35%; 1H NMR (400 
MHz, Chloroform-d) δ 9.09 (d, J = 7.2 Hz, 1H), 8.06 (s, 1H), 6.57-6.52 (m, 3H), 3.69 (s, 2H), 3.31 
(d, J = 22.1 Hz, 2H), 3.23 (s, 1H), 2.78 (s, 2H), 2.49 (s, 3H), 2.35 (s, 2H), 2.13 (s, 2H), 1.98 (s, 
2H), 1.39 (d, J = 4.7 Hz, 4H), 1.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 199.1, 167.6, 167.3, 
157.5, 153.7, 152.0, 148.1, 132.0, 131.3, 126.4, 121.3, 107.4, 97.5, 77.2, 76.8, 72.7, 52.5, 48.7, 
42.8, 36.5, 36.2, 34.3 (2), 31.2 (2), 23.5 (2). HRMS (ESI) m/z [M+H] calculated for C27H31N4O3, 
459.2396, found 459.2375. 
 
8-morpholino-3-propyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indazol-1-
yl)isoquinolin-1(2H)-one (5a): 20 mg, Yield 65%; 1H NMR (400 MHz, Chloroform-d) δ 9.53 (s, 
1H), 7.07 (dd, J = 18.7, 1.9 Hz, 2H), 6.25 (s, 1H), 4.00 (t, J = 4.5 Hz, 4H), 3.22 (s, 4H), 2.86 (s, 




NMR (126 MHz, CDCl3) δ 193.4, 162.1, 155.4, 150.4, 149.1, 143.1, 142.8, 141.9, 117.5, 115.4, 
112.9, 109.7, 104.3, 67.2 (2), 53.4 (2), 52.4, 37.6, 35.9, 34.8, 28.4 (2), 21.2, 13.5, 13.5. HRMS 
(ESI) m/z [M+H] calculated for C26H33N4O3, 449.2553, found 449.2557.  
 
8-(4-hydroxypiperidin-1-yl)-3-propyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-
indazol-1-yl)isoquinolin-1(2H)-one (5b): 18 mg, Yield 55%; 1H NMR (500 MHz, Chloroform-
d) δ 9.03 (s, 1H), 6.98 (d, J = 3.3 Hz, 2H), 6.15 (s, 1H), 3.86 (s, 1H), 3.41 (s, 2H), 2.87 (s,  2H), 
2.78 (s, 2H), 2.52-2.44 (m, 5H), 2.35 (s, 2H), 2.12-2.03 (m,  2H), 1.92-1.81 (m, 2H), 1.67 (h, J = 
7.4 Hz, 2H), 1.05 (s, 6H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 193.5, 162.0, 
155.8, 150.3, 149.1, 142.9, 142.4, 141.8, 117.4, 115.5, 112.4, 110.1, 104.2, 53.4, 52.4 (2), 37.6, 
35.9, 34.9 (2), 30.9, 29.7, 28.4 (2), 21.1, 13.5, 13.5. HRMS (ESI) m/z [M+H] calculated for 






indazol-1-yl)isoquinolin-1(2H)-one (5c): 18 mg, Yield 55%; 1H NMR (400 MHz, Chloroform-
d) δ 9.56 (s, 1H), 9.35 (d, J = 7.3 Hz, 1H), 6.55 (dd, J = 26.8, 2.0 Hz, 2H), 6.19 (d, J = 1.9 Hz, 
1H), 2.87 (s, 2H), 2.80 (s, 1H), 2.57 (s, 3H), 2.52 (t, J = 7.4 Hz, 2H), 2.43 (s, 2H), 2.33 (s, 3H), 
2.26 (t, J = 10.5 Hz, 2H), 2.16 – 2.08 (m, 2H), 1.79 – 1.58 (m, 7H), 1.13 (s, 6H), 1.01 (t, J = 7.4 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ193.5, 165.8, 151.2, 149.9, 149.0, 143.1, 142.1, 141.6, 
140.8, 107.7, 105.3, 105.0, 100.2, 52.4, 46.3, 37.7, 35.8, 34.9 (2), 32.1, 31.6, 31.4, 28.4 (2), 21.2 





yl)isoquinolin-1(2H)-one (5d): 14 mg, Yield 45%; 1H NMR (400 MHz, Chloroform-d) δ 9.59 (s, 
1H), 6.99 (dd, J = 26.4, 2.1 Hz, 2H), 6.17 (s, 1H), 3.13 (s, 6H), 2.79 (s, 2H), 2.50 (s, 5H), 2.35 (s, 
2H), 2.27 – 2.01 (m, 2H), 1.68 (h, J = 7.4 Hz, 2H), 1.05 (s, 6H), 0.95 (t, J = 7.3 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 193.4, 161.7, 155.8, 150.3, 149.1, 143.0, 142.2, 141.9, 117.4, 115.5, 112.7, 
109.8, 104.3, 54.3, 52.4 (2), 46.1 (2), 37.6, 35.9, 34.9, 28.5 (2), 21.2, 13.5, 13.5. HRMS (ESI) m/z 






1,2-dihydroisoquinolin-8-yl)piperazine-1-carboxylate (5e): 20 mg, Yield 53%; 1H NMR (500 
MHz, Chloroform-d) δ 8.93 (s, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 2.1 Hz, 1H), 6.16 (d, J 
= 2.0 Hz, 1H), 3.75 (s, 4H), 3.08 (s, 4H), 2.79 (s, 2H), 2.51 – 2.43 (m, 5H), 2.35 (s, 2H), 1.66 (h, 
J = 7.4 Hz, 2H), 1.42 (s, 9H), 1.05 (s, 6H), 0.94 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 193.4, 161.8, 155.4, 154.9, 150.4, 149.1, 143.0, 142.5, 141.9, 117.5, 115.6, 112.9, 110.0, 104.2, 
79.8, 53.0 (2), 52.4 (2), 37.6, 35.9, 34.9, 31.6, 28.5 (4), 21.1, 13.5, 13.5. HRMS (ESI) m/z [M+H] 
calculated for C31H42N5O4, 548.3237, found 548.3226.  
 
8-((1-methylpiperidin-4-yl)amino)-3-propyl-6-(3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-
indazol-1-yl)isoquinolin-1(2H)-one (5f): 13 mg, Yield 40 %; 1H NMR (400 MHz, Chloroform-
d) δ 9.56 (s, 1H), 9.35 (d, J = 7.3 Hz, 1H), 6.55 (dd, J = 26.8, 2.0 Hz, 2H), 6.19 (d, J = 1.9 Hz, 




2.26 (t, J = 10.5 Hz, 2H), 2.16 – 2.08 (m, 2H), 1.79 – 1.58 (m, 7H), 1.13 (s, 6H), 1.01 (t, J = 7.4 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ193.5, 165.8, 151.3, 149.9, 149.1, 143.1, 142.1, 141.6, 
140.8, 107.6, 105.3, 105.0, 100.2, 52.4, 46.3, 37.7, 35.8, 34.9 (2), 32.1, 31.6, 31.4, 28.4 (2), 21.2 




tetrahydro-1H-indazol-1-yl)isoquinolin-1(2H)-one (5g): 14 mg, Yield 45%; 1H NMR (500 
MHz, Chloroform-d) δ 9.22 (s, 1H), 7.02 (dd, J = 16.0, 2.0 Hz, 2H), 6.21 (s, 1H), 3.44 – 3.37 (m, 
2H), 3.02 (s, 3H), 2.86 (s, 2H), 2.77 (t, J = 7.4 Hz, 2H), 2.57 (s, 3H), 2.56-2.48 (m, 6H), 2.42 (s, 
2H), 1.81 – 1.71 (m, 2H), 1.12 (s, 6H), 1.03 (t, J = 7.3 Hz, 3H), 0.97 (t, J = 7.1 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 193.5, 162.0, 155.2, 150.1, 149.1, 142.9, 141.5, 117.3, 114.5, 111.4, 110.0, 
104.3, 55.5, 52.4, 50.4, 47.3 (2), 41.7, 37.5, 35.9, 35.0, 29.9, 28.4 (2), 21.2, 13.6, 13.5 (2), 11.7. 
HRMS (ESI) m/z [M+H] calculated for C29H42N5O2, 492.3338, found 492.3352. 
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                                       Chapter III      
Development of Hsp90D-Selective Inhibitors 
III.1 Hsp90D and its Significance in Cancer  
Hsp90D represents the inducible cytosolic isoform of Hsp90. Despite high structural similarity 
with the constitutively expressed isoform, Hsp90E, Hsp90D exhibits differential expression, 
function and regulation.1 Genetic knockdown of Hsp90D results in the desirable degradation of 
oncogenic client proteins, suggesting that the administration of Hsp90D-selective inhibitors could 
disrupt the progression of cancers that are driven by Hsp90α-dependent client proteins.2 In addition 
to its cytosolic presence, Hsp90α is secreted extracellularly to promote wound healing and 
inflammation.3 In highly invasive cancers, significant levels of Hsp90D are secreted from the cell 
to activate matrix metalloprotease 2 (MMP-2) and induce expression of MMP-3, which in turn 
promotes tumor invasion.4-5 Exposure of prostate stromal fibroblasts to extracellular Hsp90D 
(eHsp90D via a MEK/ERK and NF-κB dependent pathway, increases the production and 
secretion of IL-6 and IL-8, which contribute to an inflammatory microenvironment that supports 
prostate cancer progression.5 The same study also concluded that eHsp90Dacts upon activation of 
oncogenic inflammatory mediator, signal transducer and activator of transcription (STAT3).  
Extracellular Hsp90α (eHsp90D) induces inflammation through activation of NF-kß. 
Interestingly, NF-kß induces the expression Hsp90α via positive feedback resulting in a surge of 
inflammation that promotes cancer progression. Additionally, eHsp90Dinduces expression of 
Transcription Factor 12 (TCF 12) in colorectal cancer cells,  improving their ability to migrate and 
invade.6 Hsp90D also effectively contributes to the DNA damage repair response, wherein, it 
stabilizes and repairs DNA following exposure to ionizing or infrared radiation. During this 
90 
 
process, Hsp90D gets activated via phosphorylation by the ataxia-telangiectasia-mutated kinase 
(ATM).7-8 Therefore, Hsp90D-selective inhibitors could serve as radiosensitizing agents. 
Furthermore, Hsp90α plays a key role in the self-renewal of breast cancer stem cells (BCSCs) by 
facilitating the nuclear translocation of c-Myc and EZH2 to regulate levels of B lymphoma Mo-
MLV insertion region 1 homolog (BMI1), a polycomb family member with oncogenic activity in 
breast cancer.9 Moreover, high levels of plasma Hsp90D is recognized as a biomarker for liver 
cancer.10-11  Increased levels of cytoplasmic Hsp90D represents a poor prognosis of esophageal 
squamous cell carcinoma and acute leukemia.12-13 In pancreatic cancers, Hsp90D regulates cell 
invasion capacity via a pathway that involves MMP-2.14-15  
In an analysis of the Hsp90 interactome, it was observed that Hsp90D and Hsp90E 
collectively interact with 725 proteins, of which Hsp90D interacts exclusively with 135 proteins, 
while Hsp90E interacts exclusively with 410 proteins, and both isoforms share 183 substrates.16 In 
addition, analysis of gene ontology terms revealed that although Hsp90β interacts with a larger 
number of proteins, Hsp90α is involved in  added biological processes. Functionally, Hsp90β is 
more relevant to maintaining viability, while the processes dependent on Hsp90α contribute to 
adaptation during stress or specialized functions.17-19 Therefore, intra- and extracellular Hsp90D 
represent excellent targets for the generation of new anti-cancer agents. 
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III.2 Variations in the N-terminal ATP-Binding Site in the Hsp90 Isoforms. 
As discussed in the previous chapter, the Hsp90 N-terminal ATP-binding site is highly 
conserved amongst the four Hsp90 isoforms. The primary amino acid sequence of Hsp90D is ~86% 
identical to Hsp90E, however, the N-terminal ATP binding site is > 95% identical between the two 
cytosolic isoforms.20 In fact, only two residues differ between the ATP-binding sites of Hsp90D 
(Ser52, Ile91) and Hsp90E(Ala52, Leu91). The high conservation that is shared between the 
Hsp90α and Hsp90β binding sites has prevented the development of Hsp90α- or Hsp90β-selective 
inhibitorsFigure 3.1a. Radicicol (RDC) was selected as a reference ligand to study the Hsp90-
ligand interactions (Figure 3.1b). The crystal structure of RDC bound to Hsp90Dand RDC 
modeled into Hsp90β were carefully analyzed to study the binding interactions that may differ 
between these two isoforms. As depicted in Figure 3.1, two conserved water molecules exist in 
 
 
Figure 3.1: Binding of Radicicol to Hsp90D and Hsp90E. (a) Sequence alignment of 
Hsp90 isoforms; (b) Structure of Radicicol; (c) Co-crystal structure of radicicol bound to 
Hsp90D; (d) Radicicol modeled in Hsp90E binding site.  
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both Hsp90Dand Hsp90E (labeled as 1’ and 2’ in Figure 3.1c and d) and are responsible for 
mediating a hydrogen-bonding network involving Asp93, Ser52, and the phenols of RDC in 
Hsp90D, whereas in Hsp90E, Ala52 alters this spatial arrangement and limits the hydrogen-bond 
network. The resorcinol moiety interacts with Asp93 in both isoforms and is a key interaction that 
drives potency.21 
 
III.3 Binding of the Small Molecule Inhibitors to the N-terminal ATP-Binding Site of 
Hsp90D. The cytosolic isoforms, Hsp90D and Hsp90E appear to be superimposable upon overlay 
of the N-terminal ATP-binding site amino acid sequences. In contrast, Grp94 and Trap1 exhibit 
structural features that differ between Hsp90D and Hsp90E. Figure 3.2a depicts the closed 
conformation (apo conformation) of Hsp90D which is the minimum energy conformation of the 
protein and is formed when Helix 4 (H4) exists as a disordered and closed loop, which leads to a 
smaller hydrophobic Site 1 (illustrated with a dashed curve in Figure 3.2c).22 Expansion of Site 
1(open conformation) occurs when Helix 4 undergoes a conformational change that results in an 
ordered α-helical structure of amino acids 104-111,  as illustrated in Figure 3.2b and c. There are 
  
Figure 3.2: a) The closed conformation of Hsp90D and b) the open conformation of Hsp90D. 
c) the Birdseye view of the N-terminal ATP binding pocket of Hsp90. Conformationally 
flexible residues comprising Site1 are outlined with a dashed red circle. 
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three chemotypes that summarize the Hsp90 small molecule inhibitors being evaluated in clinic; 
1) benzamides, 2) purines, and 3) resorcinols. The crystal structure of compounds representing 
each Hsp90 inhibitor chemotype  revealed that some chemotypes bind the open conformation of 
the Hsp90, whereas others can be accommodated in the resting state, i.e. the closed form.22 The 
benzamide containing molecule, SNX 2112, binds and induces a conformational change to the 
open conformation, wherein, the tetrahydroindazolone fragment is accommodated into Site 1. 
Similarly, the purine containing compound, BIIB021 also binds the open conformation of the 
protein. However, the resorcinol containing compounds, such as AT13387 (Onalespib), can only 
access and bind to closed conformation, which results in a reduced entropic penalty that translates 
into increased affinity. Each chemotype contains a pharmacophore that provides key interactions 
with the adenine binding region within the ATP-binding pocket (Figure 3.2). These 










Figure 3.3: Structure and key Hsp90D binding interactions of each Hsp90 inhibitor 
chemotypes: a) SNX 2112 (PDB Code:4NH7) b) BIIB021(PDB Code: 3QDD) c) AT13387 
(PDB Code: 3QDD). 
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aminopyridine, or the resorcinol, which serve to anchor the ligand via a hydrogen-bond network 
that are coordinated via three conserved water molecules (labelled as 1’-3’ in Figure 3.1a). 
 Analysis of the co-crystal structures containing the three chemotypes that bind Hsp90D and 
Hsp90E equipotently, reveals that the key binding interaction occurs between Asp93 and the H-
bond donor from the ligand.23 The carbonyl oxygen from the benzamide, the heterocyclic nitrogen 
from purine, and the 2-position phenol of the resorcinol act as a hydrogen-bond acceptors that 
interact via the 3’ conserved water molecule. It is worth noting that the amide NH2 and the 
aminopurine NH2 interact simultaneously with Asp93 and Ser52 via conserved water molecules 
1’ and 2’, however, in the resorcinol case, the 2-phenol directly interacts with Asp93, and the 4-
phenol interacts with both Asp93 and Ser52 indirectly via water molecules 1’ and 2’. Interestingly, 
none of the examined scaffolds interact directly with Ser52, which is the only amino acid that 











residues, (Ile91(D)/Leu91(E)) lead to a smaller pocket in Hsp90D in comparison to Hsp90E and 
cannot be probed for Hsp90D binding (Figure 3.1c and d)  
 
III.4 The Discovery of the Monophenol-Based Hsp90D-selective Inhibitor As noted in the 
overlay studies, modifications to the benzamide and purine scaffolds were hypothesized to 
interrupt the planarity of the pharmacophores, which are essential for establishing contacts with 
protein via interactions with Asp93 (Figure 3.3). However, the resorcinol pharmacophore allowed 
an opportunity to evaluate the polar binding requirements of the Hsp90D surface via systematic 
removal of each phenol. For this purpose, the simplified resorcinylic compound, 2.1, a non-
selective compound (DE Kd=5.5/4 nM), was chosen for investigation. Removal of the phenols 












interacts with Ser52 via two conserved water molecules, manifested ~10-fold selectivity for 
Hsp90D versus Hsp90E (DE Kd=0.41/4.47 PM). In contrast, 6 manifested moderate binding 
affinity with ~2-fold selectivity for Hsp90E, as the 2-phenol interacts with conserved water 
molecule 3’and Asp93. Collectively, polar interactions between Hsp90D and 6 appear weaker as 
compared to the interactions manifested by 7.24  Encouraged by the binding profile of 7, 
modifications to the 4-monophenol to improve affinity and selectivity were pursued. Figure 3.5 
depicts the proposed binding mode of the compounds 8-11 that result from modifications at the 5-
position of 7. Notably, introduction of bulk at the 5-position improves selectivity, however, a loss 
of affinity (~5-fold) was also observed as compared to 7. Figure 3.6 shows the 5-bromo containing 
compound (8) modeled into the Hsp90D ATP-binding pocket (Figure 3.5). The bromine atom in 
Figure 3.6 is depicted as a brown sphere to aid in visualization that the bulk of bromine and other 
groups at the 5-position (9-11) restrict rotation of the 4-phenol and force it toward conserved water 
molecules and Ser52, and thereby, impart selectivity. 
The presence of Asn51 in close proximity to the 5-
position (Figure 3.5) allowed the installation of a 
hydroxyl onto 7 to yield the tertiary alcohol compound, 
10, which exhibits improved Hsp90D binding affinity 
over 9 with ~20-fold selectivity against Hsp90E. 5-
substitutions that may induce the open conformation of 
Hsp90 were also investigated. These efforts resulted in 
11, a compound that contains a phenyl thioether 
substitution that manifests selectivity similar to 8 
however, it also exhibits decreased affinity (Figure 
Asp93
Ser52
Figure 3.6: Compound 8 modeled 
into Hsp90D ATP-binding pocket, 





3.5).24 As hypothesized, 11, may enlist an entropic penalty during the opening of Site 1, which 
may also reduce binding affinity. In the following sections, strategies that were employed to 
optimize the binding affinity and selectivity of the monophenol will be discussed.   
 
III.5 Optimization Studies of 7 and its 5-position Substituents.  
III.5.1 Exploration of Alternative 4-Phenol Scaffolds. 
Apart from AT13887, there exist two other 
small molecule Hsp90 inhibitor scaffolds that 
are based on the resorcinol pharmacophore,  the 
isoxazole containing NVPAUY922, and the 
triazolone-based, STA9090 (Figure 3.7). 
Collectively, these three scaffolds represent the 
second generation of pan-Hsp90 inhibitors that 
have undergone clinical examination. 
Derivatives 12 and 13 were prepared according 
to the methods reported in literature to investigate the consequences of removing the 2-phenol in  
NVPAUY922 and STA9090 (Figure 3.7).25-26 Upon evaluation of 12 and 13 in a fluorescence 
polarization (FP) assay, both compounds were shown to bind Hsp90DE with affinities similar to 
7, however, a decrease in selectivity was observed (~8-fold for 12 and ~5-fold for 13).These data 
support the isoxazole/triazolone containing scaffolds to bind Hsp90D in similar orientation as the 
isoindoline scaffold, 7. 
 
Figure 3.7: Evaluation of compound 12 
and 13 using FP Assay. 
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III.5.2 Investigation of 4-Phenol Replacements. Compound 8 was chosen as a reference scaffold 
for the construction of the proposed 
molecules to investigate phenol 
replacements. For this purpose, the phenol 
was replaced with a nitrile in 14 (Figure 
3.8), whereas, 15 contained an amide 
group, both of which were 
hypothesized to extend into the 
hydrogen bonding network and 
replace water molecules 1’ and 
2’. A thiol was incorporated into 
16 in lieu of the phenol, which 
may define the spatial 
requirements of the pocket. An 
aniline was also investigated as 
a surrogate, but this substitution  
resulted in a complete loss of affinity.24  
 Synthesis of 14 commenced with acid 17, 
which was coupled with isoindoline in the presence of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDCI) and hydroxybenzotriazole hydrate 
(HOBt·H2O). The nitrile in 14 was then hydrated in 
the presence of sodium hydroxide (NaOH) and 
 







       14 >50 >50 
       15 >50 >50 
       16 >50 >50 
   Table 3.1: Kd values of phenolic 
replacement compound obtained from 
FP assay.  
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hydrogen peroxide to produce 15. Synthesis of thiol 16, began with an amide coupling reaction 
utilizing acid 18, followed by aromatic nucleophilic substitution and debenzylation in the presence 
of boron tribromide (BBr3) to produce 16.   
 Unfortunately, evaluation of these compounds in the fluorescence polarization (FP) assay 
revealed that neither the nitrile,  the amide, nor the thiol group can mimic the phenol, as the Kd’s 
were >50 PM for all three compounds.  
III.5.3 Modifications to the Tertiary Alcohol  
The tertiary alcohol containing, 10 (Figure 3.5) manifested higher affinity for Hsp90D versus 
Hsp90E when compared to the t-butyl containing compound, 9. The alcohol may also act as a 
hydrogen bond acceptor and/or a donor, and therefore, functionalities were investigated to 
determine the role of the alcohol by calculating the binding affinity and selectivity. One of the 
proposed modifications included the introduction of a nitrile group onto 19, which was 
hypothesized to interact with Asn51, as a hydrogen-bond acceptor. The azide containing 
compound, 20, represented another derivative that could replace the alcohol with a hydrogen-bond 
acceptor in the binding pocket. In addition, an amine was installed to give 21 for investigation of  
charged interactions with the protein surface. Modeling of the alcohol into the binding site (Figure 
3.5) suggested that a methoxy group could also be accommodated in lieu of the alcohol, which 
would allow for the differentiation of the hydrogen-bond acceptor/donor nature. Finally, the 
 
Figure 3.9:  Replacement and modifications of the tertiary alcohol group in 10. 
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phenolic ether was proposed in compound 23 to induce a conformational change in Hsp90D 
resulting in an open form, and subsequently allow occupation of the larger Site 1, that could 
resemble compound 11 (Figure 3.5).  
 Synthesis of compound 19, was performed by treating previously developed 10 with 
trimethylsilyl cyanide (TMSCN) in the presence of boron trifluoride diethyl etherate 
(BF3.etherate). 
 Similarly, 20 was 
produced using sodium 
azide (NaN3). Upon 
hydrogenation via 
ammonium formate and 
palladium, 20 yielded the 
corresponding amine, 21.  
Preparation of the 
methoxy containing 
analog, 22, required 
treatment of 10 with ceric ammonium nitrate in methanol. Additionally, the phenol was reacted 
with 10 in the presence of trifluoroacetic acid to produce the phenoxy containing compound, 23.   
  Interestingly, evaluation of 19 in the FP assay revealed that a nitrile could 
effectively replace the alcohol in 10, as the binding affinity of 19 was shown to resemble 10. This 
data implied that alcohol in 10 interacts with Asn51 as a hydrogen-bond acceptor. In line with the 




azide may also interact with Asn51, however, the size and linearity of the azido group may result 
in steric clash. The amine containing compound, 21, exhibited a complete loss of affinity, 
suggesting that a charged moiety is 
undesired.  Surprisingly, the methoxy 
containing analog, 22, did not bind well. The 
loss in the affinity of 22 could result from 
steric interactions between the binding site 
and methoxy group. Similarly, the phenoxy 
containing compound, 23, manifested a loss 
in binding affinity and did not interact with 
Hsp90D as anticipated. 
III.5.4 Modifications to the gem-Dimethyl  
Since the evaluated functionalities (Figure 3.9) did 
not produce an improvement in affinity and 
selectivity as was observed with 10, the alcohol was 
established as the optimal group for Hsp90D 
binding. In the following studies, a gem-dimethyl 
group was investigated. As shown in Figure 3.8, the 
dimethyl moiety could be modified to access the 
open form (Figure 3.2, 3.5 and 3.8 as well as the 
solvent channel (marked with red arrow in Figure 
3.8), and lead to entropic stabilization via displacement of water. However, proposed 
Compounds Hsp90DKd (PM) 
Hsp90EKd 
(PM) 
       19 0.51+0.008 5.1+0.11 
       20 2.74+0.20 14.91+0.11 
       21 >50 >50 
       22 36+1.56 >50 
       23 >50 >50 
Table 3.2: Kd values for 19-23 obtained from FP assay.  
Figure 3.10: Proposed model of 10 
binding to closed form of Hsp90D. 
Arrows indicate the projection of the 











modifications introduced a chiral center, and therefore the evaluation of binding may be more 
complicated. 
 A sec-butyl was introduced onto 24, to replace the isopropyl group present in 7, for 
investigation of chain elongation. A similar modification was also introduced onto 8 to produce 
compound 25. The extension of both methyl groups to form diethyl, 26, was pursued to explore 
the mutual exclusivity of the methyl 
substituents. In addition,  installation of a 
trifluoromethyl onto 27 was hypothesized 
to explore the steric bulk about the 
alcohol. A vicinal diol was incorporated 
into 26 to investigate additional hydrogen 
bonding interactions within the binding 
site.  
 Preparation of 24 required a tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4)- 
catalyzed coupling of benzyl protected bromophenol 29 with potassium (E,Z)-2-buten-
yltrifluoroborate (Scheme 3.3),24 which underwent subsequent hydrogenation to produce 24. The 
isopropenyl containing intermediate 30, was produced using conditions similar to those used to  
 




construct 24. Dihydroxylation of intermediate 30 
was performed with osmium tetraoxide and resulted 
in 28. The 5-acetylated monophenol 31,24  was 
treated with ethyl magnesium bromide to produce the 
tertiary alcohol, 25.  
 Commercially available 
acid 32, was protected with a benzyl moiety and then 
hydrolyzed with sodium hydroxide to yield the 
benzyloxy protected acid. A subsequent a lithium 
halogen exchange was then utilized and then  
quenched with 3-pentanone to give 33. Coupling of 
33 with isoindoline followed by removal of the 
protecting group led to the desired product, 26. 
Installation of the trifluoromethyl group required 
benzyl protection of  31, to 







(TMSCF3) and tetrabutyl ammonium 
fluoride (TBAF) resulted in 27.  
  Upon evaluation in the FP assay, sec-
butyl 24, exhibited reduced affinity (~3-
fold) as compared to the isopropyl 
containing compound, 7. In contrast, 
introduction of an ethyl group (25) 
resulted in an increase in binding affinity. These results suggest that 7 and 10 bind to different 
conformations of the protein and affects the orientation of ethyl chain. The binding affinity of 10 
also indicates that the ethyl group may project toward the solvent channel (Figure 3.8), and 
displace water to reduce the dielectric constant within the binding site. Unfortunately, replacement 
of the dimethyl group in 26 with diethyl decreased binding affinity, indicating that substitutions 
can only be tolerated at one location. The trifluoromethyl group (27) also proved to be an 
ineffective binder. Finally, the vicinal diol (28) did not produce an increase in binding affinity, in 
contrast, a 10-fold decrease was observed. 
III.5.5 Installation of Appendages onto the Tertiary Alcohol. The gain in binding affinity 
observed for 25 led to the hypothesis that further elongation of the chain may increase ligand 
binding. Therefore, both linear and branched aliphatic appendages were installed to distinguish the 
conformational changes that exist among the Hsp90 isoforms. Construction of analogs 35a-h was 
Compounds Hsp90DKd (PM) 
Hsp90EKd 
(PM) 
       24 1.5+0.357 30.29+2.64 
       25 0.478+0.01 5.23+0.018 
       26 37.87+1.24         >50 
       27 36+1.56         >50 
       28 6.15+0.76         >50 
Table 3.3: Kd values for 24-28 obtained from FP assay.  
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achieved via Grignard reagents prepared by reported methods.27 The n-propyl containing 
compound, 35a,  maintained affinity similar to 25, which led 
to evaluation of the n-butyl appendage, 35b. Surprisingly, 35b manifested a ~3-fold increase in 
binding affinity, but selectivity against Hsp90E remained unchanged (~13-fold). Extension of the 
chain to a n-pentyl (35c) led to a minor loss in affinity. Collectively, the binding data obtained 
with compounds 35d-f suggested that branching in close proximity to the tertiary alcohol is not 
tolerable. The hypothesis that alkyl side chains project into the solvent channel (Figure 3.8) was 
further explored via the methoxy (35g) and  terminal alcohol (35k) that could mimic water 










Fold        
selectivity 
35a 0.480+0.05 4.57+0.07 ~10 
35b 0.184+0.02 2.4+0.39 ~13 
35c 0.229+0.01 2.07+0.08 ~8 
35d 11.81+0.87 >50 >5 
35e 4.60+0.87 >50+0.02 ~10 
35f 0.596+0.03 5.16 ~10 
35g 0.447+0.02 4.98+0.285 ~10 
35h 2.49+0.25 30.5+2.29 ~12 
35i 2.22+0.21 >50 ~21 
35j 0.045+0.02 0.426+0.07 ~10 
35k 3.71+0.25 17.94+2.80 ~5 
Table 3.4:  Kd values for 35a-k obtained from 





manifested a ~3-fold loss in affinity (compared to 35b), whereas the alcohol containing compound 
35k, manifested ~24-fold loss in affinity. These data suggested that the unprotected alcohol (35k) 
may interact with solvent molecules and dilute enthalpic interactions. However, the methoxy (35k) 
appears to prevent solvent access to the binding site. Unfortunately, the introduction of a terminal 
alkene as in 35h and 35i led to compounds that manifested a loss in affinity, suggesting that the 
alkene exhibits disfavored interactions by imparting rigidity. Subsequently,  35g was constrained 
via a propargyl ether to produce 35j, which could orient the ether toward the solvent channel 
(Figure 3.10) and make contact with Asn51 and Phe138, and thereby reduce the entropic penalty. 
In agreement with this hypothesis, compound 35j exhibited a Kd of ~45nM, however, selectivity 
versus Hsp90E remained unaffected (~10-fold). 
 Evaluation of compounds 35a-k implied that the solvent channel could be probed via 
substitutions on the tertiary alcohol, and ultimately produced compound that improved affinity. 
However, except for allyl (35i), selectivity versus Hsp90Eranged between 5-10-fold, suggesting 
that modification to this region drive affinity, but have no effect on selectivity. 
 
 
Figure 3.9: Proposed binding mode 




III.5.6 Substitutions to Probe the Hsp90D Open Conformation. As discussed in the earlier 
sections, Hsp90 undergoes a 
conformational change upon 
ligand  binding to result in a 
larger Site 1 (Figure 3.2 and 3.8). 
Although Site 1 is conserved 
among the cytosolic isoforms, 
quaternary changes in the Hsp90 
structure have been observed as 
a consequence of ligand binding.28 
Compounds have been reported to exhibit 
moderate preference for binding to Hsp90D 
over Hsp90E, but the rationale for their 
binding preference is lacking.29-30 The 
observed Hsp90Dselectivity for ligand 
binding may arise from differences in the transition 
state energies for the ligand-Hsp90DE complex. 
Compounds 36a-e were prepared to probe and 
potentially bind Site 1 in Hsp90D, by treating 31 with 
the appropriate Grignard reagent.  
Following their preparation, 36a-e were 
evaluated for binding affinities toward Hsp90D and E. 
In comparison to 10, 36a-c exhibited a loss of binding 
Figure 3.11: Proposed binding 
mode of 36d in the open 
conformation of the Hsp90D ATP-








Fold        
selectivity 
36a 3.87+0.32 39.32+2.64 ~10 
36b 3.84+0.31 >50 >13 
36c 3.03+0.19 >50 >13 
36d 0.25+0.01 3.67+0.14 ~15 
36e 0.33+0.87 4.28+0.07 ~13 










for 10). This 
observation 
led to the 
hypothesis 
that compounds with linker 
ranging from 0 to 2 carbons were 
unfit for binding and/or inducing 
the open conformation. However, 
the 3-carbon linker as in 
compound 36d, exhibited 
improved affinity (Kd ~0.25PM) 
and ~15-fold selectivity. 
Surprisingly, 36d overcame the 
combined entropic penalty by 
rotation of the propylene linker to 
induce a conformational change 
in the protein. The four-carbon linker as in compound 36e, also exhibited a similar binding profile, 
albeit with a minor loss in affinity.  




Fold        
selectivity 
39a 0.279+0.048 2.74+0.34 ~10 
39b 0.256+0.31 2.55+0.19 ~10 
39c   0.381+0.001 4.84+0.19 ~12 
39d 0.726+0.03 3.98+0.04 ~6 
39e 0.243+0.006 4.15+0.65 ~17 
39f 0.278+0.064 2.12+0.08 ~8 
39g 0.056+0.004 0.328+0.059 ~6 
39h 0.086+0.009 0.563+0.026 ~7 
39i 0.057 +0.004 0.639+0.119 ~11 






The binding profile of 36d led us to speculate that further modification to the phenyl ring 
may provide compounds with improved affinity and selectivity through binding to probing Site 1. 
Therefore, substituted phenyl derivatives, 39a-i, were produced using the benzyl protected 
intermediate 34, which upon treatment with allyl magnesium bromide yielded the chiral alcohol, 
37. Intermediate 37, was then coupled with the desired aromatic bromides via Heck coupling 
conditions, followed by simultaneous removal of the benzyl group and reduction of the alkene to 
afford the desired products, 39a-i.  
Evaluation of the chlorine substituted compounds 39a-c, determined that binding affinity 
and selectivity largely remained unaffected. In fact, a slight loss of affinity was observed with the 
4-chlorine substituted compound, 39i. This implied that the chlorine atom could be accommodated 
on the ring without a significant loss of affinity. Methyl groups were also installed on the phenyl 
ring, which determined that the 2-methyl substituted compound, 39d, lost affinity as well as 
selectivity. In contrast, the 3-methyl containing compound, 39e, improved selectivity (~17-fold) 
while maintaining affinity, whereas, the 4-methyl containing compound 39f, retained affinity but 
lost selectivity. Finally, a nitrogen-scan was performed to probe potential hydrogen-bonds with 
Tyr139, and/or improved pi-pi stacking with Phe138 and Trp162 (Figure 3.10). Expectedly, 
binding improved for all pyridyl analogs (39g-i), but a gain in selectivity was not observed. Instead, 




Flexibility of the 3-carbon linker chain was investigated by introduction of an alkyne or an 
alkene. It was hypothesized that restricting rotation with an alkene or an alkyne would project the 
phenyl ring directly into Site 1 while reducing entropy. Therefore, the alkyne group was introduced 
within the linker chain at various positions (40 and 41). Additionally, trans (42) and cis (43) 
variants of compound 36d were 
also investigated (Figure 3.12).  
Synthesis of 40 
commenced upon the treatment 
of 31 with a Grignard reagent 
containing the desired alkyne 
(Scheme 3.8).  Construction of 41 
required generation of the alkynyl 
anion via lithium diisopropylamide (LDA), which then reacted with 31 to yield 41. The synthesis 
of trans-alkene 42 was achieved utilizing Heck coupling conditions, enlisting palladium(0) 
bis(dibenzylideneacetone) (Pd(dba)2) and tri-o-tolylphosphine (P(o-tolyl)3) before deprotection to 
 
 




Fold        
selectivity 
40 0.861+0.011 22.35+0.64 ~26 
41 0.034+0.001 0.048+0.011 ~1 
42   0.260+0.09 3.97+0.15 ~15 
43 0.343+0.004 4.55+0.08 ~13 




give 42. However, the cis variant was accessed via reduction of alkyne 40 in the presence of 
Lindlar’s catalyst.   
Evaluation of these compounds using an FP assay was performed and revealed interesting 
binding profiles. For example, compound 40 exhibited a loss of affinity (~3-fold), however, 
selectivity was found to be improved by ~26-fold, which represents an improvement over the 
parent compound, 36d. Compound 41 manifested improved binding affinity (Kd ~35nM), but also 
a similar affinity for Hsp90E resulting in lack of selectivity. The trans analog, 42, exhibited 
affinity and selectivity comparable to the parent compound, 36d, whereas, the cis analog (43) was 
ineffective.  
III.6 Cellular Studies  
Biological evaluation of the prepared compounds will be discussed in the next chapter.  
III.7 Conclusions  
 Monophenol, 7, represents the first rationally designed Hsp90D-selective inhibitor. The 4-
monophenol analogs of the resorcinol chemotypes, NVPAUY922 and STA9090, were prepared 
(12 and 13) and evaluated. Studies determined 7 was best suited for subsequent optimization. 
Substitutions at the 5-position in 7 led to the compounds 8-11, which established the presence of 
a bulky group regulates Hsp90Dbinding affinity and gave ~30-fold selectivity over Hsp90E. 
These compounds served as hits for further development. In particular, 10 was selected for its 
superior binding affinity toward Hsp90Dand ~20-fold selectivity versus Hsp90E.  
Initial derivatives of 10 were sought to replace the alcohol with various functional groups, 
which uncovered the nitrile to mimic the binding affinity of 10.  The introduction of appendages 
onto the tertiary alcohol was pursued and both elongated and branched chain compounds, 25 and 
35a-k were prepared, the n-butyl analog provided optimal binding affinity, whereas, branching of 
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the chain was found unfavorable. Of note, introduction of propargyl ether into 35j led to an 
enhancement in affinity, without any improvement of selectivity.  
While the alkyl chain was explored to investigate the closed conformation of Hsp90, the 
introduction of a phenyl ring was pursued to investigate the open conformation of Hsp90D. It was 
determined that the 3-carbon linker found in 36d is optimal and manifested ~250nM Kd for 
Hsp90D and ~15-fold selectivity over Hsp90ß. Furthermore, structure-activity relationship studies 
on the phenyl ring determined that a 3-methyl substitution (39e) maintained affinity and 
selectivity, and warrants further investigation. Finally, flexibility of the linker chain in 36d was 
pursued via 40-43. It was discovered that placement of the alkyne is critical for regulating 
selectivity and potency, as 40 lost affinity but gained selectivity, whereas, 41, lost selectivity but 
was equipotent against Hsp90α and Hsp90ß. 
   In order to understand the mechanisms of binding of the compounds 35b and 36d, co-
crystallization studies are underway in collaboration with Dr. Robert Matts at Oklahoma State 
University.  
III.8 Methods and Experiments 
Chemistry 
All reactions were performed in oven-dried glassware under argon atmosphere unless otherwise 
stated. Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed through a 
column of activated alumina prior to use. Anhydrous dimethyl sulfoxide (DMSO), methanol, and 
N,N-dimethylformamide (DMF) were purchased and used without further purification. Flash 
column chromatography was performed using silica gel (40−63 μm particle size). The 1H (500 and 
400 MHz) and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz 
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spectrometer. Data are reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, bs = 
broad singlet, m = multiplet; coupling constant(s) in Hz. High resolution mass spectral data were 
obtained on a time-of-flight mass spectrometer and analysis was performed using electrospray  
 
Fluorescence Polarization Assay  
 
Assay buffer (25 µL, 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 20 mM 
Na2MoO4, 0.01% NP-40, and 0.5 mg/mL BGG) was added to 96-well plate (black well, black 
bottom) followed by the desired compound at the indicated final concentrations in DMSO (1% 
DMSO final concentration). Subsequently, 10nM Recombinant Hsp90Dor Hsp90Eor cGrp94 or 
Trap-1 and 6 nM FITC-GDA were added in 50 µL and 25 µL assay buffer respectively resulting 
in a 100 µL final volume. Plates were incubated for 24 h at 4°C on a rocker. Fluorescence was 
determined using excitation and emission filters of 485 and 528 nm, respectively. Percent FITC-
GDA bound was determined by assigning the DMSO millipolarization unit (mP) value as the 
100% bound value and 0% for FITC-GDA in assay buffer without any protein. Polarization values 
(in mP units) was measured at 37 °C with an excitation filter at 485 nm and an emission filter at 
528 nm. Polarization values were correlated to % tracer bound and compound concentrations. The 






carboxamide (12)25: Yield 70%; 1H NMR (500 MHz, Chloroform-d) δ 7.41 – 7.32 (m, 4H), 7.29 
(dd, J = 8.4, 2.2 Hz, 1H), 7.24 (d, J = 2.1 Hz, 1H), 6.74 (t, J = 5.8 Hz, 1H), 6.66 (d, J = 8.4 Hz, 
1H), 3.73 (t, J = 4.7 Hz, 4H), 3.55 (s, 2H), 3.42 (qd, J = 7.3, 5.8 Hz, 2H), 3.11 (hept, J = 6.9 Hz, 
1H), 2.51 (s, 4H), 1.21 (t, J = 7.3 Hz, 3H), 1.02 (d, J = 6.9 Hz, 6H). 13C NMR (126 MHz, CDCl3) 
δ 167.6, 159.2, 156.5, 154.7, 134.8, 130.5 (2), 129.5, 128.7, 125.7 (2), 119.7, 115.5, 114.5, 66.9 
(2), 63.2 (2), 53.6, 34.3, 26.5, 22.2 (2), 14.6. HRMS (ESI) m/z [M+H] calculated for C26H32N3O4, 
450.2387, found 450.2400. 
 
5-(4-hydroxy-3-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-ol (13)26: 
Yield 35%; 1H NMR (500 MHz, Chloroform-d) δ 7.43 (d, J = 2.0 Hz, 1H), 7.28 (d, J = 8.6 Hz, 
1H), 7.03 (dd, J = 10.5, 2.7 Hz, 2H),7.00- 6.93 (m, 2H), 6.50 (d, J = 8.4 Hz, 1H), 6.40 (dd, J = 3.2, 
0.8 Hz, 1H), 3.74 (s, 3H), 3.01 (hept, J = 6.9 Hz, 1H), 0.84 (d, J = 6.9 Hz, 6H). 13C NMR (126 
MHz, CDCl3) δ 156.0, 155.3, 147.6, 136.4, 134.8, 130.4, 128.8, 126.3, 126.2, 125.3, 120.9, 120.3, 
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118.2, 114.8, 110.0, 101.6, 33.0, 26.4, 22.0 (2). HRMS (ESI) m/z [M+H] for C20H21N4O2, 
349.1659, found 349.1699. 
 
2-bromo-4-(isoindoline-2-carbonyl)benzonitrile (14): To a solution of 17 (200 mg, 0.88 mmol, 
1 eq. ) in DCM (5 mL) were added N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (338 mg, 1.76 mmol, 2.0 eq.), hydroxybenzotriazole hydrate (238mg, 1.76 mmol, 2 
eq.) , N,N-Diisopropylethylamine (567 mg, 4.4 mmol, 5 eq.) and isoindoline hydrochloride (155 
mg,1 mmol, 1.1 eq.). Reaction was stirred overnight at rt, before solvent was removed in vacuo, 
then water (10 mL) was added to the remaining crude mass, acidified with 1N HCl and extracted 
with ethyl acetate (10 mL x2). The organic layer was dried over sodium sulfate, filtered and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) 
to afford 14 (240 mg, 85%) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.91 (d, J = 1.4 
Hz, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.62 (dd, J = 7.9, 1.5 Hz, 1H), 7.39 – 7.29 (m, 3H), 7.20 (dt, J 
= 7.4, 1.1 Hz, 1H), 5.02 (t, J = 1.2 Hz, 2H), 4.75 (q, J = 1.3 Hz, 2H). 13C NMR (126 MHz, CDCl3) 
δ 166.7, 141.9, 135.6, 135.5, 134.5, 131.6, 128.2, 127.8, 125.9, 125.8, 123.0, 122.5, 117.1, 116.5, 




2-bromo-4-(isoindoline-2-carbonyl)benzamide (15): To a solution of 14 (50 mg, 0.15 mmol, 1 
eq.) in DMSO:ethanol (1:3) (3 mL) were added 2N sodium hydroxide solution (0.15 mL, 0.3 
mmol, 2 eq.) and 30 % hydrogen peroxide solution (0.034 mL, 0.3 mmol). The resulting mixture 
was extracted with ethyl acetate (3 × 5 mL). The resulting mixture was stirred for 2 h before the 
addition of water (5 mL). The organic layers were combined, washed with saturated sodium 
chloride solution (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The 
residue was purified by flash chromatography (SiO2, 1:3 hexane/ ethyl acetate) to give 15 as a 
white amorphous solid (35 mg. 71 %).1H NMR (500 MHz, Chloroform-d) δ 7.83 (d, J = 1.5 Hz, 
1H), 7.74 (d, J = 7.8 Hz, 1H), 7.58 (dd, J = 7.8, 1.6 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.19 (d, J = 7.6 
Hz, 1H), 6.15 (s, 1H), 5.88 (s, 1H), 5.02 (s, 2H), 4.75 (d, J = 1.5 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 168.3, 167.6, 139.9, 137.9, 135.9, 135.8, 131.9, 130.1, 128.0, 127.7, 125.9, 123.0, 122.5, 





(3-bromo-4-mercaptophenyl) (isoindolin-2-yl)methanone (16): The intermediate 18 (100mg, 
0.46 mmol, 1 eq.)  was dissolved in DCM (3 mL), to this solution were introduced, N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (175 mg, 0.92 mmol, 2.0 eq.), 
hydroxybenzotriazole hydrate (124.2 mg, 0.92 mmol, 2 eq.), N,N-Diisopropylethylamine (296 mg, 
2.3 mmol, 5 eq.) and isoindoline hydrochloride (80 mg, 0.5 mmol, 1.1 eq.) Reaction was stirred 
overnight at rt, before solvent was removed in vacuo, subsequently, water (10 mL) was added to 
the remaining crude mass, acidified with 1N HCl and extracted with ethyl acetate (10 mL x2). The 
organic fractions were combined, dried over sodium sulfate, filtered and concentrated. The 
resulting residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to obtain 
(3-bromo-4-fluorophenyl)(isoindolin-2-yl)methanone, which was dissolved in DMF (3 mL). To 
this solution, benzyl mercaptan (171 mg, 1.38 mmol, 3 eq.) and potassium carbonate (190 mg, 
1.38 mmol, 3 eq.) were added and heated to 140o C for 3h. The reaction was quenched with water 
(10 mL) and extracted with ethyl acetate (10 mL X 3). The organic fractions were combined, 
washed with brine (10 mL X 2), dried over sodium sulfate and subsequently, evaporated to result 
in a residue, which was passed through a pad of silica to yield (elution with 1:1 ethyl 
acetate:hexanes) to yield a crude mass. DCM (3 mL) was added to this mass, cooled to 0oC and 
1M boron tribromide solution in DCM (1.38 mL, 1.38 mmol, 3 eq.) was added slowly. Reaction 
was quenched with a brine (10 mL), extracted with ethyl acetate (10 X 3), dried over sodium 
sulfate and purified using column chromatography (SiO2, 1:3 ethyl acetate/hexanes) to produce 
16 (44 mg, 26% overall) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.84 (dd, J = 6.5, 
2.1 Hz, 1H), 7.55 (ddd, J = 8.4, 4.6, 2.1 Hz, 1H), 7.38 – 7.34 (m, 2H), 7.33 – 7.28 (m, 1H), 7.22 
(q, J = 8.2 Hz, 2H), 7.15 – 7.14 (m, 1H), 5.02 (s, 2H), 4.80 (d, J = 1.4 Hz, 2H). 13C NMR (126 
MHz, CDCl3) δ 167.8, 136.0, 132.6, 130.1, 128.0, 128.0, 127.9, 127.7, 125.9, 123.0, 122.5, 116.7, 
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116.6, 55.0, 52.6. HRMS (ESI) m/z [M+H] calculated for C15H13BrNOS, 335.9875, found 
335.9849. 
 
2-(2-hydroxy-5-(isoindoline-2-carbonyl)phenyl)-2-methylpropanenitrile (19):  A solution of 
10 (25 mg, 0.084 mmol, 1 eq.) in DCM (3 mL) under argon, was treated with trimethylsilyl cyanide 
(10 mg, 0.1 mmol, 1.2 eq.), cooled to 0°C, treated with BF3 etherate (15 mg, 0.1 mmol, 1.2 eq.), 
allowed to warm to room temperature and stirred for 2 h. The mixture was treated with sodium 
bicarbonate solution (5 mL), extracted with DCM (2 × 5 mL), the combined extracts washed with 
water (10 mL), dried over sodium sulfate, concentrated in vacuo and purified by chromatography 
[SiO2; heptane-EtOAc (6:4)] to furnish 19 (13 mg, 55 %) isolated as a white solid. 1H NMR (500 
MHz, Chloroform-d) δ 7.42 (m, 1H), 7.37 (d, J = 2.1 Hz, 1H), 7.35 – 7.29 (m, 3H), 7.18 (d, J = 
7.5 Hz, 1H), 6.90 (d, J = 8.2 Hz, 1H), 5.02 (s, 2H), 4.83 (s, 2H), 1.70 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 170.5, 157.6, 136.5, 131.2, 127.8 (2), 127.5, 127.4, 125.3 (2), 122.9, 122.4, 117.2 (2), 





(3-(2-azidopropan-2-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (20): A solution of 10 
(25 mg, 0.084 mmol, 1 eq.) in DCM (3 mL) under argon, was treated with sodium azide (17 mg, 
0.25 mmol, 3 eq.), cooled to 0°C, treated with BF3 etherate (15 mg, 0.1 mmol, 1.2 eq.), allowed to 
warm to room temperature and stirred for 4 h. The mixture was treated with 1N sodium bicarbonate 
solution (5 mL), extracted with DCM (2 × 5 mL), the combined extracts washed with water (10 
mL), dried over sodium sulfate, concentrated in vacuo and purified by chromatography [SiO2; 
heptane-EtOAc (6:4)] to furnish 20 (15 mg, 65 %) isolated as a white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.82 (s, 1H), 7.51 – 7.49 (m, 2H), 7.39 – 7.29 (m, 3H), 7.21 (d, J = 7.4 Hz, 1H), 
6.99 (d, J = 8.8 Hz, 1H), 5.05 (s, 2H), 4.86 (s, 2H), 1.77 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 
170.0, 156.5, 136.5, 136.3, 128.8, 128.3 (2), 127.8, 127.5, 125.7, 122.9, 122.4, 117.7, 64.4, 55.2, 
52.7, 26.7 (2). HRMS (ESI) m/z [M+Na] calculated for C18H18N4O2Na, 345.1327, found 345.1348.  
 
(3-(2-aminopropan-2-yl)-4-hydroxyphenyl) (isoindolin-2-yl)methanone (21): Intermediate  20 
(10 mg, 0.031 mmol, 1 eq.) was dissolved in ethanol (3 mL) contained in a 15 mL sealed vessel.  
Subsequently, ammonium formate (20 mg, 0.3 mmol, 10 eq.) and Palladium on carbon (10%) were 
introduced in the reaction vessel, which was sealed, and heated to 80o C for 10 h. Solvent was 
removed in vacuo, and water (5 mL) was then added to the remaining mass and extracted with 
ethyl acetate (10 mL X 3), dried, evaporated to result in a mass that was purified using preparative 
thin layer chromatography. (SiO2, 1:9 methanol:DCM) to yield 21 (7 mg, 68%) as a white solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.45 (d, J = 2.1 Hz, 1H), 7.41 (dd, J = 8.3, 2.1 Hz, 1H), 7.31 
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(m, 3H), 7.17 (d, J = 7.4 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 5.01 (s, 2H), 4.85 (s, 2H), 1.60 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 170.6, 159.7, 136.7, 136.5, 130.8, 127.8, 127.7, 127.4, 126.8, 
125.8, 122.9, 122.4, 116.9, 55.2, 54.4, 52.6, 31.4 (2). HRMS (ESI) m/z [M+H] calculated for 
C18H21N2O2, 297.1603, found 297.1619.  
 
(4-hydroxy-3-(2-methoxypropan-2-yl)phenyl)(isoindolin-2-yl)methanone (22): Ceric 
ammonium nitrate (15 mg, 0.027 mmol, 0.3 eq.) was added to a solution of 10 (25 mg, 0.084 
mmol, 1 eq.) in methanol (5 mL), contained in a sealed reaction vessel, which was heated to 80oC 
for 12 h, cooled, solvent evaporated under vacuum, and extracted with water (10 mL) and ethyl 
acetate (20 mL X 2). The organic fractions were collected, dried using sodium sulfate, concentrated 
to yield a residue that was purified using column chromatography (SiO2, 4:6 ethyl 
acetate:hexanes) to produce 22 (13 mg, 50%) as white solid. 1H NMR (500 MHz, Chloroform-d) 
δ 9.04 (s, 1H), 7.46 (dd, J = 8.3, 2.1 Hz, 1H), 7.39 (d, J = 2.1 Hz, 1H), 7.37 – 7.23 (m, 3H), 7.18 
(d, J = 7.2 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 5.02 (s, 2H), 4.85 (d, J = 6.6 Hz, 2H), 3.25 (s, 3H), 
1.63 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 170.3, 157.6, 136.6, 136.4, 128.8, 128.2, 127.8, 127.8, 
127.5, 126.8, 122.9, 122.4, 116.5, 80.2, 55.1, 52.6, 50.9, 26.4 (2). HRMS (ESI) m/z [M+H] 




(4-hydroxy-3-(2-phenoxypropan-2-yl)phenyl)(isoindolin-2-yl)methanone (23): Phenol (60 
mg, 0.67 mmol, 8 eq.) was introduced to a solution of 10 (25 mg, 0.084 mmol, 1 eq.) in 
trfluoroacetic acid :DCM (1:9, 5 mL) contained in a sealed vessel. The reaction was heated to 45oC 
for 24 h,  cooled, and the solvent removed under vacuum. Water (10 mL) and Ethyl acetate (20 
mL X 2) was used for extraction. Organic layers were combined, dried over sodium sulfate and 
concentrated to result in a residue mass that was purified using preparative thin layer 
chromatography. (SiO2, 3:7 ethyl acetate:hexanes) to yield 23 (8 mg, 25%) as a white solid. 1H 
NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 2.0 Hz, 1H), 7.40 (m, 1H), 7.31 (d, J = 28.4 Hz, 
4H), 7.20 (d, J = 7.3 Hz, 1H), 7.18 – 7.10 (m, 2H), 6.77 (m, 3H), 5.05 (s, 2H), 4.88 (s, 2H), 1.64 
(s, 6H). 13C NMR (101 MHz, CDCl3) δ 171.0, 155.9, 155.5, 138.4, 136.5, 136.3, 135.7, 128.0, 
127.8, 127.5, 127.2 (2), 127.0, 126.2 (2), 122.9, 122.4, 117.2, 116.1, 55.2, 53.4, 52.7, 29.6 (2). 
HRMS (ESI) m/z [M+H] calculated for C24H24NO3, 374.1756, found 374.1773.  
 
(3-(sec-butyl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (24): (4-(benzyloxy)-3-
bromophenyl)(isoindolin-2-yl)methanone (29) (100 mg, 0.24 mmol, 1 eq.) was dissolved in 
122 
 
THF:water (8:2) (10 mL). Subsequently, Potassium (2Z)-2-buten-2-yltrifluoroborate (60 mg, 0.36 
mmol, 1.5 eq.), cesium carbonate (156 mg, 0.48 mmol, 2 eq.) and 
tetrakis(triphenylphosphine)palladium (0) (27 mg, 0.024 mmol, 0.1 eq) were introduced to this 
solution in a 15 mL sealed reaction vessel, purged with argon before closing the cap and heating 
to 100oC for 10 h. The reaction mass was transferred to a round bottom flask and solvent was 
removed under vacuum. Water (10 mL) was added to the crude and ethyl acetate (20 mL X 2) was 
used for extraction. Organic layers were combined, dried over sodium sulfate and concentrated to 
result in a residue that was passed through a small pad of silica (eluted with 4:6 ethyl 
acetate:hexanes), concentrated, to give a brown residue. Obtained residue was dissolved in ethyl 
acetate (10 mL), and hydrogenation was performed using palladium on carbon (10%). Upon 
completion of reaction as indicated by TLC, the reaction mixture was filtered through a pad of 
Celite and column chromatography (SiO2, 3:7 ethyl acetate:hexanes) then furnished 24 (28 mg, 
40%) as a white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.35 (d, J = 2.2 Hz, 1H), 7.29 – 7.16 
(m, 4H), 7.10 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 5.20 (s, 1H), 4.95 (s, 2H), 4.74 (s, 2H), 
2.94 (q, J = 7.0 Hz, 1H), 1.66 – 1.52 (m, 2H), 1.20 – 1.17 (d, 3H), 0.82 (t, J = 7.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 170.7, 154.7, 133.3, 128.9, 127.7, 127.4, 126.7, 125.9, 122.9, 122.4, 
115.0, 55.2, 52.6, 33.9, 29.7, 20.3, 12.1. HRMS (ESI) m/z [M+H] calculated for C19H22NO2, 







General procedure A: 
 
A solution of the desired Grignard’s reagent (0.85 mmol, 5 eq.) in THF was added to a solution of 
31 (50 mg, 0.17 mmol, 1 eq.) in THF (5 mL) at 0oC. The reaction mixture was stirred at 0oC for 
15 min, allowed to warm to rt. Upon completion of the reaction, as indicated by TLC, reaction was 
quenched with 1N HCl (2 mL) and then extraction was performed using ethyl acetate (10 mL X 
3). Organic layers were combined, washed with water (10 mL), dried over sodium sulfate and 
concentrated. The resulting residue was purified using flash chromatography (SiO2, 4:6 ethyl 
acetate:hexanes) to result in the desired final products, which purified again using a preparative 
TLC (SiO2, 2:98 methanol:DCM). 
 
(4-hydroxy-3-(2-hydroxybutan-2-yl)phenyl)(isoindolin-2-yl)methanone (25): Prepared using 
general procedure A, yield 74 %, off white solid. 1H NMR (400 MHz, Chloroform-d) δ 9.59 (s, 
1H), 7.31 (dd, J = 8.3, 2.1 Hz, 1H), 7.19 (s, 3H), 7.17 (d, J = 2.1 Hz, 1H), 7.09 (d, J = 7.3 Hz, 1H), 
6.79 (d, J = 8.3 Hz, 1H), 4.93 (s, 2H), 4.80 – 4.66 (m, 2H), 1.85 (m, 2H), 1.57 (s, 3H), 0.83 (t, J = 
7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.6, 158.1, 136.5, 136.4, 129.6, 127.8, 127.6, 127.5, 
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127.1, 126.1, 122.9, 122.4, 117.2, 78.9, 55.2, 52.6, 35.3, 28.1, 8.4. HRMS (ESI) m/z [M+H] 
calculated for C19H22NO3, 312.1600, 312.1624.  
 
4-(benzyloxy)-3-(3-hydroxypentan-3-yl)benzoic acid (33): A solution of 32 (1 g, 4.6 mmol, 1 
eq.) in acetone (20 mL) was treated with benzyl bromide (2g, 11.5 mmol, 2.5 eq.) and potassium 
carbonate (1.9 g, 13.8 mmol, 3 eq.). The resulting mixture was stirred, heated at 50o C for 10 h. 
Solvent was removed under vacuum, then, water (50 mL) and ethyl acetate (50 mL X 3) were used 
for extraction. Organic fractions were combined, dried over sodium sulfate, and concentrated 
under vacuum to result in a white solid mass. This residue was dissolved in Ethanol (30 mL), 2N 
aq. Sodium hydroxide solution was then added, and the reaction was heated to 60oC till completion 
of the reaction, which was monitored using TLC. Ethanol was then removed from the reaction 
mixture and the water (50 mL) was added to the concentrated reaction mass. Subsequently, 1N 
HCl was added to adjust the pH ~3. Extraction was then performed using ethyl acetate (50 mL X 
2). Organic layers were then combined, washed with water, dried over sodium sulfate and 
concentrated to produce a white mass.  A quick chromatography (SiO2, 3:7 ethyl acetate:hexane) 
was performed to obtain 4-(benzyloxy)-3-bromobenzoic acid as white solid. 
In the following step, 4-(benzyloxy)-3-bromobenzoic acid (200 mg, 0.65 mmol, 1 eq.) was 
dissolved in THF (10 mL), cooled to -78oC, and a 2.5 M solution of n-BuLi (0.8 mL, 2 mmol, 3 
eq.) in hexanes was added slowly. The reaction was stirred at -78oC for 30 mins, before 3-
Pentanone (0.35 mL, 3.25 mmol, 5 eq.) was introduced. Reaction was allowed to warm to 0o C, 
and stirred for additional 1 h before it was quenched with saturated ammonium chloride solution 
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(10 mL).  Extraction was then performed using ethyl acetate (30 mL X 2). The resulting organic 
fractions were combined, dried, evaporated to result in a residue, which was purified using column 
chromatography (SiO2, 4:6 ethyl acetate:hexanes) to yield 33 (30 mg, 15 %) as a white solid. 1H 
NMR (400 MHz, Chloroform-d) δ 8.17 (d, J = 2.2 Hz, 1H), 8.02 (dd, J = 8.6, 2.2 Hz, 1H), 7.46 – 
7.35 (m, 5H), 7.04 (d, J = 8.6 Hz, 1H), 5.20 (s, 2H), 2.13 (m, 2H), 1.90 – 1.78 (m, 2H), 0.78 (t, J 
= 7.4 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 170.9, 160.3, 133.3, 130.9, 130.7, 128.9 (2), 128.5, 
127.6 (2), 121.5, 111.9, 99.9, 77.9, 70.9, 32.4 (2), 8.3 (2). HRMS (ESI) m/z [M+H] calculated for 
C19H23O4, 315.1596, found 315.1615. 
 
(4-hydroxy-3-(3-hydroxypentan-3-yl)phenyl)(isoindolin-2-yl)methanone (26): 33 (25 mg, 
0.08 mmol, 1 eq.) was dissolved in DCM (3 mL) together with N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (30 mg, 0.16 mmol, 2.0 eq.), hydroxybenzotriazole hydrate (22 
mg, 0.16 mmol, 2 eq.), N, N-Diisopropylethylamine (51 mg, 0.4 mmol, 5 eq.) and isoindoline 
hydrochloride ( 14 mg, 0.09 mmol, 1.1 eq.). The resulting mixture was stirred at rt for 12 h, before 
solvent was removed in vacuo, subsequently, water (10 mL) was added to the remaining crude 
mass, acidified with 1N HCl and extracted with ethyl acetate (10 mL x2). The organic fractions 
were combined, dried over sodium sulfate, filtered and concentrated. The resulting residue was 
purified by a quick flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to obtain a white crude 
mass. In the subsequent reaction, the obtained solid mass (~20 mg) was dissolved in DCM (5mL), 
cooled to 0oC, subsequently, 1M DCM solution of boron tribromide (0.144 mL, 0.144 mmol, 3 
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eq.) was added.  The reaction was stirred and allowed to gradually warm to rt over 1 h, before the 
reaction was quenched with water (10 mL). DCM fraction was separated, and aqueous layer was 
washed with DCM (10 mL X2). Organic fractions were combined, dried over sodium sulfate, and 
concentrated to yield a residue that was purified using preparative TLC (SiO2, 3:7 ethyl 
acetate:hexanes) to result in 26 (9 mg, 34 %) as white solid. 1H NMR (500 MHz, Chloroform-d) δ 
9.67 (s, 1H), 7.34 (dd, J = 8.4, 2.1 Hz, 1H), 7.29 – 7.16 (m, 3H), 7.14 (d, J = 2.1 Hz, 1H), 7.10 (d, 
J = 7.2 Hz, 1H), 6.82 (d, J = 8.4 Hz, 1H), 4.94 (s, 2H), 4.75 (s, 2H), 1.94 (m, 2H), 1.80 (m, 2H), 
0.84 (t, J = 7.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 170.4, 159.1, 136.5, 136.5, 127.8, 127.7, 
127.5, 127.2, 126.8, 126.5, 122.9, 122.4, 117.4, 82.7, 55.2, 52.7, 34.3 (2), 7.88 (2). HRMS (ESI) 
m/z [M+H] calculated for C20H24NO3, 326.1756, found 326.1779.  
 
1-(2-(benzyloxy)-5-(isoindoline-2-carbonyl)phenyl)ethan-1-one (34): To a round bottom flask 
containing 31 (1 g, 3.5 mmol, 1 eq.) dissolved in acetone (30 mL) were added potassium carbonate 
(580 mg, 4.2 mmol, 1.2 eq) and benzyl bromide (0.53 mL, 4.2 mmol, 1.2 eq.). Reaction was then 
refluxed for 12 h, cooled, solvent removed under vacuum, and remaining mass was extracted using 
water (50 mL) and ethyl acetate (50 X 2). Organic fractions were collected, washed with water (50 
mL), dried over sodium sulfate, concentrated and purified using column chromatography (SiO2, 
3:7 ethyl acetate:hexanes) to afford 34 (1.1 g, 84%) as white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 8.05 (d, J = 2.3 Hz, 1H), 7.77 (dd, J = 8.6, 2.3 Hz, 1H), 7.50 – 7.27 (m, 8H), 7.15 
(dd, J = 27.6, 8.0 Hz, 2H), 5.25 (s, 2H), 5.03 (s, 2H), 4.86 (s, 2H), 2.64 (s, 3H). 13C NMR (126 
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MHz, CDCl3) δ 198.9, 169.0, 159.2, 136.4, 136.2, 135.6, 133.2, 129.5, 129.1, 128.8 (2), 128.5, 
128.0, 127.8, 127.6 (2), 127.5, 122.9, 122.4, 113.0, 70.9, 55.0, 52.7, 32.1. HRMS (ESI) m/z 
[M+Na] calculated for C24H21NO3Na, 394.1419, found 394.1435.  
 
(4-hydroxy-3-(1,1,1-trifluoro-2-hydroxypropan-2-yl)phenyl)(isoindolin-2-yl)methanone 
(27): A solution of 34 (25 mg, 0.07 mmol, 1 eq.) in THF (5 mL) was cooled to 0oC, 
trifluoromethyltrimethylsilane (35 PL, 0.21 mmol, 3 eq.) and 1M THF solution of tetra-n-
butylammonium fluoride (TBAF) (0.21 mL, 0.21 mmol, 3 eq.) were then introduced. The reaction 
was then allowed to warm to rt and reaction was monitored for consumption of starting material 
using TLC. Upon completion, reaction was quenched with sat. ammonium chloride solution, 
extracted with ethyl acetate (10 mL X 3). Organic fractions were combined, dried over sodium 
sulfate and evaporated to produce a residue that was subjected to subsequent reaction without 
purification. In the following step, the obtained residue was dissolved in DCM (5 mL), cooled to 
0oC, and 1M DCM solution of BCl3 (0.21 mL, 0.21 mmol, 3 eq.) was then added slowly. Reaction 
was stirred at 0oC till completion, as monitored via TLC.  Water (5mL) was then added to the 
reaction mixture, and extraction was performed using ethyl acetate (10 mL X 3). Organic fractions 
were combined washed with water (20 mL), dried (Na2SO4), and evaporated under vacuum to 
result in a mass that was purified using column chromatography (SiO2, 3:7 ethyl acetate:hexanes) 
to afford 27 (11 mg, 45%) as white solid. 1H NMR (500 MHz, Chloroform-d) δ 9.41 (s, 1H), 7.31 
– 7.20 (m, 4H), 7.10 (q, J = 3.0 Hz, 2H), 6.71 (d, J = 8.4 Hz, 1H), 6.22 (s, 1H), 4.92 (s, 2H), 4.65 
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(q, J = 14.4 Hz, 2H), 1.69 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.9, 158.9, 136.0, 135.8, 128.8 
(2), 127.9, 127.7, 127.0, 126.6, 122.9, 122.5, 121.6, 118.6, 77.2, 55.1, 52.7, 22.6. HRMS (ESI) m/z 
[M+H] calculated for C18H17F3NO3, 352.1161, found 352.1176.   
 
(4-hydroxy-3-(prop-1-en-2-yl)phenyl)(isoindolin-2-yl)methanone (30): A reaction vessel was 
charged with 29 (100 mg, 0.24 mmol, 1 eq.), potassium isopropenyltrifluoroborate (53 mg, 0.36 
mmol, 1.5 eq.),  cesium carbonate (156 mg, 0.48 mmol, 2 eq.), 
tetrakis(triphenylphosphine)palladium (0) (27 mg, 0.024 mmol, 0.1 eq). Into this vessel, solvent 
(10 mL, 1:9, water: THF) was added, purged with argon, sealed with Teflon lined cap and heated 
to 100oC for 10 h.  Reaction was cooled, solvent removed under pressure, and the remaining mass 
extracted using water (30 mL) and ethyl acetate (30 mL X 2). Organic fractions were combined, 
dried, and evaporated to a white mass. Boron trichloride solution (0.72 mL of 1M DCM solution, 
0.72 mmol, 3 eq.) was then added to a 0oC cooled solution of the obtained mass in DCM (5 mL). 
Upon completion as monitored by TLC, the reaction was quenched with sat. ammonium chloride 
solution (10 mL). Extraction was performed using water (20 mL) and DCM (20 mL X 2), 
subsequently, DCM fractions were combined, dried over sodium sulfate and adsorbed on silica for 
purification using flash chromatography (SiO2, 3:7 ethyl acetate:hexanes) to afford 30 (46 mg, 
70%) as off white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.37 – 7.32 (m, 2H), 7.29 – 7.17 
(m, 4H), 7.10 (d, J = 7.5 Hz, 1H), 6.90 (d, J = 8.3 Hz, 1H), 6.07 (s, 1H), 5.37 (p, J = 1.6 Hz, 1H), 
5.12 (dd, J = 1.8, 0.9 Hz, 1H), 4.95 (s, 2H), 4.77 (s, 2H), 2.07 (t, J = 1.2 Hz, 3H). 13C NMR (126 
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MHz, CDCl3) δ 170.1, 153.7, 141.5, 136.5, 136.4, 128.9, 128.4, 127.8, 127.7, 127.5, 127.4, 122.9, 
122.4, 116.5, 115.4, 55.2, 52.6, 24.1. HRMS (ESI) m/z [M+H] calculated for C18H18NO2, 
280.1338, found 280.1335.  
 
(3-(1,2-dihydroxypropan-2-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (28): 
Compound 30 (25 mg, 0.09 mmol, 1 eq.) was dissolved in 2mL of acetone: t-butanol: water solvent 
mixture. Osmium tetraoxide (0.1 mL of 4% aq. solution) and N-methylmorpholine-N-Oxide (40 
mg, 0.34 mmol, 3.8 eq.) were then added and the reaction was stirred for 1 h at rt, quenched with 
water and extracted with ethyl acetate (20 mLX 2). Organic layers were combined washed with 
water and adsorbed on silica for purification (SiO2, 4:6 ethyl acetate:hexanes) which afforded 28 
(19 mg, 67%) as white solid. 1H NMR (500 MHz, Chloroform-d) δ 9.76 (s, 1H), 7.39 (dd, J = 8.4, 
2.0 Hz, 1H), 7.35 – 7.27 (m, 4H), 7.17 (d, J = 7.3 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 5.07 – 4.92 
(m, 2H), 4.90 – 4.76 (m, 2H), 4.54 (s, 1H), 3.95 (d, J = 11.2 Hz, 1H), 3.60 – 3.43 (m, 2H), 1.55 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 170.7, 158.8, 136.3, 136.0, 127.9, 127.8, 127.7, 127.6, 126.8, 
126.1, 122.9, 122.4, 117.4, 78.0, 68.6, 55.2, 52.7, 24.9. HRMS (ESI) m/z [M+H] calculated for 




(4-hydroxy-3-(2-hydroxypentan-2-yl)phenyl)(isoindolin-2-yl)methanone (35a): Prepared 
using general procedure A, 40 mg, Yield 72%, white solid: 1H NMR (500 MHz, Chloroform-d) δ 
9.90 (s, 1H), 7.38 – 7.25 (m, 4H), 7.21 (q, J = 3.0 Hz, 1H), 7.17 (d, J = 7.0 Hz, 1H), 6.82 (dd, J = 
8.3, 3.8 Hz, 1H), 5.11 – 4.93 (m, 2H), 4.81 (m, 3.8 Hz, 2H), 4.18 – 3.87 (m, 1H), 1.82 (m, 2H), 
1.62 (s, 3H), 1.40 – 1.19 (m, 2H), 0.89 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 170.8, 158.1, 
136.4, 136.3, 130.4, 127.8, 127.5, 127.4, 126.7, 125.9, 122.9, 122.4, 117.2, 78.2, 55.2, 52.7, 45.0, 
28.3, 17.3, 14.3. HRMS (ESI) m/z [M+H] calculated for C20H24NO3, 326.1756, found 326.1768.  
 
(4-hydroxy-3-(2-hydroxyhexan-2-yl)phenyl)(isoindolin-2-yl)methanone (35b): Prepared 
using general procedure A, 44 mg, Yield 77%, white solid: 1H NMR (500 MHz, Chloroform-d) δ 
9.95 (s, 1H), 7.37 – 7.23 (m, 4H), 7.19 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 7.4 Hz, 1H), 6.81 (d, J = 
8.3 Hz, 1H), 5.05 – 4.93 (m, 2H), 4.86 – 4.73 (m, 2H), 1.93 – 1.74 (m, 2H), 1.61 (s, 3H), 1.27 (tdd, 
J = 14.3, 9.0, 5.0 Hz, 4H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.9, 158.1, 
136.4, 136.2, 130.4, 127.8, 127.5, 127.4, 126.6, 125.8, 122.9, 122.4, 117.2, 78.1, 55.2, 52.7, 42.5, 





(4-hydroxy-3-(2-hydroxyheptan-2-yl)phenyl)(isoindolin-2-yl)methanone (35c): Prepared 
using general procedure A, 39 mg, Yield 65%, white solid: 1H NMR (500 MHz, Chloroform-d) δ 
7.37 (dd, J = 8.3, 2.1 Hz, 1H), 7.35 – 7.27 (m, 3H), 7.24 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 7.5 Hz, 
1H), 6.85 (d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.82 (d, J = 16.1 Hz, 2H), 1.94 – 1.76 (m, 2H), 1.64 (s, 
3H), 1.36 – 1.19 (m, 6H), 0.88 – 0.82 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 170.7, 158.0, 136.3, 
130.0, 127.8, 127.6, 127.5, 126.9, 125.9, 122.9, 122.4, 117.3, 78.6, 55.2, 52.7, 42.7, 31.9, 28.5, 




Prepared using general procedure A, 38 mg, Yield 70%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.80 (s, 1H), 7.40 – 7.25 (m, 4H), 7.21 (d, J = 2.1 Hz, 1H), 7.18 (d, J = 7.4 Hz, 
1H), 6.84 (d, J = 8.3 Hz, 1H), 5.08 – 4.94 (m, 2H), 4.80 (q, J = 14.3 Hz, 2H), 3.36 (s, 1H), 2.17 (p, 
J = 6.8 Hz, 1H), 1.60 (s, 3H), 0.99 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.7, 158.1, 136.5, 136.3, 129.6, 127.8, 127.6, 127.5, 126.7, 126.7, 122.9, 122.4, 
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117.3, 81.2, 55.2, 52.7, 37.5, 24.8, 17.5, 17.1. HRMS (ESI) m/z [M+H] calculated for C20H24NO3, 
326.1756, found 326.1763.  
 
(4-hydroxy-3-(2-hydroxy-4-methylpentan-2-yl)phenyl)(isoindolin-2-yl)methanone (35e): 
Prepared using general procedure A, 35 mg, Yield 61%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.79 (s, 1H), 7.38 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.26 (d, J = 2.1 
Hz, 1H), 7.18 (d, J = 7.4 Hz, 1H), 6.86 (d, J = 8.3 Hz, 1H), 5.00 (t, J = 11.1 Hz, 2H), 4.81 (q, J = 
14.3 Hz, 2H), 1.92 – 1.84 (m, 1H), 1.79 – 1.71 (m, 2H), 1.68 (s, 3H), 0.92 (d, J = 6.4 Hz, 3H), 0.85 
(d, J = 6.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.6, 158.0, 136.5, 136.3, 130.3, 127.8, 127.5, 
127.5, 127.0, 126.0, 122.9, 122.4, 117.2, 79.1, 55.2, 52.7, 51.3, 29.4, 24.6, 24.5, 24.5. HRMS (ESI) 
m/z [M+H] calculated for C21H26NO3, 340.1913, found 340.1926.  
 
(4-hydroxy-3-(2-hydroxy-5-methylhexan-2-yl)phenyl)(isoindolin-2-yl)methanone (35f):  
Prepared using general procedure A, 40 mg, Yield 65%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.81 (s, 1H), 7.39 – 7.24 (m, 4H), 7.21 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 7.4 Hz, 
1H), 6.83 (d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.80 (s, 2H), 3.80 (s, 1H), 1.77-1.93 (m, 2H), 1.63 (s, 
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3H), 1.49 (dp, J = 13.3, 6.6 Hz, 1H), 1.29 – 1.11 (m, 2H), 0.86 (dd, J = 8.9, 6.6 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 170.8, 158.1, 136.5, 136.3, 130.2, 127.8, 127.5, 127.5, 126.8, 125.8, 122.9, 
122.3, 117.3, 78.4, 55.2, 52.6, 40.5, 32.9, 28.3, 28.2, 22.6, 22.6. HRMS (ESI) m/z [M+H] 
calculated for C22H28NO3, 354.2069, found 354.2065.  
 
(4-hydroxy-3-(2-hydroxy-5-methoxypentan-2-yl)phenyl)(isoindolin-2-yl)methanone (35g):  
Prepared using general procedure A,  33 mg, Yield 55%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 10.44 (s, 1H), 7.40 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.18 (d, J = 7.4 
Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H), 5.85 (s, 1H), 5.01 (s, 2H), 4.84 (s, 2H), 3.50 – 3.42 (m, 2H), 
3.39 (s, 3H), 2.34 (m, 1H), 1.93 (m, 1H), 1.87 – 1.72 (m, 2H), 1.60 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 170.5, 158.7, 136.6, 136.5, 130.1, 127.7, 127.4, 127.1, 126.2, 122.9, 122.4, 117.2, 77.6, 
77.2, 73.3, 58.7, 55.2, 52.6, 40.6, 30.0, 24.5. HRMS (ESI) m/z [M+H] calculated for C21H26NO4, 
356.1862, found 356.1878.  
 
(4-hydroxy-3-(2-hydroxyhex-5-en-2-yl)phenyl)(isoindolin-2-yl)methanone (35h): Prepared 
using general procedure A, 31 mg, Yield 55%, white solid: 1H NMR (500 MHz, Chloroform-d) δ 
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9.65 (s, 1H), 7.40 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 – 7.27 (m, 3H), 7.17 (d, J = 7.5 Hz, 1H), 6.87 (d, 
J = 8.3 Hz, 1H), 5.87 – 5.75 (m, 1H), 5.07 – 4.94 (m, 4H), 4.88 – 4.75 (m, 2H), 3.23 (t, J = 1.5 Hz, 
1H), 2.17 – 2.02 (m, 3H), 1.93 (m, 1H), 1.68 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.5, 158.0, 
138.0, 136.5, 136.3, 129.6, 127.8, 127.7, 127.5, 127.2, 126.0, 122.9, 122.4, 117.4, 115.2, 78.8, 
55.2, 52.7, 41.6, 28.9, 28.4. HRMS (ESI) m/z [M+H] calculated for C21H24NO3, 338.1756, found 
338.1769.  
 
(4-hydroxy-3-(2-hydroxypent-4-en-2-yl)phenyl)(isoindolin-2-yl)methanone (35h): A solution 
of the allyl magnesium bromide (0.85 mmol, 5 eq.) in THF was added to a solution of 31 (50 mg, 
0.17 mmol, 1 eq.) in THF (5 mL) at -20oC. The reaction mixture was stirred at -20oC for 15 min, 
allowed to warm to rt. Upon completion of the reaction, as indicated by TLC, reaction was 
quenched with 1N HCl (2 mL) and then extraction was performed using ethyl acetate (10 mL X 
3). Organic layers were combined, washed with water (10 mL), dried over sodium sulfate and 
concentrated. The resulting residue was purified using flash chromatography (SiO2, 4:6 ethyl 
acetate:hexanes) to produce 35h (27mg, 50%) as white solid. 1H NMR (500 MHz, Chloroform-d) 
δ 9.55 (s, 1H), 7.43 (dd, J = 8.3, 2.1 Hz, 1H), 7.39 – 7.29 (m, 4H), 7.20 (d, J = 7.5 Hz, 1H), 6.91 
(d, J = 8.3 Hz, 1H), 5.82 (m, 1H), 5.28 – 5.19 (m, 2H), 5.03 (s, 2H), 4.84 (s, 2H), 2.84 (m, 1H), 
2.59 (m, 1H), 1.66 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.4, 157.9, 136.5, 136.4, 132.6, 129.5, 
127.8, 127.8, 127.5, 127.4, 125.9, 122.9, 122.4, 120.8, 117.4, 77.2, 55.2, 52.6, 46.5, 28.5. HRMS 





(35j): Methyl propargyl ether (0.06 mL, 0.7 mmol) was added to benzene (2 mL) in a round bottom 
flask. Ethyl magnesium bromide (0.3 mL 3M solution in THF, 1 mmol) was then introduced 
dropwise at rt. Reaction was stirred for 30 mins, 31 (25 mg, 0.09 mmol, 1 eq.) was quickly added 
to this solution and heated to 80o C. Reaction was monitored via TLC for completion, 
subsequently, sat ammonium chloride solution was added to the reaction, acidified with 1N HCl 
and extracted with ethyl acetate (10 mL X 2).  Purification with column chromatography (SiO2, 
3:7 ethyl acetate:hexanes) afforded 35j (18 mg, 58%) as white solid. 1H NMR (600 MHz, 
Chloroform-d) δ 8.97 (s, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.34 (dd, J = 8.3, 2.2 Hz, 1H), 7.28 – 7.17 
(m, 3H), 7.09 (d, J = 7.6 Hz, 1H), 6.80 (d, J = 8.3 Hz, 1H), 4.93 (s, 2H), 4.76 (t, J = 11.3 Hz, 3H), 
4.09 (s, 2H), 3.28 (s, 3H), 1.79 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 170.4, 156.9, 136.5, 136.2, 
128.6, 128.1, 127.8, 127.5, 127.2, 126.4, 122.9, 122.4, 117.6, 87.9, 82.2, 71.9, 59.8, 57.8, 55.2, 
52.7, 31.2. HRMS (ESI) m/z [M+H] calculated for C21H22NO4, 352.1549, found 352.1561. 
 
(3-(2,5-dihydroxypentan-2-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (35k): In a vial 
containing solution of 35h (20 mg, 0.06 mmol, 1 eq.) in dioxane:water (2 mL, 8:2) was added 
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osmium tetraoxide (0.1 mL of 4% aq. solution), 2,6-Lutidine (0.05 mL, 0.45 mmol, 8 eq.), and 
sodium metaperiodate (26 mg, 0.12 mmol, 2 eq.). Reaction was stirred for 12 h at rt, before 
quenching the reaction with 10 mL water and extraction with ethyl acetate (10 mL X 3). Organic 
layers were combined, washed with brine, dried with sodium sulfate, concentrated and purified 
using a quick flash chromatography (5:5 ethyl acetate:hexane) to result in a mass  containing the 
desired aldehyde. The resulting mass was dissolved in THF (5 mL), cooled to 0o C and sodium 
cyanoborohydride (18 mg, 0.3 mmol, 5 eq.) was introduced. Reaction was warmed to rt and the 
progress was monitored using TLC for consumption of the aldehyde via 2,4-
Dinitrophenylhydrazine stain. Upon completion, reaction was concentrated extracted with water 
(5 ml) and ethyl acetate (10 mL). organic layer was dried over sodium sulfate, concentrated and 
purified using column chromatography (SiO2, 3:7 ethyl acetate:hexane) to afford 35k (12 mg, 
62%) as white solid. 1H NMR (500 MHz, Chloroform-d) δ 10.22 (s, 1H), 7.31 (dd, J = 8.3, 2.1 Hz, 
1H), 7.29 – 7.20 (m, 4H), 7.14 – 7.08 (m, 1H), 6.81 (d, J = 8.3 Hz, 1H), 4.93 (s, 2H), 4.76 (s, 2H), 
3.70 – 3.55 (m, 2H), 2.23 (m, 1H), 1.88 (m, 1H), 1.75 – 1.59 (m, 2H), 1.56 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.56, 158.60, 136.58, 136.38, 130.12, 127.79, 127.48, 127.11, 126.22, 122.93, 
122.42, 117.26, 99.99, 77.74, 77.23, 55.23, 52.67, 40.24, 29.96, 26.76. 13C NMR (126 MHz, 
CDCl3) δ 170.6, 158.6, 136.6, 136.4, 130.1, 127.8, 127.5, 127.1, 126.2, 122.9, 122.4, 117.2, 99.9, 
77.7, 77.2, 55.2, 52.7, 40.2, 29.9, 26.7. HRMS (ESI) m/z [M+H] calculated for C20H24NO4, 




(4-hydroxy-3-(1-hydroxy-1-phenylethyl)phenyl)(isoindolin-2-yl)methanone (36a): Prepared 
using general procedure A, 41 mg, Yield 68%, white solid: 1H NMR (500 MHz, Chloroform-d) δ 
9.08 (s, 1H), 7.46 – 7.41 (m, 3H), 7.38 – 7.28 (m, 6H), 7.25 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 7.3 
Hz, 1H), 6.89 (d, J = 8.3 Hz, 1H), 4.98 (s, 2H), 4.82 – 4.61 (m, 2H), 2.00 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 170.3, 157.6, 145.7, 136.5, 136.3, 130.8, 128.4, 128.3, 127.8, 127.7, 127.5, 127.0, 
126.9, 125.6, 122.9, 122.3, 117.5, 78.9, 55.1, 52.7, 30.6. HRMS (ESI) m/z [M+H] calculated for 
C23H22NO3, 360.1600, found 360.1599.  
 
(4-hydroxy-3-(2-hydroxy-1-phenylpropan-2-yl)phenyl)(isoindolin-2-yl)methanone (36b):  
Prepared using general procedure A, 45 mg, Yield 72%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.62 (s, 1H), 7.38 (dd, J = 8.4, 2.0 Hz, 1H), 7.31 (m, 3H), 7.25 (m, 3H), 7.18 (d, 
J = 7.1 Hz, 1H), 7.05 – 6.98 (m, 3H), 6.89 (d, J = 8.3 Hz, 1H), 5.06 – 4.82 (m, 2H), 4.62 – 4.42 
(m, 2H), 3.83 (s, 1H), 3.25 – 3.05 (m, 2H), 1.59 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.7, 
157.9, 136.5, 136.3, 130.8 (2), 129.4, 128.2 (2), 128.0, 127.8, 127.5, 126.8, 126.8, 125.7, 122.9, 
122.4, 117.5, 77.8, 77.3, 54.9, 52.6, 48.1, 27.2. HRMS (ESI) m/z [M+H] calculated for C24H24NO3, 





Prepared using general procedure A, 46 mg, Yield 70%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.70 (s, 1H), 7.30 (dd, J = 8.3, 2.1 Hz, 1H), 7.28 – 7.14 (m, 6H), 7.11 – 7.03 (m, 
4H), 6.78 (d, J = 8.3 Hz, 1H), 5.02 – 4.86 (m, 2H), 4.80 – 4.64 (m, 2H), 3.65 – 3.55 (s, 1H)2.61 
(m, 2H), 2.22 – 1.97 (m, 2H), 1.63 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.6, 158.1, 141.6, 
136.4, 136.3, 129.8, 128.5, 128.3, 127.8, 127.6, 127.5, 127.1, 125.9, 125.8, 122.9, 122.4, 117.4, 




Prepared using general procedure A, 48 mg, Yield 70%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 10.08 (s, 1H), 7.52 – 7.45 (m, 3H), 7.45 – 7.36 (m, 3H), 7.32 – 7.20 (m, 5H), 6.96 
(d, J = 8.3 Hz, 1H), 5.14 (d, J = 4.1 Hz, 2H), 4.95 – 4.81 (m, 2H), 4.51 – 4.43 (m, 1H), 2.73 (t, J 
= 7.7 Hz, 2H), 2.04 (m, 2H), 1.89 – 1.69 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.9, 158.1, 
142.0, 136.3, 136.2, 130.2, 128.3 (2), 128.3 (2), 127.8, 127.5, 127.5, 126.6, 125.8, 125.6, 122.9, 
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122.4, 117.3, 77.9, 55.2, 52.7, 42.2, 35.9, 28.2, 25.9. HRMS (ESI) m/z [M+H] calculated for 
C26H28NO3, 402.2069, found 402.2071. 
 
(4-hydroxy-3-(2-hydroxy-6-phenylhexan-2-yl)phenyl)(isoindolin-2-yl)methanone (36e): 
Prepared using general procedure A, 46 mg, Yield 65%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.84 (s, 1H), 7.37 – 7.27 (m, 3H), 7.27 – 7.18 (m, 3H), 7.17 – 7.09 (m, 5H), 6.83 
(d, J = 8.3 Hz, 1H), 5.06 – 4.91 (m, 2H), 4.88 – 4.69 (m, 2H), 3.95 (s, 1H), 2.57 (t, J = 7.8 Hz, 
2H), 1.88 (m, 2H), 1.62 (s, 5H), 1.46 – 1.27 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.8, 158.1, 
142.3, 136.4, 136.2, 130.3, 128.3 (2), 128.2 (2), 127.8, 127.5, 127.5, 126.8, 125.8, 125.6, 122.9, 
122.4, 117.3, 78.2, 55.2, 52.7, 42.4, 35.7, 31.6, 28.2, 23.7. HRMS (ESI) m/z [M+H] calculated for 
C27H30NO3, 416.2226, found 416.2230.  
 
(4-(benzyloxy)-3-(2-hydroxypent-4-en-2-yl)phenyl)(isoindolin-2-yl)methanone (38): A 
solution of the allyl magnesium bromide (7.8 mmol, 3 eq.) in THF was added to a solution of 34 
(1 g mg, 2.6 mmol, 1 eq.) in THF (5 mL) at -20oC. The reaction mixture was stirred at -20oC for 
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15 min, allowed to warm to rt. Upon completion of the reaction, as indicated by TLC, reaction was 
quenched with 1N HCl (20 mL) and then extraction was performed using ethyl acetate (20 mL X 
3). Organic layers were combined, washed with water (10 mL), dried over sodium sulfate and 
concentrated. The resulting residue was purified using flash chromatography (SiO2, 4:6 ethyl 
acetate:hexanes) to produce 38 (0.72 g, 73%) as white solid. 1H NMR (500 MHz, Chloroform-d) 
δ 7.68 (d, J = 2.1 Hz, 1H), 7.52 (dd, J = 8.4, 2.2 Hz, 1H), 7.48 – 7.38 (m, 5H), 7.38 – 7.26 (m, 3H), 
7.18 (d, J = 7.4 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 5.65 (dddd, J = 15.7, 11.5, 7.9, 6.8 Hz, 1H), 5.21 
(s, 2H), 5.10 – 5.00 (m, 4H), 4.87 – 4.74 (m, 2H), 3.57 (s, 1H), 2.92 (ddt, J = 13.8, 6.7, 1.3 Hz, 
1H), 2.63 (ddt, J = 13.6, 7.8, 1.2 Hz, 1H), 1.64 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.2, 
157.0, 136.5, 136.4, 135.9, 134.9, 134.3, 129.1, 128.9, 128.5, 127.8, 127.6, 127.5, 127.4, 126.3, 
122.9, 122.4, 118.4, 118.4, 112.1, 112.0, 74.1, 70.7, 55.1, 52.6, 46.1, 27.1. HRMS (ESI) m/z 
[M+H] calculated for C27H28NO3, 414.2069, found 414.2050.  
 
General procedure B: 
 
Intermediate 38 (50 mg, 0.12 mmol, 1 eq.) and the desired aromatic bromide (0.144 mmol, 1.2 eq.) 
were suspended in triethanolamine (0.5 mL) contained in a 5mL reaction vessel. Palladium acetate 
(Pd(OAc)2) (2.5 mg, 0.012 mmol) was added to this reaction mixture, vessel was sealed with 
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Teflon lined cap and heated to 110oC for 10 h. The reaction was cooled, Water (20 mL) was added 
to dilute the reaction and extracted with ethyl acetate (20 mL X 2). Organic fractions were 
combined, washed with brine, dried over sodium sulfate, and passed through a short column (SiO2, 
5:5 ethyl acetate:hexanes) to result in the residue containing the desired coupled product which 
was dissolved in ethyl acetate:ethanol (5 mL, 4:1) in a sealed reaction vessel. Palladium on carbon 
(10%) and cyclohexene (0.12 mL, 1.2 mmol, 10 eq.) were added then and the sealed vessel was 
then heated to 100o C for 12 h. Subsequently, reaction mixture was passed through a pad of celite, 
solvent was removed under vacuum and the remaining mass was purified using preparative TLC 
(SiO2, 3:7 ethyl acetae:hexanes) to afford products 39a-i as white solid. 
 
(3-(5-(2-chlorophenyl)-2-hydroxypentan-2-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone 
(39a): Prepared using general procedure B, 16 mg, Yield 32%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.68 (s, 1H), 7.40 – 7.29 (m, 3H), 7.28 – 7.23 (m, 2H), 7.20 (t, J = 2.7 Hz, 1H), 
7.18 – 7.09 (m, 4H), 6.86 (d, J = 8.3 Hz, 1H), 5.01 (s, 2H), 4.81 – 4.73 (m, 2H), 3.36 (s, 1H), 2.61 
(t, J = 7.6 Hz, 2H), 2.01 – 1.84 (m, 2H), 1.74-1.63 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.4, 
158.0, 155.2, 141.8, 136.5, 136.3, 129.5, 128.3 (2), 128.3 (2), 127.8, 127.4, 127.2, 125.9, 125.8, 
122.9, 122.4, 117.4, 78.7, 55.2, 52.6, 42.2, 35.8, 28.9, 25.7. HRMS (ESI) m/z [M+Na] calculated 





(39b): Prepared using general procedure B, 13 mg,  Yield 25%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.49 (s, 1H), 7.31 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 – 7.12 (m, 5H), 7.10 – 6.99 (m, 
4H), 6.79 (d, J = 8.3 Hz, 1H), 4.93 (s, 2H), 4.69 (s, 2H), 2.86 (s, 1H), 2.52 (t, J = 7.6 Hz, 2H), 
1.94-1.74 (m, 2H), 1.65 – 1.54 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.4, 158.0, 141.8, 136.5, 
136.3, 129.5, 128.4, 128.3, 128.3, 128.2, 127.8, 127.5, 127.2, 125.9, 125.8, 122.9, 122.4, 117.4, 
78.7, 55.2, 55.2, 52.6, 42.2, 35.8, 28.9, 25.8. HRMS (ESI) m/z [M+Na] calculated for 
C26H26ClNO3Na, 458.1499, found 458.1480.  
 
(3-(5-(4-chlorophenyl)-2-hydroxypentan-2-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone 
(39c): Prepared using general procedure B, 17 mg,  Yield 35%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.69 (s, 1H), 7.39 – 7.28 (m, 4H), 7.23 – 7.16 (m, 3H), 7.13 – 7.02 (m, 3H), 6.84 
(d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.82 – 4.66 (m, 2H), 3.56 – 3.48 (m, 1H), 2.64 – 2.47 (m, 2H), 
1.88 (m, 2H), 1.70 – 1.54 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.6, 158.0, 140.3, 136.3, 
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136.2, 131.5, 129.8, 129.7 (2), 128.4 (2), 127.8, 127.6, 127.5, 127.0, 125.8, 122.9, 122.4, 117.4, 
78.3, 55.2, 52.7, 42.1, 35.1, 28.5, 25.7. HRMS (ESI) m/z [M+H] calculated for C26H27ClNO3, 
436.1679, found 436.1709.  
 
(4-hydroxy-3-(2-hydroxy-5-(o-tolyl)pentan-2-yl)phenyl)(isoindolin-2-yl)methanone (39d): 
Prepared using general procedure B, 15 mg, Yield 30%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.51 (s, 1H), 7.31 (dd, J = 8.3, 2.1 Hz, 1H), 7.19 (s, 3H), 7.15 (d, J = 2.1 Hz, 1H), 
7.01 (m, 5H), 6.79 (d, J = 8.3 Hz, 1H), 4.97 – 4.85 (m, 2H), 4.74 – 4.59 (m, 2H), 2.88 (s, 1H), 2.50 
(m, 2H), 2.16 (s, 3H), 1.89 (m, 2H), 1.54 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.4, 157.9, 
140.0, 136.5, 136.3, 135.8, 130.2, 129.6, 128.6, 127.8, 127.8, 127.5, 127.2, 126.0, 125.9, 125.9, 
122.9, 122.4, 117.4, 78.7, 55.2, 52.6, 42.5, 33.1, 28.8, 24.5, 19.3. HRMS (ESI) m/z [M+H] 
calculated for C27H30NO3, 416.2226, found 416.2240.  
 
(4-hydroxy-3-(2-hydroxy-5-(m-tolyl)pentan-2-yl)phenyl)(isoindolin-2-yl)methanone (39e): 
Prepared using general procedure B, 16 mg, Yield 33%, white solid: 1H NMR (500 MHz, 
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Chloroform-d) δ 9.74 (s, 1H), 7.38 – 7.29 (m, 3H), 7.27 (s, 1H), 7.17 (d, J = 2.1 Hz, 1H), 7.15 – 
7.07 (m, 2H), 6.99 – 6.90 (m, 3H), 6.84 (d, J = 8.3 Hz, 1H), 5.00 (d, J = 3.9 Hz, 2H), 4.81 – 4.69 
(m, 2H), 3.62 (d, J = 2.8 Hz, 1H), 2.61 – 2.48 (m, 2H), 1.91 (dddd, J = 45.2, 13.8, 11.6, 4.9 Hz, 
2H), 2.29 (s, 3H),, 1.75 – 1.54 (m, 5H). 13C NMR (126 MHz, CDCl3) δ 170.6, 158.0, 141.9, 137.9, 
136.4, 136.2, 129.9, 129.2, 128.2, 127.8, 127.6, 127.5, 126.9, 126.6, 125.8, 125.3, 122.9, 122.4, 
117.4, 78.3, 55.2, 52.7, 42.3, 35.8, 28.5, 25.9, 21.4. HRMS (ESI) m/z [M+H] calculated for 
C27H30NO3, 416.2226, found 416.2232.  
 
(4-hydroxy-3-(2-hydroxy-5-(p-tolyl)pentan-2-yl)phenyl)(isoindolin-2-yl)methanone (39f): 
Prepared using general procedure B, 14 mg, , Yield 28%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 9.64 (s, 1H), 7.37 (dd, J = 8.3, 2.1 Hz, 1H), 7.36 – 7.27 (m, 3H), 7.19 (d, J = 2.1 
Hz, 1H), 7.09 (d, J = 7.4 Hz, 1H), 7.07 – 7.00 (m, 4H), 6.85 (d, J = 8.3 Hz, 1H), 5.00 (s, 2H), 4.82 
– 4.66 (m, 2H), 3.19 (d, J = 2.7 Hz, 1H), 2.58 – 2.51 (m, 2H), 2.28 (s, 3H), 1.91 (m, 2H), 1.63 (s, 
5H). 13C NMR (126 MHz, CDCl3) δ 170.5, 158.0, 138.8, 136.5, 136.3, 135.3, 129.6, 129.0 (2), 
128.2 (2), 127.8, 127.7, 127.4, 127.1, 125.8, 122.9, 122.4, 117.4, 78.5, 55.2, 52.6, 42.2, 35.4, 28.7, 





(39g): Prepared using general procedure B, 12 mg, yield 26%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 11.15 (s, 1H), 8.50 – 8.45 (m, 1H), 7.66-7.63 (m, 1H), 7.39 (dd, J = 8.3, 2.1 Hz, 
1H), 7.36-7.27 (m, 3H), 7.20 – 7.14 (m, 3H), 6.88 (d, J = 8.4 Hz, 1H), 5.02 (s, 2H), 4.85 (s, 2H), 
3.01-2.96 (m, 1H), 2.86-2.81 (m, 1H), 2.20 – 2.10 (m, 1H), 1.99 – 1.88 (m, 2H), 1.87-1.75 (s, 1H), 
1.63 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.5, 160.8, 159.0, 147.6, 137.4, 136.7, 136.5, 129.8, 
127.7, 127.4, 127.3, 126.9, 126.5, 124.1, 122.9, 122.4, 121.4, 117.2, 79.2, 55.2, 52.6, 39.7, 35.2, 
32.0, 22.7. HRMS (ESI) m/z [M+H] calculated for C25H27N2O3, 403.2022, found 403.2007.  
 
(4-hydroxy-3-(2-hydroxy-5-(pyridin-3-yl)pentan-2-yl)phenyl)(isoindolin-2-yl)methanone 
(39h): Prepared using general procedure B, 12mg, Yield 25%, white solid: 1H NMR (500 MHz, 
Cfhloroform-d) δ 9.98 (s, 1H), 8.26 (d, J = 39.4 Hz, 2H), 7.42 – 7.36 (m, 1H), 7.32 (dd, J = 8.3, 
2.1 Hz, 1H), 7.29 – 7.20 (m, 3H), 7.16 – 7.04 (m, 2H), 6.80 (d, J = 8.3 Hz, 1H), 4.93 (s, 2H), 4.82 
– 4.65 (m, 2H), 2.50 (hept, J = 7.0 Hz, 2H), 1.84-1.73 (m, 2H), 1.59-1.52 (m, 5H). 13C NMR (126 
MHz, CDCl3) δ 170.5, 158.2, 149.3, 149.3, 146.9, 146.9, 136.5, 136.3, 130.0, 127.8, 127.7, 127.5, 
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127.1, 126.0, 122.9, 122.4, 117.2, 117.2, 78.1, 77.3, 55.2, 52.7, 42.3, 28.9, 25.5. HRMS (ESI) m/z 




(39i): Prepared using general procedure B, 15 mg, Yield 32%, white solid: 1H NMR (500 MHz, 
Chloroform-d) δ 8.23 – 8.18 (m, 2H), 7.30 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 – 7.17 (m, 4H), 7.06 (d, 
J = 7.5 Hz, 1H), 7.00 – 6.95 (m, 2H), 6.78 (d, J = 8.3 Hz, 1H), 4.91 (d, J = 13.6 Hz, 2H), 4.79 – 
4.65 (m, 2H), 3.41 (s, 1H), 2.57-2.44 (m, 2H), 1.89 – 1.70 (m, 2H), 1.69-1.60 (m, 2H), 1.57 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 170.46, 158.3, 151.7, 148.7 (2), 136.4, 136.3, 130.1, 127.8, 
127.5, 126.9, 126.0, 124.2 (2), 122.9, 122.4, 122.3, 117.1, 77.6, 55.2, 52.7, 42.1, 34.9, 29.0, 24.4. 
HRMS (ESI) m/z [M+H] calculated for C25H27N2O3, 403.2022, found 403.2049. 
 
(4-hydroxy-3-(2-hydroxy-5-phenylpent-4-yn-2-yl)phenyl)(isoindolin-2-yl)methanone (40): 3-
Chloro-1-phenyl-1-propyne (0.15 mL, 1 mmol, 3 eq.) was added to a round bottom flask 
containing THF (5 mL) under argon. Subsequently, the reaction mixture was cooled to 0oC, zinc 
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chloride (13.6 mg, 0.1 mmol, 0.3 eq.) and magnesium turnings (50 mg, 2 mmol, 6 eq) were added 
and stirred and allowed to warm to rt for 30 mins. In this duration, reaction turned into a red colored 
solution. This solution was transferred quickly to a reaction vessel containing 31 (100 mg, 0.3 
mmol, 1 eq) dissolved in THF (5 mL), at 0oC via glass syringe. The resulting reaction mixture was 
stirred, warmed to rt and monitored via TLC for the consumption of 31. Upon completion the 
reaction was quenched with 1N HCl (3 mL) and extracted with ethyl acetate (20 mL X 2). Organic 
layers were combined, dried over sodium sulfate, evaporated to yield a residue that was purified 
using flash chromatography (SiO2, 3:7 ethyl acetate:hexanes) to afford 40 (45 mg, 31%) as beige 
solid. 1H NMR (500 MHz, Chloroform-d) δ 9.40 (s, 1H), 7.42 (dd, J = 8.3, 2.1 Hz, 1H), 7.39 – 
7.34 (m, 3H), 7.34 – 7.16 (m, 7H), 6.92 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 5.05 – 4.93 
(m, 2H), 4.75 (s, 2H), 3.15 (d, J = 16.9 Hz, 1H), 2.98 (d, J = 16.9 Hz, 1H), 1.80 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 170.6, 157.8, 136.4, 136.2, 131.6 (2), 128.6, 128.4 (2), 128.3, 128.2, 127.7, 
127.4, 127.3, 125.7, 122.8, 122.7, 122.4, 117.7, 84.8, 84.5, 77.2, 55.1, 52.6, 33.9, 27.6. HRMS 




Phenyl-1-propyne (41 mg, 0.35 mmol, 2 eq.) dissolved in THF (3 mL) was cooled to -78oC, 
subsequently, lithium diisopropylamide (LDA) (0.38 mL 1M solution in THF, 0.38 mmol, 2.2 eq.) 
was introduced and the reaction was stirred at -78oC for 15 min, and at 0oC for 30 min. This 
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solution was transferred, via a syringe into a round bottom flask containing 31 (50 mg, 0.177 
mmol, 1 eq) in THF (3 mL) at 0oC. Upon addition, the reaction was warmed to 40o C and stirred 
for 1 h, before quenching with ammonium chloride solution and extraction with ethyl acetate (20 
mL X 2). Organic layers were combined, dried over sodium sulfate, and evaporated to yield a 
residue that was purified using flash chromatography to produce 41 (36 mg, 51%) as white solid. 
1H NMR (500 MHz, Chloroform-d) δ 9.40 (s, 1H), 7.42 (dd, J = 8.3, 2.1 Hz, 1H), 7.39 – 7.34 (m, 
3H), 7.34 – 7.16 (m, 7H), 6.92 (d, J = 8.3 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 5.05 – 4.93 (m, 2H), 
4.75 (s, 2H), 3.15 (d, J = 16.9 Hz, 1H), 2.98 (d, J = 16.9 Hz, 1H), 1.80 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.6, 157.8, 136.4, 136.2, 131.6 (2), 128.6, 128.4 (2), 128.3, 128.2, 127.7, 127.4, 
127.3, 125.7, 122.8, 122.7, 122.4, 117.7, 84.8, 84.5, 77.2, 55.2, 52.6, 33.9, 27.6. HRMS (ESI) m/z 




(42): 38 (50 mg, 0.12 mmol, 1 eq.) was dissolved in dioxane (2 mL) contained in a reaction vessel. 
Subsequently, palladium(0) bis(dibenzylideneacetone) (Pd(dba)2) (4 mg, 5 mol %) and tri-o-
tolylphosphine (P(o-tolyl)3) (3.6 mg, 10 mol %) and N,N-Dicyclohexylmethylamine (47mg, 0.24 
mmol, 2 eq.), iodobenzene (27 mg, 0.13 mmol, 1.1 eq.) were added to the reaction vessel, the 
solution was purged with argon, sealed with a teflon cap, and heated to 90o C for 6 h. Water (5 
mL) was added to the reaction mixture and extracted with ethyl acetate  (10 mL X 2). Organic 
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layers were washed with brine, dried over sodium sulfate and evaporated to result in a residue that 
was passed through a short column (SiO2, 3:7 ethyl acetate:hexanes) to obtain fractions containing 
the desired product. The combined fractions were evaporated to yield a residue that was dissolved 
in DCM (3 mL), cooled to 0o C and treated with boron trichloride solution (0.36 mL 1M solution 
in DCM, 0.36 mmol, 3 eq.). Reaction was stirred at 0oC for 30 mins, quenched with water (10 
mL), DCM removed under vacuum and extracted with ethyl acetate (10 mL X 2). Organic layers 
were combined, washed with brine, dried over sodium sulfate and evaporated to yield a crude 
mass, which upon purification (SiO2, 3:7 ethyl acetate:hexanes) produced 42 (18 mg, 38%) as a 
beige solid. 1H NMR (500 MHz, Chloroform-d) δ 9.55 (s, 1H), 7.32 (dd, J = 8.3, 2.1 Hz, 1H), 7.27 
– 7.10 (m, 7H), 6.92 (d, J = 7.5 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 6.40 (d, J = 15.8 Hz, 1H), 6.09 
(dt, J = 15.5, 7.5 Hz, 1H), 4.92 (s, 2H), 4.67 (s, 2H), 3.64 (s, 1H), 2.84 (ddd, J = 13.9, 7.2, 1.4 Hz, 
1H), 2.64 (ddd, J = 13.9, 7.8, 1.2 Hz, 1H), 1.59 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 170.6, 
158.0, 136.8, 136.4, 136.2, 135.1, 129.7, 128.6 (2), 127.9, 127.8, 127.6, 127.4, 127.2, 126.2 (2), 
125.7, 123.9, 122.9, 122.4, 117.5, 77.6, 55.2, 52.6, 45.8, 28.2. HRMS (ESI) m/z [M+H] calculated 
for C26H25NO3Na, 422.1732, found 422.1729. 
 
(Z)-(4-hydroxy-3-(2-hydroxy-5-phenylpent-4-en-2-yl)phenyl)(isoindolin-2-yl)methanone 
(43): Intermediate 40 (25 mg, 0.06 mmol) was dissolved in ethyl acetate (3 mL). Lindlar’s catalyst 
(3 mg) was then added and reaction mixture was hydrogenated at rt for 2 h. The reaction mixture 
was filtered through a pad of Celite and obtained filtrate was evaporated to give a crude mass that 
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was purified using preparative TLC (SiO2, 3:7 ethyl acetate:hexanes) to furnish 43 (11mg, 46 % ) 
as a beige solid. 1H NMR (400 MHz, Chloroform-d) δ 9.58 (s, 1H), 7.39 (dd, J = 8.3, 2.1 Hz, 1H), 
7.35 – 7.28 (m, 3H), 7.27 – 7.10 (m, 5H), 6.95 – 6.81 (m, 1H), 6.64 (d, J = 11.8 Hz, 1H), 5.80-
5.65 (m, 1H), 5.00 (s, 2H), 4.76 (s, 2H), 3.58 (s, 1H), 3.10-2.855 (m, 2H), 1.64 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.5, 158.1, 136.8, 136.3, 133.0, 129.5, 128.6 (2), 128.3, 128.3 (2), 127.9, 
127.8, 127.5, 127.1, 127.0, 126.0, 125.8, 122.9, 122.4, 117.5, 78.0, 55.1, 52.6, 40.7, 28.5. HRMS 
(ESI) m/z [M+H] calculated for C26H25NO3, 400.1907, found 400.1907.  
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                            Chapter IV 
                   Optimization of the Hsp90D-selective Compounds   
IV.1 Benzenethiols Containing Hsp90D-selective Inhibitors 
As discussed in the previous chapter, benzenethiol containing hit 11, was hypothesized to 
preferentially bind Hsp90D and induce a conformational change by projecting the benzenethiol 
moiety into Site 1 (Figure 4.1b). The Hsp90 tertiary structure resulting from ligand binding is 
regulated by transition states of Hsp90-ligand complexes that differ energetically between Hsp90 
isoforms D and Ewhich arecytosolic isoforms that exhibit >95% identity in their N-terminal 
ATP-binding site.1-4 
 The benzenethiol provides steric bulk at the 5-position that orients the 4-phenol into a 
conformation that is favored for interaction with Ser52 (Ala52 in Hsp90E, imparting the observed 
selectivity versus Hsp90EIn the open conformation of Hsp90D, Site 1 is outlined with residues 
that contain aromatic and non-polar side chains, as illustrated in Figure 4.1c, which together create 
a hydrophobic environment in the binding pocket. Analysis of the co-crystal structures of purine- 
Asp93
Ser52
Figure 4.1: a) Compound 11 b) 11 (yellow) modeled into the open conformation of Hsp90D 




and benzamide-based Hsp90 inhibitors revealed that both scaffolds open Site 1.5-6 The 
methylenedioxyphenyl ring in the purine-based compounds and the tetrahydroindazolone 
fragment of SNX 2112, induce opening by occupying the extended Site1. An overlay of these 
scaffolds also uncovered 
that Site 1 occupying 
fragments share two 
pharmacophores; 1) a 
steric bulk (iodine atom, 
and CF3 group, Figure 
4.2), which displace 
water molecules present 
near the binding pocket, 
resulting in an 
entropically stable 
ligand-Hsp90 complex; 2) a hydrogen-bond acceptor 
(methylenedioxy and ketone) that interacts with Tyr139 
(Figure 4.2).  
Since PU-H71 and 11 share a thioether linkage, 
an overlay was performed with the proposed binding 
mode of 11 and the observed binding pose of PU-H71 in 
the Hsp90Dco-crystal structure. Interestingly, this study 
revealed that the benzenethiol in 11 does not align with 
 
Figure 4.2:  Binding modes of PU-H71 and SNX 2112 in the 
Hsp90D ATP-binding site. 
 
Figure 4.3:  An overlay of 
observed binding mode of PU-H71 
and the proposed binding mode of 




the methylenedioxyphenyl ring 
(Figure 4.3), and implies that 11 
exhibits a binding pose that differs 
from PU-H71. PU-DZ8, another 
purine containing compound, which 
contains a methylene in lieu of the 
thioether linker (Figure 4.4),7 
maintains cellular efficacy and client 
degradation as observed for PU-H71.7  In 
addition, the methylene linker projects the 
methylenedioxyphenyl ring into Site 1 at an 
angle that is minimally different than the 
thioether linkage.5 As such, the thioether 
linkage contained in 11 was replaced with a 
methylene to produce 44. In addition, a 
compound lacking the linker was also sought 
(45). 
Synthesis of the proposed compounds is outlined in Scheme 4.1, wherein, benzyl protected 
monophenol 29,3 was coupled with benzyltrifluoroborate via palladium acetate (Pd(OAc)2). The 
desired product, 44, was obtained upon unmasking the phenol using a solution of boron trichloride 
(BCl3). Compound 45 was prepared via a Pd(OAc)2 catalyzed reaction between 8 and phenyl 
boronic acid in the presence of diisopropylethylamine (DIPEA).  Upon their preparation, 44 and 
 
 
Figure 4.4:  Structures and Kd values of the proposed 
compounds 44 and 45. 
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45 were evaluated in an FP assay to determine their apparent Kds. Unlike 11, compound 44 and 45 
bound poorly to Hsp90D, while 45 manifested no affinity.  
IV.2 Chimeric Hsp90D-
selective Compounds. 
In an attempt to hybridize the 
purine and monophenol 
scaffolds,  a 
methylenedioxyphenyl ring was 
proposed  to replace, the 
thiophenol moiety in 11. 
Although overlay studies 
indicated that the methylenedioxy may not orient in 
a manner similar to purine compounds, the 
potential for hydrogen bonding interactions with 
Tyr139 (Figure 4.1c) warranted the evaluation of 
46 (Figuer 4.5). Construction of 46 was achieved 
via a Buchwald-Hartwig coupling reaction between 
protected phenol 29 and 1,3-Benzenedioxole-5-
thiol, which was prepared following a reported 
method.8 46 was found to exhibit ~5-folds 
improvement in affinity (Kd ~0.71 PM, Table 4.1) 
in an FP assay, which aligned with the original 
hypothesis. Furthermore, as the presence of a bulky 






atom or group was proven to be benefical for increaesed affinity with the purine (at 2’-position of 
methylenedioxyphenyl ring) and benzamide scaffold (CF3 group),9-10 an iodine atom was installed 
onto the 2’-position of 46 to mimic 
this bulk (48). Upon its preparation,  
48 was evaluated for  binding affinity 
to reveal that 48 exhibits a minimal 
loss in affinity (Kd ~0.91 PM) as 
compared to the unsubstituted 
compound, 46 (Table 4.1). An aniline 
was also incorporated in lieu of the 
thioether to produce 47, which lacked 
binding to both isoforms, suggesting that the rotational freedom afforded by thioether is beneficial 
for orientation of the methylenedioxyphenyl ring. Upon reviewing the overlays of PU-H71 and 11, 





       46 0.715+ 0.03 >50 >70 
       47 >25 >50 >2 
       48 0.91+ 0.05 >50 >55 
       49 0.92+ 0.03 >50 >55 
       50 >50 >50 - 





it became apparent that a methylene linker could be accomodated between the thiol and 
methylenedioxyphenyl ring, and was therefore incorporated into 49. Compound 49 was 
constructed similar to the route used for the preparation of 46, wherein 51 was treated with the 
requisite thiol, 52.11 Upon evaluation, 49 was shown to exhibit a loss of affinity as compared to 
46. A bulky group was then pursued to investigate the binding orientation of 49, by coupling 53 
with 51 to produce the bromine containing compound, 50. 9, 12 Unfortunately, 50, did not bind 
either Hsp90Dor Hsp90E, suggesting that the bulky 
bromide is a poor fit  and exhibits a steric clash with 
the protein surface. 
Modeling of 49 into the binding site suggested 
that a methylene linker, may provide access to the 
solvent as noted in Figure 4.6. Occupation of the 
solvent channel has resulted in an enhancement in 
affinity as noted in prior chapters, therefore, a methyl was introduced onto the linker as shown 
with 54. Treatment of the required alcohol 59 with Lawessen’s reagent resulted in thiol 60,13 which 
was subsequently coupled with 51 to furnish the desired product, 54. Unfortunately, upon the 
evaluation of 54, it was determined that the additional methyl group was detrimental to affinity 
(Table 4.2). Compound 55 was prepared by oxidation of 49 with m-chloroperbenzoic acid (m-
Figure 4.6: Binding pose of 49 









CPBA), which contained a sulfoxide to potentially interact with Asn51. But it too manifested little 
affinity toward both isoforms. Compound 56, which was also hypothesized to project into the 
solvent channel, contained a n-propyl chain as a mimic of the n-butyl observed in compound 35b 
as discussed in the prior chapter. Interestingly, 56 exhibited moderate affinity  (Kd ~2.28 PM) and 
~20-fold selectivity for Hsp90E. 
Therefore, 56 presented a scaffold 
akin to the t-butyl containing 
compound, 9 (Chapter 3), used for the 
development of Hsp90D-selective 
inhibitors. A sulfonyl group was also 
installed into 57 to investigate 
potential binding interactions with 
Asn51. However, the sulfonyl containing compound manifested a complete loss in affinity. 










       54 3.476+ 0.40 >50 >15 
       55 >50 >50 - 
       56 2.28+ 0.14 44.25+0.14 ~20 
       57 >50 >50 - 
       58 0.521+ 0.018 27.74+3.07 ~53 




improvement in affinity (Kd ~0.521 PM) over the methylenedioxy (46), with ~53-fold selectivity 
versus Hsp90E.  
 Collectively, the binding data from the hybridized 4-phenol series of compounds (Figure 
4.2 and 4.5) suggested that binding affinity improved with the introduction of hydrogen-bond 
acceptor groups through interactions with Tyr139, but 2’-substituted derivatives produced  
decreased affinity, which is unlike the trend observed for purine-based compounds. Therefore,  
structure-activity relationship studies were proposed on compound 11 and about the benzenethiol 
ring to investigate Site 1.  
IV.3 Structure-Activity Relationship Studies on the Benzenethiol Ring.  
As outlined in Figure 4.1c, residues that 
comprise Site 1 exhibit primarily hydrophobic 
side chains. Therefore, a methyl scan was 
initiated in addition to the proposed methoxy 
substitutions, which could mimic the 
methylenedioxy interactions with Tyr139. The 
unsubstituted compound, 11, binds 
Hsp90Dwith Kd ~4.87 PM and is >20-fold selective versus Hsp90E
 The preparation of compounds 61a-t was achieved by coupling the methoxymethyl acetal 
(MOM) intermediate 51, with the corresponding thiols via a Buchwald-Hartwig conditions. While 




efficiently for the synthesis of 61d-t, coupling of the methyl ether-containing compounds 61a-c, 
required the (dibenzylideneacetone)palladium(0) (Pd(dba)2) and 2-dicyclohexylphosphino-









4.34+0.58 >50 >12 
61b 
 
1.44+0.12 >50        >35 
61c 
    
2.57+0.15 >50        >20 
61d 
 
2.94+0.24 >50 >17 
61e 
 
1.74+0.44 >50 >28 
61f 
 
2.70+0.40 44.25+0.14 ~16 
61g 
 
0.845+0.13 >50 >63 
61h 
 
0.724+0.08 37.51+3.87 ~51 
61i 
 
7.736+0.93 >50 >7 
61j 
 
>50 >50 - 
61k 
 
3.029+0.26 >50 >16 




triisopropylbiphenyl (XPhos) catalytic system (Scheme 4.4). Upon evaluation of the methoxy 
containing compounds, 61a-c in an FP assay, the 3-methoxy (61b) derivative was found to exhibit 
improved affinity as compared to 61c, while the 2-methoxy (61a) also increased affinity. A 
subsequent methyl scan with compounds 61d-f, revealed the 3-methyl compound (61e) to exhibit 
improved affinity (Kd ~1.74 PM), whereas the 2-methyl (61d) (Kd ~2.94 PM) and 4-methyl 
derivatives (61f) (Kd ~2.74 PM) provided moderate improvement in affinity. Furthermore, 
substitutions were installed onto the phenyl ring to determine mutual exclusivity for occupation of 
Site1. Since 58 manifested high affinity (Kd ~0.521PM), other di-substituted products were 
pursued. The 3,4-dimethyl substituted compound, 61g, was prepared and found to manifest ~0.845 
PM binding affinity with >60-fold selectivity, whereas the 3,5-dimethyl derivative (61h) bound 
Hsp90D with a Kd ~0.724 PM. Unfortunately, selectivity was limited when compared to 61g. 
When compounds containing, 2,5-and 2,4-dimethyl substituents were investigated a loss of affinity 
was observed (61i Kd ~7.73 PM).  
  Preparation of the 3,4,5-trimethyl substituted compound, 61k, was sought to explore the 
potential for occupation of Site 1 in an orientation that resembled the binding pose of compounds 
61g and 61h. 3,4,5-Trimethylbenzenethiol was prepared using an approach previously reported 
and was used to construct  61k.14  Unfortunately, 61k did not bind Hsp90D as effectively as 61g 






led to 61l (Table 4.4), 
however, it did not 
manifest similar 






the presence of the 
difluoro substitution is 
not beneficial for Site 
1. The 3,4-dimethoxy 
containing compound, 
61n, resembles 58, but 
contains the open form 
of the ethylenedioxy ring. Surprisingly, 61n maintained binding affinity as compared to 58, but 
resulted in a loss of selectivity (22-fold (61n) versus 53-fold (58)), implying ring constraint is 
accommodated by Hsp90Emore effectively. Improvement in binding affinity afforded by the 3,5-
dimethyl compound, 61h, warranted investigation of the 3,5-dichloro compound, 61o. 









4.34+0.58 >50 >12 
61m 
 
4.77+0.21 >50        >11 
61n 
    
0.529+0.07 11.66+1.07        ~22 
61o 
 
4.45+0.58 >50 >12 
61p 
 
0.899+0.02 >50 >56 
61q 
 
7.04+0.15 >50 >7 
61r 
 
0.463+0.06 22.28+2.79 ~48 
61s 
 
0.565+0.06 >50 >88 
61t 
 
4.38 +0.24 >50 >12 




Disappointingly, 61o did not increase affinity, reinforcing the notion that the chlorine atom is not 
beneficial. Noting the 3-methyl and 3-methoxy substitutions manifest improved affinities, a 3-
methoxy-5-methyl substituted derivative, 61p, was synthesized via the 3-methoxy-5-methyl 
benzenethiol,15 and was found exhibit similar affinity as 3,5-dimethyl (61h). A fluorine atom at 
the 3-position was also introduced into 61q, to investigate the role of the fluorine atom as a 
hydrogen-bond acceptor and for interactions with Tyr139. However, FP assay results determined 
61q to manifest decreased binding affinity. Evaluation of the 3-ethyl derivative, 61r, resulted in 
~4-fold improvement (Kd ~463 nM, ~48-fold selective) in binding affinity compared to the 3-
methyl analog, 61e. Consequently, the 3-position was homologated to the corresponding n-propyl 
analog (61s), that resulted in slight loss of affinity (Kd ~565 nM) relative to 61r, however, 
selectivity against Hsp90E improved (>88-fold).   Similarly, the 3-ethoxy derivative (61t) was 
proposed (61r), but unfortunately, a loss of ~3-fold affinity was observed.   
IV.4 Selectivity of the Hsp90D-selective Compounds Against Grp94 and Trap1 
The developed Hsp90D-selective scaffolds were screened for their affinity towards the 
endoplasmic reticulum residing isoform, Grp94 and then select compounds were also screened 
against the mitochondrial isoform, Trap1.  
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Upon evaluation in the FP assay, the tertiary alcohol, 10, showed reduced binding toward Grp94. 
Similarly, the alcohol derivative containing a n-butyl chain (35b) exhibited binding affinity 
>25PM against Grp94. However, the phenpropyl containing compound (36d) bound Grp94 with 
only ~4-fold selectivity, implying that occupation of Site1 with a flexible propylene linker 
increases affinity for Grp94 as well.  The benzenethiol compound, 58, exhibited ~20-fold 
selectivity versus Grp94, whereas, the 3,4-dimethyl (61g) showed >50-fold selectivity against both 
Grp94 and Trap1. Furthermore, the 3-ethyl derivative (61r) bound Grp94 with ~74-fold selectivity 
and Trap1 with ~60-fold selectivity.Finally, the 3,5-dimethyl analog (61h) exhibited ~70-fold 
selectivity versus Grp94, while it bound Trap1 with only ~17-fold selectivity. These binding 
preferences suggest that the substitution pattern on the benzenethiol ring plays a critical role for 
selectivity against the organelle residing Hsp90 isoforms. The future design of Hsp90D-selective 
   




compounds may avoid binding to Grp94 or Trap1 by incorporating these substituents as optimized 
 
 
                    
Figure 4.9: a) Co-crystal structure of 58 with Hsp90D. b) Co-crystal structure of 61g with 
Hsp90D c) Overlay of the co-crystal structures of 58 and 2.1 bound to 
Hsp90DPDBXAB d) Overlay of the Co-crystal structures of 58 and PU-H71 bound to 




















in this SAR study.  
IV.5 Analysis of the Co-Crystal Structures of 58 and 61g with Hsp90D 
In collaboration with Dr. Robert Matts at Oklahoma State University, Hsp90D-selective 
compounds, 58 and 61g, were successfully co-crystallized with the Hsp90D N-terminal domain. 
Not surprisingly, binding poses of the analyzed compounds, 58 and 61g, were identical to the 
binding pose identified during modeling studies (Figure 4.9 a and b). Participation of the 4-phenol 
in the hydrogen bonding network resembles the proposed model. In fact, compounds 58 and 61g 
induce the opening of Site 1 and interact with residues Leu48, Ser52, Asp93 and Thr184 through 
conserved water molecules. In addition, the ethylenedioxyphenyl ring present in 58, was found to 
interact with Tyr139 via a non-conserved water molecule (Figure 4.9a), whereas, 61h lacked such 
interactions. The selectivity of benzenethiol series of compounds for Hsp90D is rationalized by 
using the overlay of the binding poses for the non-selective compound, 2.1 and 58 bound to 
Hsp90D (Figure 4.9c). As can be observed, inclusion of the benzenethiol at the 5-position in the 
4-monophenol induced a conformational change that resulted in the opening of Site 1, unlike 2.1, 
which binds to the closed form (resting state) of Hsp90D. Orientation of the benzenethiol fragment 
in Site 1 is dissimilar to the thioether that is projected with PU-H71 (Figure 4.9d).  Accommodation 
of the thioether in the 4-phenol series requires a shift in the binding plane toward the adenine 
binding pocket (Figure 4.9c), which brings the 4-phenol closer to Ser52, a residue that 
differentiates the Hsp90D-subpocket from Hsp90E, and Asp93, which exhibits critical interactions 
with ligands in the Hsp90 N-terminal ATP-binding site.16-17 Consequently, Hsp90D preferentially 




IV.6 Discovery of the Aminophenol-containing Hsp90D-selective Scaffold   
The presence of a bromine atom at the 5-position appeared to enhance Hsp90D-selectivity for the 
monophenol 8, as previously explained (Figure 4.10). Therefore, the impact of a bromine atom at 
the 5-position in resorcinol compound 62 was hypothesized to increase selectivity while 
maintaining affinity. However, upon evaluation in an FP assay, 62 lost complete selectivity. The 
lack of selectivity can be explained by the contact 
that the 2-phenol makes with Asp93, as well as 
interactions with Thr184 via water molecule 3’, 
which negates any preferential interaction 
between the 4-phenol and Ser52. However, the 
incorporation of an aniline group into the 4-
position (63) led to ~2-fold  selectivity for 
Hsp90D, but >10-fold reduction in affinity was also observed.3 Consequently, it was concluded 
that the phenol at the 2-position is detrimental to selectivity. Therefore, replacements of the 2-
phenol were sought. Computational studies established that the binding energy between an 
unsubstituted phenol and an acetate ion could be ~ 25.4 kcal/mol, whereas an unsubstituted aniline 
 
Figure 4.10: Investigation of selectivity of resorcinol and aminophenol cores in the 




may only manifest a binding energy of ~18 kcal/mol.18-19 Therefore, aniline in 64 was theorized to 
interact with Asp93 poorly in comparison to the 2-phenol of 62, and thus, provide a non-specific 
gain in binding affinity toward both isoforms without a loss in selectivity. It was reasoned that 
interaction of the aniline with Asp93 could be compensated via the 4-phenol in 64.  
 65 was prepared using a previously reported procedure,20 and was then coupled with 
isoindoline by enlisting 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and 
hydroxybenzotriazole (HOBt), and subsequently treating with boron tribromide (BBr3) to produce 
64 (Scheme 4.6). 
 Upon evaluation in an FP assay, 64 was found to bind Hsp90DandHsp90E with a Kd of 




















IV.7 Biological Studies 
IV.7.1 Antiproliferative Effect on Cancer Cells 
Hsp90D-selective compounds, 35b and 36d which belong to the tertiary-alcohol series, and 61g, a 
compound belonging to the benzenethiol series, were evaluated against the NCI-60 cancer cell 
panel at a single dose of 10PM. Results obtained are shown in Figure 4.12 (35b), 4.13 (36d) and 
4.14 (61g). These inhibitors exhibited moderate antiproliferative activity in the NCI-60 cell panel, 
however, particular cell lines were consistently affected upon treatment with these Hsp90D-
selective inhibitors. The leukemia cell line, K562, NSCLC cells, NCI-H522, colon cancer cell line, 
KM12, melanoma cell lines, UACC-62, ovarian cancer cell line, SK-OV-3 and more specifically, 
the renal cancer cell line, UO-31 resulted in decreased proliferation when Hsp90D-selective 
inhibitors. Further studies are underway to identify the dependency of these cancer cell lines upon 
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IV.8 Conclusions and Future Directions 
The benzenethiol containing Hsp90D-selective compounds have been optimized for the occupation 
of Site 1, which ultimately led to compounds 58, 61g, 61r and 61h. These inhibitors exhibited 
superior affinity and selectivity over the parent compound, 11. The binding modes of 58 and 61g 
were confirmed to align well with the modelling studies and uncovered the plane of monophenol 
to shift closer to residues Ser52 and Asp93, which allows for the selective binding of Hsp90D. In 
addition, it was also discovered that aminophenol, 64, could rescue the affinity loss by the 
resorcinol, while maintaining ~22-fold selectivity versus Hsp90E. In the future, the aminophenol 
and the optimized thioether fragment will be combined to guide the development of Hsp90D-
selective inhibitors that should exhibit affinities <50 nM and selectivities >50-fold versus Hsp90E  
 The NCI-60 screening of compounds representing various Hsp90D-selective scaffolds has 
allowed the identification of cell lines that appear to be depend upon Hsp90D for their growth. 
Critical evaluation of the upregulated biological pathways and clients driving the growth of these 
cancer cell lines may highlight the therapeutic relevance on Hsp90D-selective inhibition. 
Ultimately, these findings will aid in the rationalization and development of Hsp90D-selective 
compounds as an alternative chemotherapeutic approach to treat cancers.  
 
IV.9 Methods and Experiments  
Chemistry 
All reactions were performed in oven-dried glassware under argon atmosphere unless otherwise stated. 
Dichloromethane (DCM), tetrahydrofuran (THF), and toluene were passed through a column of 
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activated alumina prior to use. Anhydrous methanol, dimethyl sulfoxide (DMSO), and N,N-
dimethylformamide (DMF) were purchased and used without further purification. Flash column 
chromatography was performed using silica gel (40-63 μm particle size). The 1H (500 and 400 MHz) 
and 13C NMR (125 and 100 MHz) spectra were recorded on 500 and 400 MHz spectrometer. Data are 
reported as p = pentet, q = quartet, t = triplet, d = doublet, s = singlet, br s = broad singlet, m = multiplet; 
coupling constant(s) in Hz. High resolution mass spectral data were obtained on a time-of-flight (TOF) 
mass spectrometer and analysis was performed using electrospray ionization (ESI). 
Fluorescence Polarization Assay  
 
Assay buffer (25 µL, 20 mM HEPES pH 7.3, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 20 mM 
Na2MoO4, 0.01% NP-40, and 0.5 mg/mL BGG) was introduced into 96-well plate (black well, 
black bottom) followed by the desired compound at the indicated final concentrations in DMSO 
(1% DMSO final concentration). Subsequently, 10 nM Recombinant Hsp90Dor Hsp90Eor 
cGrp94 or Trap-1 and 6 nM FITC-GDA were added in 50 µL and 25 µL assay buffer respectively 
resulting in a 100 µL final volume. Plates were incubated for 24 h at 4°C on a rocker. Fluorescence 
was determined using excitation and emission filters of 485 and 528 nm, respectively. Percent 
FITC-GDA bound was determined by assigning the DMSO millipolarization unit (mP) value as 
the 100% bound value and 0% for FITC-GDA in assay buffer without any protein. Polarization 
values (in mP units) was measured at 37 °C with an excitation filter at 485 nm and an emission 
filter at 528 nm. Polarization values were correlated to % tracer bound and compound 
concentrations. The concentration of inhibitor at which the 50% displaced tracer was observed, 




(3-benzyl-4-hydroxyphenyl)(isoindolin-2-yl)methanone (44) : (4-(benzyloxy)-3-
bromophenyl)(isoindolin-2-yl)methanone (29) (100 mg, 0.24 mmol, 1 eq.), palladium acetate (2.6 
mg, 0.012 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos) (11.5 mg, 0.024 
mmol), potassium benzyltrifluoroborate (57 mg, 0.29 mmol, 1.2 eq.) and cesium carbonate (156 
mg, 0.48 mmol, 2 eq.) were taken in a 15 mL reaction vessel containing THF:water (9:1) (5 mL). 
Subsequently, reaction mixture was purged with argon for 15 min, vessel was then sealed and 
heated for 12 h. Upon completion, the vessel was cooled, and solvent volume was reduced under 
vaccum and extracted with water (30 mL) and ethyl acetate (20 mL X 2). Organic layers were 
combined, dried over sodium sulfate and concentrated to result in a crude mass. A quick column 
chromatography was performed and the fractions containing the desired product were 
concentrated. The obtained crude product was then dissolved in DCM (5 mL) and cooled to 0o C. 
Boron trichloride (BCl3) solution (0.72 mL of 1M DCM solution, 0.72 mmol, 3 eq.)  was then 
added slowly and the reaction was stirred for 30 min, before quenching with water (10 mL). The 
resulting reaction mixture was then extracted with DCM (20 mL X 2). The collected DCM 
fractions were washed with water (30 mL) and dried over sodium sulfate. Purification of the 
residue obtained from evaporating organic fraction afforded 44 (35 mg, 44%) as white solid. 1H 
NMR (500 MHz, Chloroform-d) δ 7.29 – 7.04 (m, 10H), 6.70 (d, J = 8.2 Hz, 1H), 6.27 (s, 1H), 
4.92 (s, 2H), 4.67 (s, 2H), 3.94 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 170.5, 155.9, 139.6, 136.5, 
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136.3, 130.0, 128.8 (2), 128.6 (2), 128.2, 127.8, 127.5, 127.4, 127.1, 126.4, 122.9, 122.3, 115.5, 
55.2, 52.6, 36.0. HRMS (ESI) m/z [M+H] calculated for C22H20NO2, 330.1488, found 330.1493. 
 
(6-hydroxy-[1,1'-biphenyl]-3-yl)(isoindolin-2-yl)methanone (45): (3-bromo-4-
hydroxyphenyl)(isoindolin-2-yl)methanone (8) (50 mg, 0.158 mmol, 1 eq.) was suspended in 
water (3 mL). Subsequently, N,N-diisopropylethylamine (0.08 mL, 0.48 mmol, 3 eq.) and 
Pd(OAc)2 (3 mg, 0.013 mmol) were added, the reaction vessel was sealed and heated to 100o C for 
1 h. After cooling to rt, the reaction mixture was extracted with ethyl acetate (20 mL). Organic 
fraction was dried over sodium sulfate and concentrated to result in a residue that was purified 
using flash chromatography (SiO2, 2:8 ethyl acetate:hexanes) to afford 45 (33 mg, 33%) as white 
solid. 1H NMR (400 MHz, Chloroform-d) δ 7.58 – 7.51 (m, 6H), 7.49 – 7.40 (m, 1H), 7.39 – 7.29 
(m, 3H), 7.20 (d, J = 7.3 Hz, 1H), 7.12 – 7.03 (m, 1H), 5.05 (s, 2H), 4.90 (s, 2H). 13C NMR (101 
MHz, CDCl3) δ 170.0, 154.1, 136.9, 136.5, 136.4, 136.1, 129.6, 129.4 (2), 129.1, 129.0 (2), 128.4, 
128.3, 128.1, 127.5, 122.9, 122.4, 115.8, 55.2, 52.6. HRMS (ESI) m/z [M+H] calculated for 







General procedure A 
 
The intermediate 29 (100 mg, 0.24 mmol, 1 eq.) was added to a reaction vessel containing 
palladium acetate (3 mg, 0.012 mmol) and 1,1'-Bis(diphenylphosphino)ferrocene (dppf) (13 mg, 
0.024 mmol), sodium tert-butoxide (95 mg, 1 mmol, 3 eq), and the desired thiol/aniline (0.29 
mmol, 1.2 eq.) suspended and/or dissolved in toluene (3 mL). The reaction mixture was purged 
with argon, sealed and heated to 130o C for 6 h. Subsequently, solvent was removed under vacuum 
and water (20 mL) was added to the remaining mass and extracted with ethyl acetate (30 mL X 2). 
Organic fractions were then collected, dried and concentrated to a residue mass that was passed 
through a pad of silica (3:7 ethyl acetate:hexanes) to result in a crude product which was dissolved 
in 5 mL DCM, cooled to 0o C, and subjected to BCl3 (0.72 mL 1M DCM solution, 0.72 mmol, 3 
eq.) via slow addition. Upon quenching with water and removal of DCM under vacuum, the 
remaining reaction mixture was extracted with ethyl acetate (20 mL X 2). Organic fractions were 
combined, dried and evaporated to a residue which was purified via a flash chromatography (SiO2, 





Prepared using general procedure A; 42 mg, Yield 45%, white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.74 (d, J = 2.1 Hz, 1H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.37-7.24 (m, 3H), 7.17 
(d, J = 7.4 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.81 (dd, J = 8.1, 1.9 Hz, 1H), 6.77 – 6.67 (m, 2H), 
5.95 (s, 2H), 5.00 (s, 2H), 4.80 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.1, 148.5, 147.5, 136.3, 
134.6, 130.7, 129.3, 127.8, 127.5, 126.5, 123.3, 122.9, 122.4, 119.3, 115.4, 115.4, 110.1, 109.0, 




Prepared using general procedure A; 36 mg, Yield 40%, beige solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.31 – 7.19 (m, 4H), 7.12 (d, J = 7.3 Hz, 1H), 6.94 – 6.87 (m, 1H), 6.81 (dd, J = 
8.1, 2.3 Hz, 1H), 6.73 – 6.62 (m, 2H), 6.54 (dt, J = 8.2, 2.2 Hz, 1H), 5.88 (d, J = 2.2 Hz, 2H), 4.92 
(s, 2H), 4.76 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 171.2, 148.2, 147.5, 142.9, 137.0, 136.4, 
136.1, 133.1, 127.7, 127.7, 127.4, 122.8, 122.3, 119.2, 114.2, 113.7, 113.0, 108.5, 102.6, 101.0, 





(3-(benzo[d][1,3]dioxol-5-ylthio)-4-(benzyloxy)phenyl)(isoindolin-2-yl)methanone (50 mg, 0.1 
mmol, 1 eq.) obtained during the preparation of 46, was dissolved in  trifluoroacetic acid (TFA): 
acetonitrile (1:9) (3 mL) along with N-iodosuccinimide (25 mg , 0.11 mmol, 1.1 eq.) and the 
reaction was stirred at rt for 12 h. The reaction was then separated between water (50 mL) and 
ethyl acetate (50 mL), organic layer was washed with water, dried over sodium sulfate and 
concentrated to give a crude mass that was quickly passed through a pad of silica (5:5 ethyl acetate: 
hexanes). The fractions were evaporated to a mass that was dissolved in DCM (3 mL) and cooled 
to 0o C. BCl3 was then added slowly to the solution and stirred at 0oC for 1 h. Reaction mixture 
quenched with water (10 mL) and evaporated under vacuum to remove DCM. After extraction 
with Ethyl acetate (20 mL X 2), the organic fractions were collected, dried and evaporated to give 
a crude mass. The resulting mass was purified with flash chromatography to furnish 48 (11 mg, 
21%) as off white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 2.2 Hz, 1H), 7.60 (dd, 
J = 8.4, 2.1 Hz, 1H), 7.32 – 7.21 (m, 3H), 7.17 (s, 1H), 7.09 (dd, J = 17.0, 7.9 Hz, 2H), 6.55 (s, 
1H), 6.30 (s, 1H), 5.86 (s, 2H), 4.94 (s, 2H), 4.76 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 158.3, 
149.4, 147.7, 136.3, 136.3, 135.3, 131.7, 129.8, 127.9, 127.5, 122.9, 122.4, 118.9, 118.4, 115.9, 
108.7, 106.8, 102.0, 99.9, 86.5, 55.2, 52.7. HRMS (ESI) m/z [M+H] calculated for C22H17INO4S, 




(3-bromo-4-(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (51): To a solution of 8 (2 
g, 6.3 mmol, 1 eq.) and N,N-diisopropylethylamine (DIPEA)(2.3 mL, 12.6 mmol, 2 eq.) in DCM 
(30 mL) was introduced chloromethyl methyl ether (1.5 mL 5M solution in THF, 7.56 mmol, 1.2 
eq.) at 0oC. After stirring at 0o C for 1 h, the reaction was slowly quenched with sat. sodium 
bicarbonate solution (10 mL) and extracted with DCM (20 mL X 2). DCM fractions were 
combined, washed with water, dried over sodium sulfate and evaporated to give a residue that was 
purified using flash chromatography to afford 51 (2.1 g, 92%) as white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.84 (d, J = 2.1 Hz, 1H), 7.53 (dd, J = 8.5, 2.1 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.21 
(dd, J = 17.0, 8.0 Hz, 2H), 5.32 (s, 2H), 5.02 (s, 2H), 4.84 (s, 2H), 3.56 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 168.5, 155.1, 136.3, 136.2, 132.4, 131.2, 127.9, 127.6, 127.6, 122.9, 122.4, 115.3, 
112.6, 94.9, 56.5, 55.1, 52.6. HRMS (ESI) m/z [M+H] calculated for C17H17BrNO3, 362.0386, 
found 346.1404. 
General procedure B 
 
In a reaction vessel containing 51 (50 mg, 0.136 mmol, 1 eq), palladium acetate (2 mg, 0.008 
mmol) and 1,1'-Bis(diphenylphosphino)ferrocene (dppf) (8 mg, 0.016 mmol), sodium tert-
butoxide (48 mg, 0.5 mmol, 3 eq), and the desired thiol (RSH) (0.16 mmol, 1.2 eq.) suspended 
and/or dissolved in toluene (3 mL). The reaction mixture was purged with argon, sealed and heated 
to 130o C for 6 h. Subsequently, solvent was removed under vacuum and water (20 mL) was added 
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to the remaining mass and extracted with ethyl acetate (30 mL X 2). Organic fractions were then 
collected, dried and concentrated to a residue mass that was passed through a pad of silica (3:7 
ethyl acetate:hexanes) to result in a crude product. The obtained mass was dissolved in methanol 
(5 mL), the solution was acidified to pH 3 with 2 N HCl solution and stirred for 4 h at 45o C. Upon 
completion, the methanol was removed under vacuum and the remaining mass was extracted with 
water (10 mL) and ethyl acetate (20 mL X 2). After combining and drying the organic layer, a 




Prepared using general procedure B; 39 mg, Yield 72 %, off white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.64 – 7.49 (m, 2H), 7.37 – 7.29 (m, 3H), 7.21 (d, J = 7.3 Hz, 1H), 7.03 (d, J = 
8.4 Hz, 1H), 6.84 (s, 1H), 6.73 – 6.62 (m, 2H), 6.54 (dd, J = 7.9, 1.7 Hz, 1H), 5.90 (s, 2H), 5.01 
(s, 2H), 4.72 (s, 2H), 3.83 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.2, 158.6, 147.8, 147.0, 
136.4, 136.3, 135.5, 130.9, 130.8, 129.0, 127.8, 127.5, 122.9, 122.4, 122.2, 118.3, 114.8, 109.0, 






yl)methanone (50): Prepared using general procedure B; 42 mg, Yield 65 %, off white solid. 1H 
NMR (400 MHz, Chloroform-d) δ 7.64 (d, J = 2.2 Hz, 1H), 7.57 (dd, J = 8.4, 2.2 Hz, 1H), 7.38 – 
7.29 (m, 3H), 7.21 (d, J = 7.2 Hz, 1H), 7.06 – 6.97 (m, 3H), 6.49 (s, 1H), 5.92 (s, 2H), 5.02 (s, 
2H), 4.78 (s, 2H), 3.97 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 169.1, 158.9, 148.0, 147.3, 136.4, 
136.3, 135.8, 130.9, 129.2, 129.1, 127.8, 127.5, 122.9, 122.4, 118.0, 115.0, 114.8, 113.0, 110.4, 
101.9, 55.1, 52.6, 41.5. HRMS (ESI) m/z [M+H] calculated for C23H19BrNO4S, 486.0194, found 
488.0156. 
 
1-(benzo[d][1,3]dioxol-5-yl)ethane-1-thiol (60): To solution of 1-(benzo[d][1,3]dioxol-5-
yl)ethan-1-ol (59) (1g, 6 mmol, 1 eq.) in toluene (20 mL) was added Lawessons reagent (2.6 g, 6.6 
mmol, 1.1 eq.) and the reaction mixture was stirred at 80 °C. Water (10 mL) was added, and the 
resulting mixture was cooled to room temperature. The organic layer was separated and 
sequentially washed with saturated sodium bicarbonate solution (10 mL) and brine (100 mL). The 
organic layer was dried over sodium sulfate and evaporated. The resulting oil was purified by silica 
gel chromatography (SiO2, 1:9 ethyl acetate:hexanes), which afforded 60 (0.45 g, 44%) as 
colorless oil. 1H NMR (500 MHz, Chloroform-d) δ 6.90 (d, J = 1.9 Hz, 1H), 6.82 – 6.79 (m, 1H), 
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6.74 (d, J = 8.0 Hz, 1H), 5.95 (s, 2H), 4.19 (qd, J = 6.9, 4.8 Hz, 1H), 1.99 (d, J = 4.9 Hz, 1H), 1.64 
(dd, J = 6.9, 0.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 147.8, 146.5, 139.8, 119.4, 108.1, 106.9, 
101.0, 38.7, 26.3. HRMS (ESI) m/z [M+H] calculated for C9H11O2S, 183.0474, found 183.0495. 
 
(3-((1-(benzo[d][1,3]dioxol-5-yl)ethyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone 
(54): Prepared using general procedure B; 38 mg, Yield 68 %, off white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.57 – 7.49 (m, 2H), 7.37 – 7.28 (m, 3H), 7.20 (d, J = 7.3 Hz, 1H), 7.03 – 6.99 
(m, 1H), 6.92 (s, 1H), 6.76 (d, J = 1.8 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 6.61 (dd, J = 8.0, 1.9 Hz, 
1H), 5.89 (q, J = 1.4 Hz, 2H), 5.05 – 4.96 (m, 2H), 4.71 (s, 2H), 4.10 (q, J = 7.0 Hz, 1H), 1.62 (d, 
J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.2, 158.9, 147.8, 147.0, 136.4, 136.3, 136.1, 
135.9, 130.9, 128.8, 127.8, 127.5, 122.9, 122.4, 120.5, 118.2, 114.7, 108.1, 107.2, 101.1, 55.0, 
52.6, 49.3, 21.8. HRMS (ESI) m/z [M+H] calculated for C24H22NO4S, 420.1264, found 420.1240. 
 
(3-((benzo[d][1,3]dioxol-5-ylmethyl)sulfinyl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone 
(55): To solution of (3-((benzo[d][1,3]dioxol-5-ylmethyl)thio)-4-hydroxyphenyl)(isoindolin-2-
yl)methanone (49) (25 mg, 0.06 mmol, 1 eq.)  in DCM (2 mL) was added m-chloroperbenzoic acid 
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(m-CPBA) (32 mg, 0.18 mmol, 3 eq.) at 0o C, allowed to warm to rt and stirred for 1 h. The solvent 
was removed under vacuum, and water (5 mL) was added. The resulting mixture was extracted 
with DCM (10 mL X 2) and the combined organic phases were dried over anhydrous sodium 
sulfate and filtered. Evaporation of the solvent in vacuo followed by flash column chromatography 
(SiO2, 1:3 ethyl acetate:hexanes) afforded  55 (12 mg, 47 %) as off white solid. 1H NMR (400 
MHz, Chloroform-d) δ 8.89 (s, 1H), 7.85 – 7.70 (m, 2H), 7.38 – 7.28 (m, 4H), 7.20 (d, J = 7.2 Hz, 
1H), 7.03 (d, J = 8.6 Hz, 1H), 6.73 (d, J = 7.9 Hz, 1H), 6.65 (d, J = 1.8 Hz, 1H), 6.56 (dd, J = 8.0, 
1.8 Hz, 1H), 5.95 (s, 2H), 5.01 (s, 2H), 4.73 (s, 2H), 4.31 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 
158.1, 150.9, 148.7, 135.9, 132.1, 128.9, 127.9, 127.7, 124.9, 122.9, 122.9, 122.5, 119.9, 118.9, 
118.0, 110.8, 108.6, 102.8, 101.5, 99.9, 63.0, 54.9, 52.8. HRMS (ESI) m/z [M+H] calculated for 
C23H20NO5S, 422.1056, found 422.1065.  
 
 
(4-hydroxy-3-(propylthio)phenyl)(isoindolin-2-yl)methanone (56): Prepared using general 
procedure B ; 23 mg, Yield 54 %, white solid. 1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 
2.2 Hz, 1H), 7.53 (dd, J = 8.4, 2.2 Hz, 1H), 7.38 – 7.27 (m, 3H), 7.19 (s, 1H), 7.06 (d, J = 8.4 Hz, 
1H), 5.02 (s, 2H), 4.84 (s, 2H), 2.77 – 2.65 (m, 2H), 1.60 (h, J = 7.4 Hz, 2H), 1.00 (t, J = 7.3 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 169.4, 158.4, 135.0 (2), 130.1 (2), 129.0, 127.8, 127.5, 122.9, 
122.4, 119.6, 114.6, 55.1, 52.7, 38.7, 23.0, 13.2. HRMS (ESI) m/z [M+H] calculated for 




(4-hydroxy-3-(propylsulfonyl)phenyl)(isoindolin-2-yl)methanone (57): To solution of (4-
hydroxy-3-(propylthio)phenyl)(isoindolin-2-yl)methanone (56) (25 mg, 0.08 mmol, 1 eq.)  in 
DCM (2 mL) was added m-chloroperbenzoic acid (m-CPBA) (41 mg, 0.24 mmol, 3 eq.) at 0o C, 
allowed to warm to rt and stirred for 1 h. The solvent was removed under vacuum, and water (5 
mL) was added. The resulting mixture was extracted with DCM (10 mL X 2) and the combined 
organic phases were dried over anhydrous sodium sulfate and filtered. Evaporation of the solvent 
in vacuo followed by flash column chromatography (SiO2, 1:3 ethyl acetate:hexanes) afforded  57 
(8 mg, 30 %) as off white solid. 1H NMR (500 MHz, Chloroform-d) δ 9.28 (s, 1H), 7.94 (d, J = 
2.2 Hz, 1H), 7.82 (dd, J = 8.6, 2.2 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.20 (d, J = 7.4 Hz, 1H), 7.14 (d, 
J = 8.6 Hz, 1H), 5.03 (s, 2H), 4.84 (s, 2H), 3.24 – 3.10 (m, 2H), 1.91 – 1.67 (m, 2H), 1.05 (t, J = 
7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 168.0, 157.8, 135.9, 135.5 (2), 128.6 (2), 128.0, 127.7, 
122.9, 122.5, 119.4, 119.3, 58.7, 55.1, 52.8, 16.2, 12.8. HRMS (ESI) m/z [M+H] calculated for 





(58): Prepared using general procedure B ; 25 mg, Yield 45 %, white solid. 1H NMR (500 MHz, 
Chloroform-d) δ 7.80 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 8.4, 2.2 Hz, 1H), 7.40 – 7.28 (m, 3H), 7.19 
(d, J = 7.4 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.82 – 6.72 (m, 4H), 5.02 (s, 2H), 4.83 (s, 2H), 4.24 
(s, 4H). 13C NMR (126 MHz, CDCl3) δ 158.1, 143.2, 136.4, 135.2, 130.9, 129.4, 127.8, 127.5, 
126.1, 122.9, 122.4, 122.3, 120.7, 118.7, 118.2, 117.9, 117.1, 116.9, 115.5, 64.3 (2), 64.3 (2). 
HRMS (ESI) m/z [M+H] calculated for C23H20NO4S, 406.1107, found 406.1115. 
General procedure C  
 
In a reaction vessel containing 51 (50 mg, 0.136 mmol, 1 eq), (dibenzylideneacetone)palladium(0) 
(Pd(dba)2) (5 mg, 0.008 mmol) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl 
(XPhos) (8 mg, 0.016 mmol), sodium tert-butoxide (48 mg, 0.5 mmol, 3 eq), and the desired thiol 
(RSH) (0.16 mmol, 1.2 eq.) suspended and/or dissolved in toluene (3 mL). The reaction mixture 
was purged with argon, sealed and heated to 130o C for 6 h. Subsequently, solvent was removed 
under vacuum and water (20 mL) was added to the remaining mass and extracted with ethyl acetate 
(30 mL X 2). Organic fractions were then collected, dried and concentrated to a residue mass that 
was passed through a pad of silica (3:7 ethyl acetate:hexanes) to result in a crude product. The 
obtained mass was dissolved in methanol (5 mL), the solution was acidified to pH 3 with 2 N HCl 
solution and stirred for 4 h at 45o C. Upon completion, the methanol was removed under vacuum 
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and the remaining mass was extracted with water (10 mL) and ethyl acetate (20 mL X 2). After 
combining and drying the organic layer, a flash chromatography (4:6 ethyl acetate: hexanes) was 
performed to afford the desired monophenols. 
 
(4-hydroxy-3-((2-methoxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (61a):  Prepared 
using general procedure C; white solid, 19 mg, Yield 37 %. 1H NMR (400 MHz, Chloroform-d) δ 
7.87 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.5, 2.2 Hz, 1H), 7.38 – 7.24 (m, 4H), 7.18 (d, J = 7.2 Hz, 
1H), 7.14 – 7.08 (m, 2H), 6.95 – 6.83 (m, 2H), 5.02 (s, 2H), 4.84 (s, 2H), 3.96 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.1, 159.1, 157.0, 136.4, 136.3, 135.9, 131.2, 131.2, 129.2, 129.0, 127.8, 
127.5, 122.9, 122.8, 122.4, 121.7, 117.7, 115.5, 110.9, 55.9, 55.1, 52.7. HRMS (ESI) m/z [M+H] 
calculated for C22H20NO3S, 378.1158, found 378.1165. 
 
(4-hydroxy-3-((3-methoxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (61b): Prepared 
using general procedure C; white solid, 22 mg, Yield 44 %. 1H NMR (400 MHz, Chloroform-d) δ 
7.75 (d, J = 2.2 Hz, 1H), 7.59 (dd, J = 8.4, 2.2 Hz, 1H), 7.30 – 7.20 (m, 4H), 7.13 – 7.04 (m, 2H), 
6.70 – 6.57 (m, 3H), 4.93 (s, 2H), 4.75 (s, 2H), 3.68 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 200.3, 
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190.0, 187.1, 187.0, 184.0, 174.9, 174.5, 170.1, 169.7, 168.9, 166.7, 166.5, 164.9, 164.8, 164.7, 
162.4, 161.3, 157.7, 132.3, 67.5, 53.1, 52.3. HRMS (ESI) m/z [M+H] calculated for C22H20NO3S, 
378.1158, found 378.1166. 
 
(4-hydroxy-3-((4-methoxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (61c): Prepared 
using general procedure C; white solid, 20 mg, yield 40 %. 1H NMR (500 MHz, Chloroform-d) δ 
7.53 – 7.44 (m, 2H), 7.35 (dd, J = 8.4, 2.1 Hz, 1H), 7.32 – 7.28 (m, 3H), 7.26 (dd, J = 6.4, 2.4 Hz, 
1H), 7.14 (t, J = 8.1 Hz, 2H), 6.99 (d, J = 2.1 Hz, 1H), 6.96 – 6.90 (m, 2H), 4.93 (s, 2H), 4.60 (d, 
J = 1.6 Hz, 2H), 3.81 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.4, 160.3, 154.3, 136.6 (2), 136.5, 
136.3, 130.5, 129.3, 127.7, 127.4, 126.4, 125.7, 122.9, 122.2, 115.3 (2), 113.9, 94.8, 56.4, 54.9, 
52.5. HRMS (ESI) m/z [M+H] calculated for C22H20NO3S, 378.1158, found 378.1156. 
 
(4-hydroxy-3-(o-tolylthio)phenyl)(isoindolin-2-yl)methanone (61d) : Prepared using general 
procedure B; white solid, 30 mg, Yield  62%. 1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 
2.1 Hz, 1H), 7.68 (dd, J = 8.5, 2.2 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.23 – 7.05 (m, 5H), 6.80 (dd, J 
= 7.8, 1.3 Hz, 1H), 6.68 (s, 1H), 5.02 (s, 2H), 4.82 (s, 2H), 2.48 (s, 3H). 13C NMR (126 MHz, 
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CDCl3) δ 168.9, 158.5, 136.4, 136.2, 136.1, 135.6, 134.0, 131.3, 130.5, 129.7, 127.8, 127.5, 126.9, 
126.7, 126.5, 122.9, 122.4, 116.7, 115.6, 55.1, 52.7, 20.2. HRMS (ESI) m/z [M+H] calculated for 
C22H20NO2S, 362.1209, found 362.1208. 
 
(4-hydroxy-3-(m-tolylthio)phenyl)(isoindolin-2-yl)methanone (61e): Prepared using general 
procedure B; white solid, 28 mg, Yield  58%. 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, J = 
2.1 Hz, 1H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.29 – 7.19 (m, 4H), 7.12 – 7.04 (m, 3H), 6.95 – 6.89 
(m, 2H), 6.88 – 6.84 (m, 1H), 6.68 (s, 1H), 4.93 (s, 2H), 4.75 (s, 2H), 2.21 (d, J = 0.7 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 169.0, 158.5, 139.3, 136.4, 136.3, 135.7, 134.6, 131.4, 129.5, 129.2, 
128.2, 127.8, 127.6, 127.5, 124.7, 122.9, 122.4, 117.2, 115.6, 55.1, 52.7, 21.4. HRMS (ESI) m/z 
[M+H] calculated for C22H20NO2S, 362.1209, found 362.1213. 
 
(4-hydroxy-3-(p-tolylthio)phenyl)(isoindolin-2-yl)methanone (61f): Prepared using general 
procedure B; white solid, 31 mg, Yield  63%. 1H NMR (500 MHz, Chloroform-d) δ 7.82 (d, J = 
2.1 Hz, 1H), 7.64 (dd, J = 8.4, 2.2 Hz, 1H), 7.38 – 7.27 (m, 3H), 7.18 (d, J = 7.4 Hz, 1H), 7.13 (d, 
J = 8.4 Hz, 1H), 7.10 (s, 4H), 6.81 (s, 1H), 5.02 (s, 2H), 4.82 (s, 2H), 2.32 (s, 3H). 13C NMR (126 
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MHz, CDCl3) δ 169.0, 158.3, 136.9, 136.4, 136.3, 135.4, 131.1, 131.1, 130.1 (2), 129.4, 128.2 (2), 
127.8, 127.5, 122.9, 122.4, 118.1, 115.5, 55.1, 52.7, 20.9.  HRMS (ESI) m/z [M+H] calculated for 
C22H20NO2S, 362.1209, found 362.1223.  
 
(3-((3,4-dimethylphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61g): Prepared 
using general procedure B; white solid, 28 mg, Yield  55%. 1H NMR (400 MHz, Chloroform-d) δ 
7.73 (d, J = 2.1 Hz, 1H), 7.55 (dd, J = 8.4, 2.1 Hz, 1H), 7.29 – 7.19 (m, 3H), 7.09 (d, J = 7.3 Hz, 
1H), 7.03 (d, J = 8.4 Hz, 1H), 6.98 – 6.89 (m, 2H), 6.84 (dd, J = 7.9, 2.1 Hz, 1H), 6.67 (s, 1H), 
4.93 (s, 2H), 4.74 (s, 2H), 2.13 (d, J = 2.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 169.1, 158.3, 
137.9, 136.4, 136.3, 135.7, 135.3, 131.2, 131.0, 130.6, 129.5, 129.4, 127.8, 127.5, 125.9, 122.9, 
122.4, 118.2, 115.5, 55.1, 52.7, 19.8, 19.3. HRMS (ESI) m/z [M+H] calculated for C23H22NO2S, 
376.1365, found 376.1375. 
 
(3-((3,5-dimethylphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61h): Prepared 
using general procedure B; white solid, 28 mg, Yield  55%. 1H NMR (500 MHz, Chloroform-d) δ 
7.73 (d, J = 2.1 Hz, 1H), 7.57 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 – 7.19 (m, 3H), 7.07 (dd, J = 18.1, 
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7.9 Hz, 2H), 6.80 – 6.66 (m, 4H), 4.94 (s, 2H), 4.75 (s, 2H), 2.17 (d, J = 0.7 Hz, 6H). 13C NMR 
(126 MHz, CDCl3) δ 169.1, 158.5, 139.1, 136.4, 136.3, 135.6, 134.3, 131.4, 129.4, 128.7, 127.8, 
127.5, 125.5, 125.4 (2), 122.9, 122.4, 117.4, 115.6, 55.1, 52.7, 21.2 (2). HRMS (ESI) m/z [M+H] 
calculated for C23H22NO2S, 376.1365, found 376.1352. 
 
(3-((2,5-dimethylphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61i): Prepared 
using general procedure B; white solid, 30 mg, Yield  59%. 1H NMR (400 MHz, Chloroform-d) δ 
7.76 (d, J = 2.2 Hz, 1H), 7.68 (dd, J = 8.4, 2.1 Hz, 1H), 7.38 – 7.29 (m, 3H), 7.17 (t, J = 7.5 Hz, 
2H), 7.10 (d, J = 7.6 Hz, 1H), 6.99 – 6.88 (m, 1H), 6.63 (d, J = 1.9 Hz, 2H), 5.03 (s, 2H), 4.82 (s, 
2H), 2.43 (s, 3H), 2.21 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.1, 158.4, 136.7, 136.4, 136.3, 
135.3, 133.5, 133.3, 131.2, 130.5, 129.6, 127.8, 127.5 (2), 127.5, 122.9, 122.4, 116.9, 115.6, 55.1, 
52.7, 21.0, 19.7. HRMS (ESI) m/z [M+H] calculated for C23H22NO2S, 376.1365, found 376.1372. 
 
(3-((2,4-dimethylphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61j): Prepared 
using general procedure B; white solid, 28 mg,  Yield  56%. 1H NMR (400 MHz, Chloroform-d) 
δ 7.70 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.4, 2.2 Hz, 1H), 7.36 – 7.28 (m, 3H), 7.16 (d, J = 7.3 Hz, 
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1H), 7.11 (d, J = 8.4 Hz, 1H), 7.05 – 7.01 (m, 1H), 6.89 (dd, J = 7.9, 1.9 Hz, 1H), 6.78 (d, J = 8.0 
Hz, 1H), 5.00 (s, 2H), 4.79 (s, 2H), 2.42 (s, 3H), 2.28 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
169.0, 158.2, 136.8, 136.6, 136.4, 136.3, 134.9, 131.5, 130.8, 130.2, 129.5, 127.9, 127.8, 127.7, 
127.5, 122.9, 122.4, 117.7, 115.5, 55.1, 52.7, 20.8, 20.2. HRMS (ESI) m/z [M+H] calculated for 
C23H22NO2S, 376.1365, found 376.1352.   
 
(4-hydroxy-3-((3,4,5-trimethylphenyl)thio)phenyl)(isoindolin-2-yl)methanone (61k): 
Prepared using general procedure B; white solid, 35 mg, Yield  67%. 1H NMR (400 MHz, 
Chloroform-d) δ 7.82 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 8.4, 2.1 Hz, 1H), 7.32 (d, J = 25.2 Hz, 3H), 
7.18 (d, J = 7.3 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.88 (s, 2H), 6.80 (s, 1H), 5.03 (s, 2H), 4.84 (s, 
2H), 2.23 (s, 6H), 2.13 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.1, 158.3, 137.8 (2), 136.4, 
136.3, 135.3, 134.6, 134.4, 131.0, 130.3, 129.3, 127.8, 127.5 (2), 122.9, 122.4, 118.3, 115.5, 55.1, 





(3-((3,4-dichlorophenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61l): Prepared 
using general procedure B; white solid, 35 mg, Yield  63%.1H NMR (500 MHz, Chloroform-d) δ 
7.72 (d, J = 2.0 Hz, 1H), 7.60 (dd, J = 8.5, 2.1 Hz, 1H), 7.29 – 7.19 (m, 4H), 7.14 – 7.05 (m, 3H), 
6.88 (dd, J = 8.5, 2.2 Hz, 1H), 6.82 (s, 1H), 4.93 (s, 2H), 4.75 (s, 2H). 13C NMR (126 MHz, CDCl3) 
δ 168.8, 158.6, 136.2, 136.1, 135.8, 135.4, 133.5, 131.9, 131.0, 130.8, 129.8, 128.7, 127.9, 127.6, 
126.5, 122.9, 122.4, 116.1, 115.9, 55.1, 52.7. HRMS (ESI) m/z [M+H] calculated for 
C21H16Cl2NO2S, 416.0273, found 416.0254. 
 
(3-((3,4-difluorophenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61m): Prepared 
using general procedure B; white solid, 28 mg, Yield  56%. 1H NMR (500 MHz, Chloroform-d) δ 
7.74 (d, J = 2.1 Hz, 1H), 7.60 (dd, J = 8.4, 2.2 Hz, 1H), 7.24 (dt, J = 18.2, 8.5 Hz, 3H), 7.09 (dd, 
J = 13.7, 7.9 Hz, 2H), 7.01 (dt, J = 9.9, 8.3 Hz, 1H), 6.87 (ddd, J = 10.4, 7.1, 2.3 Hz, 1H), 6.82 
(dddd, J = 8.7, 3.9, 2.3, 1.5 Hz, 1H), 6.60 (s, 1H), 4.94 (s, 2H), 4.75 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 168.7, 158.4, 136.2, 136.2, 135.8, 131.8, 129.9, 127.9, 127.9, 127.6, 123.7 (dd, J = 6.4, 
3.9 Hz), 122.9, 122.4, 118.3, 118.1, 116.8, 116.6, 116.6, 115.9, 55.1, 52.7. HRMS (ESI) m/z 





Prepared using general procedure B; white solid, 33 mg, Yield  60%.  1H NMR (500 MHz, 
Chloroform-d) δ 7.68 (d, J = 2.2 Hz, 1H), 7.51 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 – 7.17 (m, 3H), 7.08 
(d, J = 7.4 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.79 – 6.66 (m, 3H), 4.92 (s, 2H), 4.71 (s, 2H), 3.76 
(d, J = 12.3 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 169.1, 157.9, 149.6, 148.8, 136.3, 136.2, 
134.6, 130.7, 129.3, 127.8, 127.5, 125.2, 122.9, 122.4, 122.2, 119.4, 115.4, 112.8, 111.9, 56.0, 
56.0, 55.1, 52.7. HRMS (ESI) m/z [M+H] calculated for C23H22NO4S, 408.1264, found 408.1268. 
 
(3-((3,5-dichlorophenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61o): Prepared 
using general procedure B; white solid, 25 mg, Yield  45%. 1H NMR (500 MHz, Chloroform-d) δ 
7.74 (d, J = 2.0 Hz, 1H), 7.64 (dd, J = 8.5, 2.1 Hz, 1H), 7.24 (dt, J = 18.3, 8.4 Hz, 3H), 7.15 – 7.07 
(m, 3H), 6.88 (t, J = 1.5 Hz, 2H), 6.62 (s, 1H), 4.94 (s, 2H), 4.76 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 168.6, 158.6, 138.9, 136.2, 136.2, 136.1, 136.0, 135.8, 132.3, 130.0, 127.9, 127.6, 126.7, 
124.8 (2), 122.9, 122.5, 116.2, 114.8, 55.2, 52.7. HRMS (ESI) m/z [M+H] calculated for 





Prepared using general procedure B; white solid, 34 mg, yield  65%. 1H NMR (400 MHz, 
Chloroform-d) δ 7.74 (d, J = 2.1 Hz, 1H), 7.58 (dd, J = 8.4, 2.2 Hz, 1H), 7.30 – 7.19 (m, 3H), 7.07 
(dd, J = 14.2, 7.9 Hz, 2H), 6.54 – 6.35 (m, 3H), 4.94 (s, 2H), 4.75 (s, 2H), 3.65 (s, 3H), 2.18 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 169.0, 160.2, 158.5, 140.6, 136.3, 135.8, 131.5, 129.5, 127.8, 
127.5, 125.8, 123.3, 122.9, 122.4, 120.4, 116.9, 115.6, 113.1, 110.3, 55.2, 55.2, 52.7, 21.5. HRMS 
(ESI) m/z [M+H] calculated for C23H22NO3S, 392.1314, found 392.1319. 
 
(3-((3-fluorophenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61q): Prepared using 
general procedure B; white solid, 28 mg, Yield  56%. 1H NMR (500 MHz, Chloroform-d) δ 7.76 
(d, J = 2.1 Hz, 1H), 7.61 (dd, J = 8.4, 2.2 Hz, 1H), 7.29 – 7.20 (m, 2H), 7.16 (td, J = 8.1, 5.9 Hz, 
1H), 7.10 (t, J = 8.3 Hz, 2H), 6.87 – 6.78 (m, 2H), 6.72 (dt, J = 9.2, 2.1 Hz, 1H), 6.63 (s, 1H), 4.94 
(s, 2H), 4.76 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 168.8, 158.6, 137.5, 137.4, 136.3, 136.2, 
136.0, 131.9, 130.7 (d, J = 8.7 Hz), 129.8, 127.9, 127.6, 122.9, 122.6 (d, J = 3.6 Hz), 122.4, 115.9, 
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115.8, 114.0 (d, J = 24.4 Hz), 113.6 (d, J = 21.4 Hz), 55.1, 52.7. HRMS (ESI) m/z [M+H] 
calculated for C21H17FNO2S, 366.0978, found 366.0978. 
 
(3-((3-ethylphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61r): Prepared using 
general procedure B; white solid,32 mg, Yield 63%. 1H NMR (500 MHz, Chloroform-d) δ 7.74 
(d, J = 2.1 Hz, 1H), 7.57 (dd, J = 8.4, 2.2 Hz, 1H), 7.22 (dd, J = 18.8, 9.8 Hz, 4H), 7.13 – 7.03 
(m, 3H), 7.00 – 6.91 (m, 2H), 6.86 (dt, J = 8.0, 1.4 Hz, 1H), 4.93 (s, 2H), 4.74 (s, 2H), 2.51 (q, J 
= 7.6 Hz, 2H), 1.12 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.0, 158.5, 145.6, 
136.3, 136.3, 135.7, 134.6, 131.4, 129.5, 129.3, 127.8, 127.5, 127.1, 126.4, 124.9, 122.9, 122.4, 
117.3, 115.6, 55.1, 52.7, 28.7, 15.4. HRMS (ESI) m/z [M+H] calculated for C23H22NO2S, 
376.1365, found 376.1346.  
 
(4-hydroxy-3-((3-propylphenyl)thio)phenyl)(isoindolin-2-yl)methanone (61s): Prepared using 
general procedure B; white solid, 29 mg, Yield  56%. 1H NMR (400 MHz, Chloroform-d) δ 7.82 
(d, J = 2.2 Hz, 1H), 7.65 (dd, J = 8.4, 2.2 Hz, 1H), 7.36 – 7.25 (m, 3H), 7.21 – 7.11 (m, 3H), 7.04 
– 6.99 (m, 2H), 6.96 – 6.92 (m, 1H), 6.88 (s, 1H), 5.01 (s, 2H), 4.82 (s, 2H), 2.52 (dd, J = 8.6, 6.8 
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Hz, 2H), 1.65 – 1.52 (m, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.1, 
158.5, 144.1, 136.4, 136.3, 135.6, 134.5, 131.3, 129.4, 129.2, 127.9, 127.7, 127.5, 127.0, 125.0, 
122.9, 122.4, 117.4, 115.6, 55.1, 52.7, 37.8, 24.4, 13.8. HRMS (ESI) m/z [M+H] calculated for 
C24H24NO2S, 390.1527, found 390.1514. 
 
(3-((3-ethoxyphenyl)thio)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (61t): Prepared using 
general procedure B; white solid, 33 mg, Yield  62%. 1H NMR (400 MHz, Chloroform-d) δ 7.83 
(d, J = 2.1 Hz, 1H), 7.67 (dd, J = 8.4, 2.2 Hz, 1H), 7.38 – 7.28 (m, 3H), 7.21 – 7.11 (m, 3H), 6.75 
– 6.66 (m, 4H), 5.02 (s, 2H), 4.83 (s, 2H), 3.97 (q, J = 7.0 Hz, 2H), 1.38 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 168.9, 159.6, 158.6, 136.4, 136.3, 136.1, 135.8, 131.6, 130.2, 129.6, 
127.8, 127.5, 122.9, 122.4, 119.5, 116.8, 115.6, 113.7, 112.7, 63.5, 55.1, 52.7, 14.7. HRMS (ESI) 
m/z [M+H] calculated for C23H22NO3S, 392.1314, found 392.1327. 
 
(2-amino-5-bromo-4-hydroxyphenyl)(isoindolin-2-yl)methanone (64): The intermediate 65 
(100mg, 0.4 mmol, 1 eq.)  was dissolved in DCM (3 mL), to this solution were introduced, N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (175 mg, 0.92 mmol, 2.0 eq.), 
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hydroxybenzotriazole hydrate (124.2 mg, 0.92 mmol, 2 eq.), N, N-Diisopropylethylamine (296 
mg, 2.3 mmol, 5 eq.) and isoindoline hydrochloride (80 mg, 0.5 mmol, 1.1 eq.) Reaction was 
stirred overnight at rt, before solvent was removed in vacuo. Subsequently, water (10 mL) was 
added to the remaining crude mass, acidified with 1N HCl and extracted with ethyl acetate (10 mL 
x2). The organic fractions were combined, dried over sodium sulfate, filtered and concentrated. 
The resulting residue was purified by flash chromatography (SiO2, 1:3 hexanes/ethyl acetate) to 
collect (2-amino-5-bromo-4-methoxyphenyl)(isoindolin-2-yl)methanone as brown solid. 
Obtained product was dissolved in DCM (3 mL), cooled to 0oC and 1M boron tribromide solution 
in DCM (1.38 mL, 1.38 mmol, 3 eq.) was added slowly. Reaction was quenched with a brine (10 
mL), extracted with ethyl acetate (10 X 3), dried over sodium sulfate and purified using flash 
chromatography (SiO2, 1:3 ethyl acetate/hexanes) to produce 64 (51 mg, 38% overall) as beige 
solid. 1H NMR (500 MHz, Chloroform-d) δ 7.35 (s, 1H), 7.23 (d, J = 5.1 Hz, 3H), 7.14 (s, 1H), 
6.33 (s, 1H), 5.56 (s, 1H), 4.86 (d, J = 38.8 Hz, 4H), 4.62 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
168.8, 154.2, 147.8, 136.3, 131.2 (2), 127.7, 122.7, 114.5 (2), 103.2 (2), 97.2, 53.4 (2). HRMS 
(ESI) m/z [M+H] calculated for C15H14BrN2O2, 333.0239, found 333.0256.  
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